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Abstract 
Leishmania are protozoan parasites responsible for the range of infections collectively known 
as leishmaniasis. Currently, drugs represent the only course of treatment. The nitroaromatic 
prodrugs are a class of agents that are used clinically used to treat trypanosomatid diseases; 
and in the parasites Trypanosoma brucei and Trypanosoma cruzi these compounds undergo 
reduction activation by enzymes homologous with bacterial type I nitroreductases (NTRs). 
From the Leishmania major genome database, we have identified a protein (LmNTR) that 
could catalyse this reaction. Based on co-factor, oxygen-insensitive activity and substrate 
range, we demonstrate that the LmNTR displays many characteristics of its bacterial 
counterparts. Gene deletion studies revealed that LmNTR is essential to the insect and 
mammalian stages of L. major. Null mutant parasites could not be generated while loss of a 
single LmNTR allele in the insect form conferred resistance to a range of nitroaromatic 
compounds without affecting their growth rate or ability to differentiate into infectious forms. 
Heterozygous lines could not establish an infection in vitro using a tissue culture model, or in 
vivo, in mice. As NTRs are absent from most eukaryotes, with trypanosomatids being a major 
exception, we exploit this difference to evaluate a library of nitroaromatic compounds against 
L. major parasites. Biochemical screens against the purified enzyme revealed that several 
compounds were effective substrates for LmNTR, generating higher activities than 
nifurtimox, the clinically used nitro-based agent that targets trypanosomes. Using phenotypic 
screens, we demonstrated that growth inhibition mirrored enzyme activity, with the most 
potent compounds generating IC50’s <100 nM whilst having little effect on mammalian cells. 
L. major NTR was shown to play a key role in parasite killing as heterozygous lines 
displayed resistance to the compounds. In conclusion, we have shown that LmNTR is 
essential to the parasite and by exploiting its prodrug activating properties, identified several 
novel agents that provide new lead structures to treat leishmanial infections. 
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1. Introduction 
1.1 Trypanosomatid diseases 
Organisms belonging to the class Kinetoplastida, order Trypanosomatida represent a group of 
obligate protozoal parasites (Stevens et al. 2001). They are characterised by having a long 
slender morphology and single flagellum that together give the cell a corkscrew-like motion 
(trypano = borer and soma = body), and by their intricate mitochondrial genome that forms a 
discrete region called the kinetoplast. Typically Trypanosomatida are monoxenous, primarily 
infecting insects, although some are heteroxenous, having complex life cycles involving more 
than one obligatory host. In humans, they are responsible for several major infections 
including human African trypanosomiasis (HAT) and Chagas disease (that are caused by the 
trypanosomes Trypanosoma brucei and Trypanosoma cruzi respectively), while more than 20 
species of Leishmania result in a spectrum of pathologies termed leishmaniasis. 
Leishmaniasis ranges from a self-limiting form called cutaneous leishmaniasis (CL), a 
disfiguring version known as mucocutaneous leishmaniasis (MCL) to visceral leishmaniasis 
(VL), a fatal infection (Wiser 2010). Together the trypanosomal and leishmanial diseases are 
endemic throughout tropical and sub-tropical regions, with more than 500 million living in 
areas deemed at risk. Current estimates indicate that more than 20 million people are infected 
by the causative agents resulting in about 75,000-100,000 premature deaths each year (Stuart 
et al. 2008). With no immediate prospect of a vaccine, drugs represent the only effective 
course of treatment available against trypanosomal and leishmanial infections. However, 
current drug regimes are problematic as many are toxic, most are costly, and resistance is 
becoming more of an issue (Wilkinson et al. 2009). Against this backdrop, the development 
of new cost-effective treatments is a priority, but given that trypanosomatid diseases mainly 
affect developing countries, these infections are not deemed commercially attractive by 
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pharmaceutical companies. This has resulted in HAT, Chagas disease and leishmaniasis 
being largely neglected in terms of drug development (Balasegaram et al. 2008). 
 
1.2 History of leishmaniasis 
Documentary evidence suggests that leishmaniasis has been plaguing the human race for 
thousands of years. Pathologies reminiscent of CL are depicted on tablets from the 7
th
 
Century BC Assyria, some of which are believed to be derived from earlier texts, while 1
st
 
Century AD pre-Inca pottery from Peru and Ecuador appear to show skin lesions and facial 
deformities similar to MCL (Cox 2002). The first descriptions of CL lesions and sores were 
made by Muslim physicians during the 10
th
 century, with the first account in English 
attributed to Alexander Russell in 1756. However, it took another 150 years for a link to be 
established between these disease pathologies and the pathogen. For CL, initial observations 
by Peter Borovsky in 1898 (cited in Cox 2002) identified the causative agent as a protozoan 
and revealed the relationship between the parasite and the host tissue, although James Homer 
Wright (Wright 1903) is usually credited with this observation; Borovsky’s work was not 
widely circulated and hence not internationally recognized. Identification of the causative 
agent of VL is more clear cut, with William Leishman (Leishman 1903) and Charles 
Donovan (Donovan 1903) independently discovering the parasite as small round or oval 
bodies, later known as Leishman-Donovan bodies, in the spleens of patients. However, it was 
Ronald Ross who recognized that the Leishman-Donovan bodies were in fact a new type of 
protozoan parasite which he named Leishmania donovani (Ross 1903). 
 
1.3 Geographical distribution and epidemiology of leishmaniasis 
Leishmaniasis is a blood borne disease transmitted through the blood feeding habits of female 
sandflies belonging to the subfamily Phlebotominae. These infections are endemic in 88 
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tropical and sub-tropical countries across the World where an estimated 350 million people 
are at risk of infection (Figure 1.3.1). Many (72) of these nations are designated as 
“developing countries” and here leishmaniasis represents a major public health problem in 
regions least able to deal with the associated economic burden. Current estimates indicate that 
up to 12 million people are infected by Leishmania. The most common and least severe form 
of the disease is CL, causing up to 1½ million new cases per year with 90% of infections 
occurring in Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia and Syria. The main 
species responsible for this pathology are L. major, L. tropica, L. aethiopica and L. infantum 
in the Old World or the L. mexicana complex, L. braziliensis complex and L. chagasi in the 
New World (Herwaldt 1999). The most severe and life threatening form of leishmaniasis is 
VL, caused mainly by L. donovani, L. infantum and L. chagasi. Each year about 500,000 
people are infected by these causative agents, predominantly in 5 regions namely Bangladesh, 
northeast India, Nepal, Sudan and Brazil, resulting in 50,000 deaths (Croft et al. 2003, Alvar 
et al. 2006, Piscopo et al. 2006). These figures make VL the second most serious protozoal 
disease in terms of morbidity after malaria. In many cases, patients may not realise they are 
infected and it is estimated that for every symptomatic case there are up to 20 asymptomatic 
infections, each acting as a reservoir for the parasite (Badaro et al. 1986, Badaro et al. 1986). 
 
Recently, as a result of military activity, population migration, modern medical practices 
(blood transfusions, organ/bone marrow transplants), congenital transfer, intravenous drug 
usage and global warming, leishmaniasis has emerged as a problem in non-endemic areas 
(Cruz et al. 2002, Wright et al. 2008, González et al. 2010, Pavli et al. 2010). Worryingly, 
VL/Human Immunodeficiency Virus (HIV) co-infections have become a major issue in 35 
countries. In this context, HIV infection exacerbates the risk of developing active VL in 
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asymptomatic carriers and this currently accounts for around 70% of all VL cases in Portugal, 
Spain, Italy and France (Desjeux et al. 2003). 
 
 
 
Figure 1.3.1: Geographical distribution of leishmaniasis 
Regions highlighted in red indicate areas where leishmaniasis is endemic. Image taken from 
Davies et al. 2003. 
 
1.4 Leishmania life cycle  
The life cycle of Leishmania is complex, involving several morphologically distinct parasite 
forms in two diverse hosts (Figure 1.4.1). As with other trypanosomatid infections, 
leishmaniasis is spread by the haematophagous feeding habits of insect vectors. The agents 
responsible are pregnant, female sandflies with male flies taking no part in disease 
transmission. In the Old World, transmission occurs through flies belonging to the genus 
Phlebotomus while Lutzomyia is the main vector in the New World (Alvar et al. 1997). 
Transmission of Leishmania can be human to human, a mechanism that occurs 
predominantly in urban environments, or zoonotic, a route prevalent in rural area with 
animals such as dogs or cattle acting as important “reservoir hosts”. 
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Figure 1.4.1: Life cycle of Leishmania 
Leishmania amastigotes replicate by binary fission within the phagolysosome of mammalian 
macrophages (1). Eventually, these parasites rupture the mammalian cell and are released into 
the host's blood/lymph system where they are taken up by other macrophages by 
phagocytosis (2). Some infected immune cells are taken up by a female sandfly during her 
blood meal (3). In the insect’s gut, the macrophage ruptures to release amastigotes (4) that 
differentiate into the promastigote life cycle stage (5). The promastigotes replicate by binary 
fission within the gut of the sandfly and adhere to the insect’s gut epithelium (6). Some 
promastigotes differentiate into metacyclic promastigotes, detach from the gut epithelium and 
travel to the insect’s cardia (7). During the fly’s next blood meal the Leishmania metacyclic 
promastigote are transferred into the mammalian blood/lymph streams where they are 
engulfed by phagocytic macrophages (8). Within the mammalian cell the metacyclic cell 
differentiates into the amastigote form (9), and the cycle repeats. Image modified from Wiser 
(2010). 
 
As a Leishmania-infected sandfly takes a blood meal, infective non-dividing metacyclic 
promastigote parasites present in the arthropod’s cardia are regurgitated into the bloodstream 
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of the mammalian host. The nature of this reflux action is not fully understood although it 
appears to involve a dysfunctional stomodeal valve. This structure, which corresponds to an 
invagination between the insect’s fore and mid gut, can be damaged by parasite expressed 
chitinases or blocked by a proteophosphoglycan gel-like substance known as the 
promastigote secretory gel (PSG) secreted by the protozoan (reviewed in Bates 2007). The 
outcome of either mechanism (damage or blockage) is that the stomodeal valve is not able to 
fully close and as a consequence, when an infected sandfly takes a blood meal, the ingested 
blood flows back along the insect’s mouthparts, and back into the wound, washing 
metacyclic promastigote parasites into the mammalian host. 
 
Once within the mammalian host, the parasite then invades macrophages or other phagocytic 
cells via opsonised phagocytosis (Mosser et al. 1992). Attachment of the pathogen to the host 
cell is mediated by the C3 component of the complement cascade which binds to the surface 
of the Leishmania cell. This is subsequently converted to an inactivated form, designated as 
iC3, by the zinc protease GP63 (Chaudhuri et al. 1988). The iC3 then functions as a ligand 
for complement receptors CR1 and CR3 on the mammalian immune cell with the interaction 
promoting uptake into the phagocytic cell. Generally, the first type of host cell to respond to 
leishmanial infection are the polymorphonuclear neutrophil granulocytes (PMN), possibly in 
response to chemotactic factors produced by the metacyclic promastigote (van Zandbergen et 
al. 2002). Once internalised, Leishmania has been reported to inhibit spontaneous death of 
the PMN cells, prolonging their life for 2-3 days as an apoptotic neutrophil (Aga et al. 2002). 
This allows the infected PMN cell to recruit and be ingested by macrophages. The 
macrophage then becomes the main host cell for the Leishmania parasite. This “Trojan horse” 
strategy (Laskay et al. 2003) allows the uptake of Leishmania, via apoptotic PMN cells 
(Fadok et al. 1998, Sun et al. 2001), without the activation of the macrophages antimicrobial 
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functions (Meagher et al. 1992). Additionally, the PSG secreted by the parasites has been 
shown to alter the L-arginine catabolism of the macrophages, resulting in the production of 
polyamines necessary for parasite proliferation within the mammalian cell (Rogers et al. 
2009). 
 
Once in the macrophage, the metacyclic promastigote is initially compartmentalised in the 
phagosome. Host cell lysosomes then fuse with this structure resulting in formation of the 
phagolysosome (also called the parasitophorous vacuole). The associated drop in pH that 
occurs during this process is believed to trigger differentiation of the metacyclic promastigote 
parasite into the intracellular amastigote form. This Leishmania stage loses its extended 
flagellum, becomes ovoid in shape and begins to divide by binary fission within the host cell. 
For reasons that have yet to be fully explained, possibly due to population density, the 
infected macrophage ruptures releasing amastigotes into the host’s bloodstream. These 
infective parasites can then invade other macrophages thus propagating the infection in the 
mammalian host, a cycle that will keep going until the host resolves the infection, is cured via 
chemotherapy or the patient dies.  
 
In some cases, Leishmania-infected macrophages can be transmitted back into the female 
sandfly when they take a blood meal. Once ingested, the infected macrophages burst 
releasing the amastigotes into the lumen of the insect’s mid-gut. In this environment, the 
parasites differentiate into non-infectious promastigotes that have the typical trypanosomatid 
body shape: long slender morphology and single flagellum. This pathogen form attaches to 
the insect gut epithelium and begins to replicate by binary fission. Attachment to the insect 
gut wall is a key step in this part of the Leishmania life cycle as it prevents the promastigote 
from being excreted in the arthropod’s faeces. This interaction is mediated by parasite 
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lipophosphoglycans (LPG) that form a glycocalyx coat that covers the entire parasite surface, 
including the flagellum. LPG contains a relatively short galactose-mannose-phosphate core 
with galactose side chains coupled to a glycophosphatidylinositol anchor that links the 
molecule to the cell membrane. The galactose side chains bind with lectins found on insect 
epithelial cells, such as the insect galectin PpGalec (Kamhawi et al. 2004), resulting in 
attachment of the parasite to the lining of the mid gut. Additionally, LPG serves to protect the 
parasite from digestive activities found in this hostile environment. Occasionally, possibly 
during a cell division event, non-dividing, infective metacyclic promastigotes are formed. 
Here, the LPGs nearly double in length, primarily through expansion of the galactose-
mannose-phosphate core, and the galactose containing side chains become capped at their 
termini with arabinosyl residues resulting in disassociation of the LPG/lectin complex. The 
metacyclic is then released into the lumen of the insect’s gut and migrates to the cardia ready 
to be transmitted back to another mammalian host. 
 
1.5 Pathology, diagnosis and treatment 
The term leishmaniasis covers a spectrum of disease pathologies caused by more than 20 
different species of Leishmania (Alvar, Canavate et al. 1997, Desjeux 2004) ranging from the 
disfiguring cutaneous and mucocutaneous forms to the life threatening visceral type. 
 
1.5.1 Cutaneous leishmaniasis 
Cutaneous leishmaniasis, also known as Baghdad Boil, Oriental Sore, Jericho Buttons and 
White Leprosy, starts with a red lesion forming at the site of the sand fly bite. Dependent on 
the Leishmania species, the wound can develop directly into an ulcer with a raised border or 
may form a nodular structure that then progresses into the ulcerated state. The ulcer may 
remain open, producing a wound classified as a “wet” lesion, as typified by infections caused 
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by L. major, or crust over to form a “dry” lesion characteristic of  L. tropica (Figure 1.5.1). 
Generally, the ulcers will self-heal often resulting in a permanent disfiguring scar, with the 
whole process taking between 2-6 months for L. major to 6-15 months for L. tropica, L. 
panamensis or L. braziliensis infections (Reithinger et al. 2007).  
 
 
Figure 1.5.1: Skin lesion and scarring caused by cutaneous leishmaniasis 
Wet (A) and dry (B) lesions indicative of cutaneous leishmaniasis present on the forearm and 
face, respectively, of the patients. Images provided by L. Harris (A) and Aytekin et al. 2006 
(B). 
 
Diagnosis of CL in endemic areas can be assessed by noting the clinical features (skin 
lesions) although definite detection of the parasite is required to categorically confirm 
infection. This can be accomplished rapidly and cheaply by the microscopic detection of 
cytoplasmic-stained (Leishman or Giemsa) amastigotes in macrophages from lesion 
scrapings or aspirates (Mehregan et al. 1999). However, harvesting samples is often painful 
to the patient and the identification of amastigotes as Leishman-Donovan bodies are often 
difficult to see without expert training. An alternative is the indirect serological techniques 
such as the leishmanin skin test (LST). This involves the intradermal injection of fixed 
promastigote cells or extracts and monitoring patients for a delayed-type hypersensitivity 
reaction (Weigle et al. 1991). Such approaches generally have higher sensitivities than the 
direct microscopic approaches, although false positive reactions are common. 
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Due to the self-healing nature of CL, treatment is usually reserved for patients where the 
lesion is particularly severe, where complicating secondary infections may arise or when 
there is a risk of developing MCL. In these cases, recommended treatments include 
intralesional or parenteral antimonials (sodium stibogluconate and meglumine antimoniate) 
or pentamidine (Blum et al. 2004). 
 
1.5.2 Mucocutaneous leishmaniasis 
 
 
Figure 1.5.2: Damage to the nasal pharynx region caused by mucocutaneous 
leishmaniasis 
Image sourced from the “Illustrated lecture notes on Tropical Medicine” provided by the 
Institute of Tropical Medicine, Antwerp. 
 
Mucocutaneous leishmaniasis, also known as espundia or American tegumentary 
leishmaniasis, is common in South America. It is most frequently associated with L. 
braziliensis but other species such as L. panamensis, L. guyanensis, L. amazonensis, L. 
major, L. tropica, and L. infantum  are reported to mediate this most disfiguring form of the 
disease (Reithinger, Dujardin et al. 2007). MCL begins in the same way as CL, with a sore 
developing at the site of the insect bite and in 95-97% cases the disease does not progress any 
further. However, in the remaining situations, the parasites can metastasise via the lymph or 
blood to other sites including to mucocutaneous junctions (the nasal pharynx and the 
genitourinal area). Here, the mucosal tissues initially become inflamed followed by ulceration 
 19 
 
that results in disfiguring lesions (Figure 1.5.2) (Marsden 1986) with the manifestation of 
MCL taking years to appear after the primary CL ulcer has healed. In many cases, the disease 
is complicated by secondary infections potentially leading to increased mortality. Diagnosis 
is carried out using similar approaches as to that described for CL i.e. clinical signs and 
symptoms, microscopical identification of amastigotes in specimens and LST; with treatment 
involving a 28 day course of pentavalent antimony or amphotericin B (Palumbo 2010). The 
prognosis depends on severity of the disease. 
1.5.3 Visceral leishmaniasis 
 
 
Figure 1.5.3: Pathology of visceral leishmaniasis 
The markings outline the enlarged liver and spleen. Image sourced from the “Illustrated 
lecture notes on Tropical Medicine” provided by the Institute of Tropical Medicine, Antwerp. 
 
Visceral leishmaniasis, also known as “kala azar”, is the most severe leishmaniasis 
pathology, which if untreated can prove fatal. It is caused mainly by L. donovani and L. 
infantum which mediate the systemic spread of infection particularly to the spleen, liver, bone 
marrow and lymph nodes. The incubation period for VL can vary, ranging from 10 days to 34 
months, although in most cases it takes 3-8 months for symptoms to appear (Stone et al. 
1952, De Alencar 1958, Manson-Bahr et al. 1964). The most common clinical indicators 
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associated with VL include fever, cough, abdominal pain, diarrhoea, epistaxis (nosebleed), 
pancytopenia (shortage of all blood cells) leading to extreme anaemia, and cachexia (a state 
of general ill health typified by weight loss, loss of appetite and physical atrophy). Probably 
the most characteristic symptom of VL, however, is an enlarged abdomen resulting from a 
grossly enlarged spleen and liver (splenohepatomegaly) (Figure 1.5.3), eventually resulting in 
the complete loss of function in these organs (Guerin et al. 2002). As a systemic infection, 
death may result regardless of whether a patient is treated or not and often is as a result of 
secondary infection, although chances of survival are greatly increased with appropriate 
treatments (Gorski et al. 2010). 
 
Diagnosis of VL usually involves the microscopical examination of spleen or bone marrow 
aspirates following cytoplasmic staining or by in vitro culturing of promastigote parasites 
from these clinical samples. Rapid seriological approaches such as the K39 dipstick and 
direct agglutination tests are available but due to cost are not generally used in many regions. 
Several drugs including pentavalent antimonials, liposomal amphotericin B, paromomycin 
and miltefosine are now available but the use of these is problematic (Sundar et al. 2005). 
 
After recovery from VL caused by L. donovani, patients sometimes go on to develop post-
kala-azar dermal leishmaniasis (PKDL). PKDL results in small measles-like lesions across 
the body which are usually self healing but can persist for years. PKDL patients are 
particularly common in areas of India where anthroponotic transmission is prevalent, with 
these individuals considered an important reservoir host for the VL-causing parasite (Ramesh 
et al. 2007). 
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1.6 Anti-leishmanial drug treatments  
The frontline treatments used against leishmaniasis are pentavalent antimonials but their use 
is problematic: these therapies are generally toxic with clinical resistance on the rise, and 
often require medical supervision when administered (Sundar 2001, Guerin, Olliaro et al. 
2002). Additionally, there is a wide variation in species sensitivity. Recent progress has been 
made in developing new leishmanicidal agents with several compounds such as amphotericin 
B, paromomycin and miltefosine coming to market. However, there are issues associated 
with these as some have teratogenic properties (thus limiting who can use these treatments), 
toxicity and cost (Berman 2005, Croft et al. 2012). 
 
 
Figure 1.6.1: Structures of drugs used against leishmaniasis 
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1.6.1 Pentavalent antimonial drugs 
Antimonial-containing compounds have been used as the frontline treatment of leishmaniasis 
for nearly 70 years following their introduction in 1945. Several variants are available 
including sodium stibogluconate (Pentostam
®
) or meglumine antimoniate (Glucantime
®
) with 
cheaper generic brands now in circulation (Moore et al. 2001). These are administered as a 
slow intravenous infusion (Pentostam
®
; manufactured by GlaxoSmithKline) or intramuscular 
injection (Glucantime
®,
 manufactured by Aventis) at 20 mg kg
-1
 day
-1
 for 20-40 days 
depending on the Leishmania species and disease pathology (Guerin, Olliaro et al. 2002, 
Minodier et al. 2007). This class of treatments has a number of side effects, exacerbated by 
the long course treatment. These side effects include but are not limited to cardiotoxicity (in 
7-10% of VL patients in Bihar state), hepatitis, pancreatitis, myalgias, fatigue, headache, 
nausea and can also result in treatment-related death (in 5-10% of VL patients in Bihar state) 
(Wiser 2010). Resistance to these drugs is steadily rising with this being a particular problem 
in certain states of India. For example, up to 60% of VL cases in Bihar are non-responsive to 
antimonial-based therapies (Croft et al. 2006). 
 
The precise mode of action for Pentostam
®
 and Glucantime
®
 is unknown but both appear to 
function as prodrugs relying on conversion of the antimony atom from its inactive 
pentavalent state (SbV) into its cytotoxic trivalent (SbIII) form. Whether this activation step 
occurs in the mammalian host cell or the parasite is unclear. It has been shown that the 
Leishmania amastigotes express several enzymes such as thiol-dependent reductase and 
arsenite reductase that can catalyse this reaction (Denton et al. 2004, Zhou et al. 2004) 
although quite how the pentavalent antimonial compound is transported into the intracellular 
parasite is unknown. In contrast, uptake of the trivalent form by the parasite may involve an 
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aquaglycerporin (Gourbal et al. 2004), although how the SbV prodrug is activated within the 
host cell or at the amastigote surface remains unknown. 
 
Based on laboratory selected drug-resistant parasites, it has been postulated that once 
activated, antimonials mediate their leishmanicidal activity by interfering with the pathogens 
thiol biology. Cells selected for antimonial resistance display elevated levels of 
trypanothione, a parasite specific conjugate consisting of two molecules of glutathione linked 
together by spermidine (Fairlamb et al. 1985). These cells possess an amplification of genes 
associated with trypanothione synthesis and/or elevated levels of a metal-thiol efflux pump 
(Dey et al. 1996, Grondin et al. 1997, Haimeur et al. 1999, Haimeur et al. 2000). 
Additionally, inhibition of the trypanothione synthesis pathway in resistant lines results in 
reversal of this phenotype (Haimeur, Brochu et al. 2000). Together this has led to the 
proposal that the antimonial drug interacts with trypanothione to form a metal-thiol 
conjugate. Elevation in the levels of trypanothione and/or the metal-thiol efflux pump results 
in this complex being rapidly and efficiently extruded from the intracellular milieu before it 
(either the SbV or SbIII form) can interact with protein thiol targets such as trypanothione 
reductase (Ouellette et al. 2004). 
 
1.6.2 Pentamidine 
Pentamidine is an aromatic diamidine first used to treat leishmaniasis in 1952. It is 
administrated through a series of intravenous or intraperitoneal injections at 4 mg kg
-1
 per 
dose, with 15-30 doses given over a course of 3-4 weeks (Guerin, Olliaro et al. 2002). 
However, the widespread use of pentamidine against leishmaniasis has been limited primarily 
due to the route of its administration and its off target effects: pentamidine can lead to serious 
side effects including tachycardia, hypotension, hyperglycemia and hypoglycaemia and less 
 24 
 
severe toxicities that promote nausea, vomiting and diarrhoea (Helmick et al. 1985, Jha et al. 
1991, Thakur et al. 1991, Berman 1997). As a result this diamidine is only recommended for 
use in locations where antimonial resistance is prevalent or where antimonials cannot be 
given to a patient (Nacher et al. 2001). 
 
The precise mode of action of pentamidine is unclear. It is thought to be taken up via a carrier 
protein which has higher affinity for the drug in amastigotes than it does in promastigotes 
although the precise nature of this transporter has yet to be determined (Coelho et al. 2007). It 
has been suggested that once within the parasite, pentamidine enters the mitochondria via a 
permease where this organic cation binds to the negatively charged, AT rich sequences of the 
DNA network of kinetoplast (Cory et al. 1992, Basselin et al. 1998). This interaction 
promotes disintegration of the mitochondrial genome and consequently triggers cell death. 
Some strains of Leishmania particularly in India have developed resistance to this drug 
possibly due to a lack of accumulation of pentamidine in the mitochondrion of resistant cells 
(Basselin et al. 2002, Mukherjee et al. 2006).  
 
1.6.3 Amphotericin B 
This polyene agent, originally developed as an anti-fungal, has been shown to be highly 
effective in the treatment of antimonial-resistant VL (Thakur et al. 1996). In fact, it is the 
drug of choice in India due to the emergence of resistance to other classes of treatments. It is 
administered intravenously, at 7-10 mg kg
-1
 for up to 20 days. This dose is limited by 
amphotericin B’s toxicity, with the observed side effects including uraemia (accumulation of 
nitrogen-based waste products in the blood), nephrotoxicity (kidney toxicity), anaemia and 
hypokalaemia (low blood potassium) (Davidson 1998, Bates et al. 2001, Harbarth et al. 
2002). Additionally, it requires slow infusion over several hours, thus increasing costs due to 
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the requirement for hospitalisation (Eriksson et al. 2001). The mode of action of 
amphotericin B is proposed to involve binding to ergosterol present in the Leishmania cell 
membrane, with reduction in the relative levels of ergosterol in L. donovani mediating 
resistance to amphotericin B in the parasite (Mbongo et al. 1998). This promotes formation of 
aqueous and non-aqueous (ionic) pores that leads to osmotic instability and destruction of the 
ion balance of the cell subsequently followed by cell death (Cohen 2010). 
 
Recently, different liposomal and micelle amphotericin B formulations such as AmBisome
®
 
have been developed resulting in treatments that have improved efficacy against Leishmania 
and significantly reduced toxicity (Bern et al. 2006). AmBisome
®
 is intravenously injected at 
10 mg kg
-1
 in 5-10 doses over 10 days. However, AmBisome
®
 is very expensive, with a 
course of the drug costing up to US$ 2500 (each 50 mg ampoule costs US$ 18, Meheus et al. 
2010), thus restricting their use in developing countries. Promisingly however, there are 
currently public-private partnerships in effect with the pharmaceutical company Gilead, in an 
effort to reduce the cost of AmBisome
® 
to the developing world. 
 
1.6.4 Miltefosine 
Miltefosine is an orally administrated alkyl phosphocholine-based drug originally synthesized 
as an anti-cancer drug but shown to have good antiparasitic properties (Unger et al. 1989). It 
has excellent in vivo activity against L. donovani, with clinical trials revealing it to be highly 
effective against both CL and VL (Croft et al. 1987, Soto et al. 2006, Bhattacharya et al. 
2007). Currently, miltefosine is registered for use in India (2002), Germany (2004) and 
Colombia (2005). Drug regimes take 28 days to complete at 100 mg kg
-1
 day
-1
, and the 
observed side effects, typically nausea and diarrhoea, are generally mild and transient 
(Sundar et al. 2004). However, a significant drawback in the use of miltefosine is 
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teratogenicity issues, prohibiting its use in women of child-bearing age unless they are taking 
contraceptives (Berman 2005). 
 
Precisely how miltefosine mediates its leishmanicidal activity is poorly understood, although 
suggestions accounting for its mode of action have been proposed. One hypothesis suggests 
that it may target alkyl-specific-acyl CoA acyltransferase, a key enzyme involved in ether 
lipid formation (Lux et al. 2000), with inhibition of this enzyme leading to plasma membrane 
instability. Alternatively, miltefosine may promote an apoptotic-like pathway that triggers 
parasite killing, but how this occurs has yet to be fully elucidated (Verma et al. 2004). 
 
1.6.5 Paromomycin 
Paromomycin is an aminoglycoside antibiotic derived from Streptomyces rimosus (Davidson 
et al. 2009). It is available in two formations as a 20% paromomycin topical ointment used in 
cases of CL (Stanimirovic et al. 1999), or as intramuscular injections to treat VL. In the case 
of VL, the standard dose is 15 mg kg
-1
 day
-1
 for 21 days, though an increased dose of 20 mg 
kg
-1
 day
-1
 for 21 days or increased duration of 15 mg kg
-1
 day
-1
 for 28 days can boost efficacy 
for some patients (Musa et al. 2010). Paromomycin is thought to mediate its leishmanicidal 
activity by inhibition of protein synthesis and it has been shown that it interacts with 
ribsomes, and can induce misreading of codons on mRNA transcripts on the leishmanial 
ribosome, preventing accurate translation and promoting the synthesis of mutant proteins 
(Maarouf et al. 1995, Fernandez et al. 2011). Accumulation of these mutant proteins might 
then compromise the survival of the parasite (Fernandez, Malchiodi et al. 2011). Although 
this course of treatment appears to be very promising, confusing and conflicting data in the 
literature show extreme variations in efficacy. For example, a recent meta-analysis of CL 
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treatment data (Kim et al. 2009) found percentage cure figures ranging from 4% (Moosavi et 
al. 2005) to 93% (Correia et al. 1996).  
 
1.6.6 Imiquimod 
A separate category of antileishmanials modulate the immune system in order to allow the 
patient to repel the infection, usually in conjunction with other drugs listed previously. The 
most commonly used of these is the imidazoquinoline imiquimod. This compound has 
exhibited antileishmanial properties through the induction of nitric oxide production in 
macrophages in experimental models (Buates et al. 1999). Furthermore, clinical studies have 
shown potential in using a topical imiquimod cream together with pentavalent antimonials 
(Arevalo et al. 2001, Miranda-Verástegui et al. 2005, Firooz et al. 2006), leading the World 
Health Organisation to include the use of imiquimod with pentavalent antimony as a second-
line therapy in New World CL in its guidelines (WHO 1999). 
 
1.7 Leishmania cell biology 
Leishmania are microorganisms that share a number of key cellular features with other 
eukaryotes – they contain a nucleus, endoplasmic reticulum, Golgi apparatus etc. However, 
as with other members of the Kinetoplastida class of protozoa, they also harbour a number of 
unusual structures whose role/number can change during the course of the parasite’s complex 
life cycle (Figure 1.7.1): for example, a lysosomal-like organelle named the megasome is 
present only in the amastigote form of certain species of Leishmania (Alexander et al. 1975). 
A few of these unusual features are discussed below (though this is not an exhaustive 
discussion). 
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Figure 1.7.1: Schematic representation of a Leishmania promastigote cell 
Important organelles are highlighted, including the glycosomes, flagellum and flagellar 
pocket, and the single mitochondrion with kinetoplast, supplied by Dr S. Wilkinson. 
 
1.7.1 Glycosome 
Glycosomes are small, spherical (~0.27 μm in diameter) organelles that contain an electron 
dense, proteinaceous matrix bounded by a single lipid bilayer. Evolutionarily, they are related 
to glyoxysomes of plants and peroxisomes of all other eukaryotes, with many of the enzymes 
and permeases typically found in these other microbodies also found in glycosomes (Borst 
1989). As such, glycosomes fulfil many of the functions of peroxisomes including protection 
against oxidative stress, β-oxidation of fatty acids and ether lipid synthesis (Opperdoes et al. 
1984, Wiemer et al. 1996, Heise et al. 1997, Wilkinson et al. 2002, Dufernez et al. 2006). 
Uniquely, they are the site where a number of important metabolic pathways including purine 
salvage, pyrimidine biosynthesis, gluconeogenesis and pentose phosphate pathway are 
compartmentalised (reviewed in Michels et al. 2006). Additionally, glycosomes also contain 
the first seven enzymes involved in glycolysis. Compartmentalisation of this pathway, 
coupled with the low permeability exhibited by the glycosomal membrane, allows for 
segregation of metabolites between this organelle and the cytosol, features that may account 
for the very high glycolytic fluxes displayed by Kinetoplastid parasites (Opperdoes et al. 
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1976, Fairlamb et al. 1980). However, it must be noted that most glycosomal studies have 
been conducted on T. brucei, particularly the bloodstream-form. As this parasite stage lacks 
mitochondrial cytochrome-dependent respiratory chains, it effectively behaves as an anaerobe 
relying on substrate level phosphorylation (i.e. glycolysis) for ATP production. 
Consequently, T. brucei bloodstream-form cells contain up to 240 glycosomes, which 
representing around 4-8 % of the cell’s volume (Opperdoes, Baudhuin et al. 1984). For other 
trypanosomatids, as few as 10 glycosomes per cell have been recorded (L. mexicana 
amastigotes, Coombs et al. 1986) suggesting that these organelles potentially have subtle 
functions in different parasites. 
 
1.7.2 Flagellum and flagellar pocket 
Several life cycle stages of Leishmania possess a single whip-like appendage called the 
flagellum that emerges from the cell body via an invagination of the plasma membrane 
known as the flagellar pocket. The flagellum has a 9+2 microtubule axoneme, as found in 
other flagellated eukaryotes, supported by a paracrystalline structure called the paraflagellar 
rod unique to trypanosomatids (Ginger et al. 2008, Ralston et al. 2008). In addition to 
functioning as a locomotory organelle, the flagellum also has a series of other roles ranging 
from acting as a sensor that samples the surrounding environment, as an attachment site 
(replicating promastigotes readily adhering to insect gut epitheilial cells) and polarity marker 
(intracellular amastigote cells use their short stubby flagellum to orientate themselves in the 
macrophage phagolysosomes) (Warburg et al. 1989, Piper et al. 1995, Burchmore et al. 2003, 
Figarella et al. 2007, Bates 2008, Ginger, Portman et al. 2008, Gluenz et al. 2010). 
 
The flagellar pocket is a separate and specialised compartment in its own right, having a 
distinct microtubular structure from the rest of the plasma membrane (Lacomble et al. 2009). 
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In T. brucei, the normal plasma membrane, known as the “pellicular plasma membrane”, 
contains an underlying dense network of microtubules known as the subpellicular 
microtubules which are largely absent from the flagellar pocket (Lacomble, Vaughan et al. 
2009). This arrangement facilitates vesicular trafficking into (endocytosis) and out of 
(exocytosis) the cell, with the structure playing key roles throughout the life cycle of the all 
trypanosomatid parasites ranging from immune evasion, mammalian cell invasion to 
nutrient/co-factor uptake (Overath et al. 1997, McConville et al. 2002, Kima 2007, Silverman 
et al. 2010).  
 
1.7.3 Mitochondria and kinetoplast 
All Leishmania contain a single, highly branched mitochondrion that has a dense matrix and 
sparse, thin, irregularly distributed cristae (de Souza et al. 2009). Like other mitochondria, 
they contain systems for oxidative energy production, as well as for the synthesis of iron-
sulphur clusters and key metabolites (ter Kuile 1994, Kakkar et al. 2007, Saunders et al. 
2010, Alfonzo et al. 2011, Serricchio et al. 2011). Mitochondria are also considered as a 
reservoir for components involved in apoptosis (programmed cell death) (Shaha 2006). 
 
As with mitochondria from other eukaryotes, the Leishmania organelle contains its own 
genome. This genome is housed in a defined bar-like region called the kinetoplast which 
consists of a network of concatenated, circular DNA, called the kDNA. Based on size and 
copy number kDNA can be split into two types. One set of kDNAs, known as maxicircles, 
are between 20-40 kb in size with approximately 40-50 copies per mitochondrion. They 
contain several genes found in the mitochondrial genomes of other organisms such as rRNA 
genes, and genes encoding for metabolic enzymes that function in this organelle. In contrast, 
the second type of kDNA, known as minicircles, are between 0.5-1.5 kb in size and have a 
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high (5000-10,000) copy number per genome (Simpson 1973, Liu et al. 2005, de Souza, 
Attias et al. 2009). At a sequence level they are highly variable and encode for specialised 
RNA molecules called guide RNA (gRNA) (Stuart et al. 2005). 
 
In many cases the genes present on the maxicircles are incomplete and classed as 
pseudogenes (also known as cryptogenes). In a process known as RNA editing, the 
“defective” genes undergo transcription to form a pre-mRNA (Perry et al. 1991, Benne 
1993). Under the direction of specific gRNAs encoded by minicircle kDNAs, the pre-mRNA 
serves as a template for a protein complex called the “editosome” (Blum et al. 1990, Worthey 
et al. 2003). This acts to modify the transcript by the insertion or deletion of uridine residues 
to form a mature mRNA which is subsequently transcribed to produce a functional 
mitochondrial protein (Alfonzo et al. 1997). 
 
1.8 Trypanosomatid genetics 
1.8.1 Trypanosomatid genomics 
In 2005, the L. major, T. brucei and T. cruzi genome sequences were published (Berriman et 
al. 2005, El-Sayed et al. 2005, Ivens et al. 2005). Comparison of their gene content and 
organisation revealed that these three genomes share a conserved core of around 6200 genes 
arranged in long, syntenic polycistronic clusters (El-Sayed et al. 2005) (Figure 1.8.1). Most 
differences between these genomes were found in genes that encode for species-specific life 
cycle adaptations and in their retroelement content (El-Sayed, Myler et al. 2005). 
 
The genome of L. major (strain MHOM/IL/80/Friedlin) is diploid, with a haploid content of 
32,816,678 bp and having on average a 59.7% GC content. These sequences are arranged 
across 36 chromosomes that vary in size from 0.3 to 2.5 Mb and consists of 911 RNA genes, 
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39 pseudogenes, and 8272 protein-coding genes (Wincker et al. 1996). Of these, 3083 
protein-coding genes appear to fall within 662 putative families of related genes, with a mean 
gene density of 252 genes per Mb (Ivens, Peacock et al. 2005). Recently, the genomes of 
several other Leishmania species (L. infantum, L. braziliensis, L. mexicana and L. tarentolae) 
have been sequenced with these all displaying a high degree similarity in terms of gene 
sequence and order to each other (Peacock et al. 2007, Rogers et al. 2011, Raymond et al. 
2012). 
 
Figure 1.8.1: Schematic diagram of Leishmania chromosomal architecture 
A standard Leishmania chromosome contains many long, unidirectional, polycistronic arrays 
of genes. At several points along the chromosome there are “strand switch” sites, both 
convergent and divergent, where the direction of the polycistronic array changes. 
 
1.8.2 Trypanosomatid gene expression 
Due to the heteroxenous nature of many kinetoplastid (T. brucei, T. cruzi, and Leishmania 
spp) parasites, large alterations in protein expression levels are required in order for these 
pathogens to survive the different environments they encounter during their complex life-
cycles. Unlike most eukaryotes, the regulation of gene expression by these parasites generally 
does not rely upon transcription through the activation/repression of gene specific promoter 
regions. Instead, the arrangement of genes in the trypanosomatid genomes appears to 
facilitate the transcription of long, continuous, unidirectional, polycistronic arrays, with 
regulation of gene expression mainly occurring at a posttranscriptional level (Clayton et al. 
2007). The genes within these arrays generally have unrelated functions and therefore do not 
conform to the operon arrangement as observed in prokaryotes (Clayton 2002). The gene 
arrays are separated by short AT-rich “strand switch regions”, or SSRs, which have a 
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distinctive secondary structure and are postulated to be the site where transcription is 
initiated, possibly driven by epigenetic factors (Tosato et al. 2001, Puechberty et al. 2007; 
Siegel et al. 2009, Thomas et al. 2009). Through a process of trans-splicing and 
polyadenylation, the polycistronic mRNA transcripts are processed into functional, single 
gene mRNA transcripts ready for translation (Clayton and Shapira 2007 and Figure 1.8.2). 
The fine tuned expression necessary for the different parasite life cycle stages, as exemplified 
by genomic and proteomic studies (Cohen-Freue et al. 2007, Pescher et al. 2011), can be 
regulated via a number of different mechanisms ranging from the processing of the matured 
mRNA, its subsequent export from the nucleus, the stability of the mature mRNA, regulation 
of translation, and then finally regulation of the protein itself, through post-translational 
modification, for example (Clayton and Shapira 2007, Kramer 2012). 
 
 
Figure 1.8.2: Schematic diagram showing the posttranscriptional processing of 
polycistronic RNA into functional mRNA in Leishmania. 
 
1.8.3 Genetic manipulation of Leishmania 
Currently, a substantial “toolbox” of reverse genetic techniques is available to investigate the 
biology of Leishmania genes within the parasite itself (Roberts 2011). These methodologies 
rely on using electroporation-based approaches to introduce genetic material into the target 
organism, with recent “nucleofection” developments in trypanosomes greatly increasing 
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efficiencies (Alsford et al. 2011, Coustou et al. 2012). DNA constructs, designed to facilitate 
gene deletion, over expression and protein localisation, can either integrate into the nuclear 
genome by homologous recombination or be maintained as episomes – for example, pTEX  
(Kelly et al. 1992). To generate stable cell lines, recombinant parasites are selected by 
exerting an appropriate drug pressure such that only cells engineered to express an 
appropriate drug resistance cassette survive. Several selectable marker systems are now in 
use with Leishmania and include G418/neomycin phosphotransferase, blasticidin/blasticidin-
S deaminase, puromycin/puromycin N-acetyl-transferase and hygromycin/hygromycin 
phosphotransferase (Cruz et al. 1990, Cruz et al. 1991, Freedman et al. 1993, Goyard et al. 
2000). To drive expression of such markers, or other genes of interest, correct mRNA 
processing must occur within the parasite. This is achieved by incorporating trans-splicing 
and polyadenylation DNA sequences either side of the marker gene. Such sequences are 
generally derived from homologous (the Leishmania species under study) or heterologous 
(from other Leishmania or Trypanosoma species) housekeeping genes such as α-/β-tubulin or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  
 
Using transfection techniques, there are many ways in which the expression level of a target 
gene can be modulated. Exogenous copies of such a gene can be cloned into either integrative 
or episomal expression vectors that when introduced into the parasite result in expression of 
the target DNA sequence (Wilkinson et al. 2008). This basic approach can be modified such 
that tagged versions of the protein can be expressed with the recombinant lines facilitating 
sub-cellular location or protein purification. Several peptide tags are available for a selection 
of different applications including purification/affinity tags such as the poly(His) tag, 
fluorescent tags such as the green and red fluorescent proteins (GFP and RFP), and epitope 
tags such as 9E10 (c-myc) and the HA-tag (Fritze et al. 2000, Liu et al. 2001, Chen et al. 
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2005). Alternatively, a gene of interest can be deleted from the parasite genome through 
targeted, homologous gene replacement (Wilkinson, Taylor et al. 2008). Due to the diploid 
nature of the Leishmania parasites, any single copy gene would have to go through two 
separate rounds of gene replacement to completely remove the gene from the genome (Cruz 
and Beverley 1990, Cruz, Coburn et al. 1991). However, attempting this on essential genes 
often results in selection of aberrant cells that have undergone chromosomal amplification or 
aneuploidy (such as trisomy), due to the unusual plasticity of the Leishmania genome 
(Bastien et al. 1992; Cruz et al. 1993). Against this backdrop, null mutant lines can be 
constructed in cells expressing an ectopic copy (integrated elsewhere in the genome or as an 
episome) of the target gene. The loss of the ectopic copy expression in such a null 
background can then be followed in the absence of selective pressures. This can be achieved 
by directly monitoring the rate of loss of an episome for example by Southern hybridisation. 
Alternatively, expression of the ectopic gene could be under the control of a regulator, with 
tetracycline generally used as an inducer, or under the control of the untranslated DNA 
sequences that normally flank a developmentally regulated gene. The former situation has 
been used extensively with T. brucei and, although described for some species, is not widely 
used for Leishmania (Clayton 1999). For the latter mechanism, the 3’UTR’s of several genes 
such as amastin and A2 have been used to “suppress” expression of a target gene in one life 
cycle stage with expression enhanced in other parasite forms (Charest et al. 1994, Rochette et 
al. 2005). 
 
In other organisms RNA interference (RNAi) has been extensively used to reduce the 
expression level of a target protein. RNAi is a cellular process in which the introduction of a 
specific sequence of double-stranded RNA results in the removal of the corresponding, 
specific mRNA from the cell. This naturally results in the rapid “knock down” in the 
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production of the target protein that the mRNA encoded. Again, this approach is extensively 
used in T. brucei research (Kolev et al. 2011). Whether it can be used to investigate gene 
function in Leishmania appears to be species dependent as most Leishmania species lack the 
biological machinery required to drive the RNAi process whereas others, notably L. 
braziliensis and others subgenus Viannia parasites, appear to express activities that facilitate 
this pathway (Lye et al. 2010). 
 
1.8.4 Genetically modified reporter parasites used in Leishmania screening 
The classical drug screening methods when determining the potency of a compound against 
Leishmania generally involves the direct quantification of parasite loads using light 
microscopy. To facilitate this, cells are usually stained with a dye such as Giemsa or 
Leishman, particularly when evaluating pathogen loads within a host cell. However, these 
systems are laborious, time consuming and not readily amenable to high throughput analysis. 
Consequently, several genetically modified Leishmania cell lines have been developed that 
express a given reporter protein whose activity can be readily assayed and measured as a 
function of parasite load. One of the first reporter expression systems developed for use in 
Leishmania was based on β-galactosidase, encoded lacZ gene from E. coli, and initially used 
as a validation assay for parasite transfection protocols (LeBowitz et al. 1991). However, it 
was not until 2003 when this was applied to drug screening (Okuno et al. 2003). Here, L. 
amazonensis promastigotes were stably transfected with a lacZ-containing episomal construct 
with expression of the reporter maintained in the mammalian life cycle stages. Tagged cells 
were readily visualised by fluorescence and light microscopy in the presence of the 
chromogenic substrate 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside. However, this 
system is not without disadvantages as it is not particularly sensitive, the episomal copy 
number (and hence reporter expression levels) varies from cell to cell, while some 
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mammalian cell types (including macrophages) express endogenous levels of β-galactosidase. 
In an effort to improve this system, the expression of other enzymatic reporters including β-
lactamase has been adapted for use with Leishmania, but these too suffer from sensitivity 
problems as compared to other systems (Buckner et al. 2005). 
 
Modifying Leishmania cell lines with GFP is now commonplace (Kamau et al. 2001, Singh 
et al. 2004, Singh et al. 2009, Bolhassani et al. 2011, Pulido et al. 2012), as this method is 
cheap, safe, simple, and allows for easy kinetic monitoring. However, there are issues of 
sensitivity associated with GFP too. Particularly in its native form, GFP (and other 
fluorescent proteins) does not give the sensitivity of reporter gene systems based on an 
enzymatic reaction. In fact, miniaturisation of an assay into a 96-well microtitre plate proved 
problematic due to this relatively low fluorescent signal, restricting the application of 
fluorescent proteins to high throughput drug screening regimens. Consequently in 2003 a 
multimeric form of GFP was developed that proved sensitive enough for analysis on 96-well 
plates (Chan et al. 2003). Another problem is that most GFP reporter systems use episomes, 
and these are not stably maintained within Leishmania. This resulted in cell lines that 
required regular addition of the relevant selection antibiotic to keep stable and quantifiable 
levels of fluorescence. This particular issue has been overcome recently, with a stably 
integrated GFP-encoding gene into both New and Old World Leishmania species allowing 
for longer studies without the need for the addition of selection antibiotics (Singh, Gupta et 
al. 2009, Bolhassani, Taheri et al. 2011). 
 
The third reporter gene system used in Leishmania relies upon the parasite expressing the 
luciferase gene whose activity can be monitored via light detection. Several luciferase-based 
episomal and integrative DNA constructs have been transfected into many different species 
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of Leishmania with stable cell lines readily obtained (Roy et al. 2000, Lang et al. 2005). 
Using luciferin as substrate, activity of the reporter can be monitored by detection of the 
resultant luminescence signal using a luminometer. This method is sensitive, rapid, 
reproducible and compatible with high throughput screening with all parasite stages 
amenable to analysis. However, disadvantages with this procedure include the requirements 
for expensive lysis and luciferin-containing assay buffers. Recent developments in imaging 
technologies coupled with novel luciferase variants now permit the imaging of parasite 
populations in a live animal model in real time (Thalhofer et al. 2010, Michel et al. 2011). 
Using such a resource, it will be of great interest to follow a course of an infection in vivo in 
the presence of drug treatment. 
 
1.9 Nitroaromatic compounds 
1.9.1 An overview of the nitroaromatics 
Nitroaromatic compounds encompass a wide range of compounds characterised by at least 
one nitro-group attached to an aromatic ring (Figure 1.9.1) (Grunberg et al. 1973). While 
some occur naturally, such as the broad spectrum antibiotics chloramphenicol and azomycin, 
most are synthetic, created through the production of plastics, dyes, solvents, pesticides, food 
additives, explosives and pharmaceuticals (Spain 1995, Peres et al. 2000, Rieger et al. 2002, 
Roldan et al. 2008). A large number of nitroaromatic compounds have medicinal use, 
particularly as antibiotics. These include nitrofurans and nitroimidazoles, two classes of 
broad spectrum antimicrobials that can be used to treat urinary and gastrointestinal tract 
infections. However, the use of many nitroaromatics have been discontinued in Europe and 
USA due to reports of mutagenicity (Takahashi et al. 2000, Padda et al. 2003, Hiraku et al. 
2004; reviewed in McCalla 1983), but elsewhere, these drugs are commonly prescribed. 
These concerns lead to a degree of paranoia and scepticism across the entire range of 
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nitroaromatics, even in cases where a compound’s toxicology had not been investigated. As 
stated by the Nobel laureate pharmacologist Sir James Black “the most fruitful basis for the 
discovery of a new drug is to start with an old drug” (Raju 2000). Based on this philosophy, 
there has been a renaissance in looking at the medicinal value of nitroaromatics, stimulated 
by the rise in antimicrobial drug resistance to existing chemotherapies and as a means to 
developing new anti-tumour drugs. This has shown that several nitro-based compounds are 
not as toxic as initially thought (Trunz et al. 2011, Tweats et al. 2012) while retrospective 
analysis of clinical trial data coupled with a costing evaluation have resulted in proposals for 
the reinstatement of nitrofurantoin as a treatment for targeting uncomplicated urinary tract 
infections in developed countries (Kashanian et al. 2008, Arya et al. 2009, McKinnell et al. 
2011). Against this backdrop, several other nitroaromatic compounds are currently 
undergoing evaluation for treatments of infectious organisms including PA-824 against 
Mycobacterium tuberculosis (which has now entered phase II clinical trials, Stover et al. 
2000, Diacon et al. 2012, Diacon et al. 2012), and fexinidazole against Trypanosoma brucei 
and Leishmania donovani (Kaiser et al. 2011, Wyllie et al. 2012) while others such as 
SN23862, CB1954 and nifurtimox are emerging as anti-cancer therapies (Denny 2003, Chen 
et al. 2009, Saulnier Sholler et al. 2006, Saulnier Sholler et al. 2009). Additionally, the 
nitrothiazole nitazoxanide is currently the first-line treatment choice for Cryptosporidium and 
Giardia protozoal infections (Abboud et al. 2001, Rossignol et al. 2001, Anderson et al. 
2007). 
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Figure 1.9.1: Structures of common nitro-compounds. 
 
1.9.2 Nitroaromatic compounds as anti-trypanosomatid agents 
The antimicrobial value of nitroaromatic compounds were first reported during the 1940’s 
when nitrofuran-based agents were shown to exhibit cytotoxic activities against a range of 
bacteria (Dodd et al. 1944). This stimulated a series of screening programmes against other 
microorganisms in an effort to find new cures against these infectious agents. One group of 
microbes to come under such scrutiny were protozoan parasites. In the case of trypansomatids 
such as T. brucei, such efforts identified nitrofurazone as a lead compound (Packchanian 
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1955, Evens et al. 1957). Unfortunately, though nitrofurazone was deemed to be effective in 
humans against the parasites, it not only failed to completely remove parasitaemia 
(undesirable due to the possibility of relapse, particularly in immune-compromised patients), 
but also caused several cases of neuropathological toxicity (polyneuritis) that ultimately 
resulted in the discontinuation of these clinical trials (Cancado et al. 1964). However, these 
studies highlighted that other nitroaromatics could be used to combat trypanosome infections, 
with nifurtimox and benznidazole proving the most interesting against Chagas disease 
(Grunberg et al. 1967, Bock et al. 1969).  
 
Nifurtimox ((RS)-3-methyl-N-[(1E)-(5-nitro-2-furyl)methylene]thiomorpholin-4-amine 1,1-
dioxide) is a 5-nitrofuran compound marketed under the name Lampit™ (Bayer AG). Since 
its introduction in 1964, it has represented the front-line treatment for acute Chagas disease 
across South America. This orally administered therapy is given at a dosage of 8-10 mg kg
-1
 
day
-1
 in 3 tablets for up to 120 days. It is readily absorbed from the gastrointestinal tract and 
metabolised in the liver, resulting in a half-life of around 3 hours (Wilkinson and Kelly 
2009). However, gastrointestinal toxicity and central nervous system side effects coupled 
with concerns about its mutagenic/carcinogenic activity, limited efficacy and variation in 
strain susceptibility have all contributed to the discontinuation of use of this drug in  Brazil, 
Argentina, Chile and Uruguay, while in the United States nifurtimox is only available 
following consultation with the CDC (Center for Disease Control) (Hidron et al. 2012). 
Despite this, interest in nifurtimox, in conjunction with the ornithine analogue eflornithine (a 
program known as nifurtimox-eflornithine combinational therapy, or NECT) has been 
renewed over the last decade in the treatment of human African trypanosomasis. Recent trials 
have shown that this combination represents an effective, safe, low cost alternative to other 
existing treatments and has resulted in NECT being added to the World Health Organisation 
(WHO) Essential Medicines List for the treatment of late-stage West African sleeping 
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sickness (Priotto et al. 2006, Checchi et al. 2007). Intriguingly, nifurtimox is also been 
trialled as therapy targeting certain cancers following the serendipitous finding that it is 
effective against paediatric neuroblastoma (Saulnier Sholler, Kalkunte et al. 2006, Saulnier 
Sholler, Brard et al. 2009; Koto et al. 2011, Saulnier Sholler et al. 2011). 
 
Benznidazole (N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide), a 2-nitroimidazole 
marketed under the name Radanil™/Rochagan™ (Hoffman-La Roche), is the current front-
line drug used against early stage Chagas disease. This is administered at 5-10 mg kg
-1
 day
-1
 
in 2 oral doses over a 30-60 day period. As with nifurtimox, benznidazole is readily absorbed 
from the gastrointestinal tract and undergoes first pass metabolism in the liver. This, in 
conjunction with its excretion in urine and faeces, results in benznidazole having a half-life of 
around 12 hours in humans. There is some evidence to suggest that benznidazole is also 
effective against the chronic stage of T. cruzi infection, though these observations tend to be 
anecdotal, with few rigorous trials and meta-analyses (Reyes et al. 2005). To evaluate the 
value of benznidazole against this disease stage, a large international program of clinical 
trials is currently underway, called the BENEFIT (BENznidazole Evaluation for Interrupting 
Trypanosomiasis) project (Marin-Neto et al. 2009). Although benznidazole is considered 
safer than nifurtimox, it is reportedly mutagenic and can still cause a range of side effects 
including agranulocytosis, seizures, dermatitis and polyneuropathy (Castro et al. 1988, Viotti 
et al. 2009). 
 
Following the discovery that nifurtimox and benznidazole are viable treatments for 
kinetoplastid disease, several other anti-trypanocidal screening programs using nitroaromatics 
have been undertaken. Interestingly, these can be broadly divided into two differing 
approaches. For nitroimidazoles, large scale screens have tended to be empirical in nature, 
with different types of compound classes and sub-classes being systematically tested directly 
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against the parasite (De Carneri 1969, Ross et al. 1972, Ross et al. 1973, Ross et al. 1973, 
Ross et al. 1975, Ross et al. 1975, Winkelmann et al. 1977, Winkelmann et al. 1978, 
Winkelmann et al. 1978, Winkelmann et al. 1978). In contrast, many other nitroaromatics 
such as nitrofurans, nitrothiophenes and nitrobenzyl-based agents have been tested in smaller 
scale screens using derivatives designed to interact with parasite-specific metabolic 
pathways, such as trypanothione homeostasis (Cerecetto et al. 1998, Cerecetto et al. 2000, 
Aguirre et al. 2004, Aguirre et al. 2006), sterol biosynthesis (Gerpe et al. 2008, Gerpe et al. 
2009) and purine uptake (Stewart et al. 2004, Baliani et al. 2005, Baliani et al. 2009). Such 
screens produced a number of promising lead structures, including fexinidazole and megazol, 
both of which are effective against T. cruzi and T. brucei in vivo (Filardi et al. 1982, Raether 
et al. 1983, Bouteille et al. 1995). Whereas fexinidazole originally did not progress further 
than animal studies, a significant research effort was made to ascertain the trypanocidal 
mechanism of megazol. These studies demonstrated that megazol enters the parasite by 
passive diffusion, and then undergoes activation by nitroreduction with both 1- and 2-electron 
reduction pathways reported (Viode et al. 1999, Barrett et al. 2000, Wilkinson, Taylor et al. 
2008). Unfortunately, further work showed that megazol causes considerable DNA damage 
to host cells and as a consequent trials with this compound were suspended (Poli et al. 2002, 
Enanga et al. 2003, Nesslany et al. 2004). However, since then progress has been made in 
testing megazol analogues and derivatives in the hope to find similar trypanocidal effects, but 
with lowered mutagenicity (Chauviere et al. 2003, Carvalho et al. 2004, Carvalho et al. 2007, 
Carvalho et al. 2008, Salomao et al. 2010). In Leishmania, trials have been performed using 
nitrofurans (nifurtimox, nitrofurazone and furazolidone for example) but these drugs lacked 
efficacy in animal models or lacked sufficient selectivity toward the parasite (Haberkorn 
1979, Berman et al. 1983, Neal et al. 1988). However, recent screens using novel nitrofuran 
derivatives and other nitroaromatic and nitroheterocyclic compounds including 
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nitroimidazoles and nitrotriazoles have shown some promise (Alipour et al. 2011, 
Papadopoulou et al. 2011, Tahghighi et al. 2011, Tahghighi et al. 2012, Wyllie, Patterson et 
al. 2012).  
 
Recently, the Drugs for Neglected Diseases initiative (DNDi, www.dndi.org) sponsored a 
study which has resulted in the re-evaluation of fexinidazole as a potential treatment for 
human African trypanosomiasis. The DNDi have signed an agreement with the 
pharmaceutical company Sanofi-Aventis for the development, manufacture and distribution 
of this nitroimidazole, and clinical trials are in progress. Torreele et al. (2010) have shown 
that although fexinidazole appears to be mutagenic in the bacterial Ames test, no genotoxicity 
was measured in in vitro, in vivo and ex vivo experiments using mammalian cells (Torreele et 
al. 2010). 
  
1.10 Activation of nitroaromatic compounds 
Antimicrobial nitroaromatic compounds generally function as “prodrugs” and must be 
activated before mediating their cytotoxic effects. This occurs by reduction of the conserved 
nitro group attached to the aromatic ring leading to formation of a nitro anion radical or 
hydroxylamine derivative, reactions catalysed by oxidoreductase enzymes known as 
nitroreductases (NTR) (Figure 1.10.1). As nitroaromatic compounds are rare in nature, 
nitroreductase activity is generally mediated by enzymes that have alternative functions in 
vivo. For example, cytochrome P450 reductase readily mediates the 1-electron reduction of 
many nitro-based compounds including metronidazole, but their biological function involves 
the transfer of reducing equivalents from NADPH to cytochrome P450 (Orna et al. 1989). 
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Figure 1.10.1: Reduction pathway of a nitroaromatic by the nitroreductases 
Shown as an example here, the nitroheterocycle 5-nitrofuran is reduced through a 1e- 
reduction by a type II NTR (downward reaction) to form a nitro anion radical. In anaerobic 
conditions this can be further reduced to the 5-nitrosofuran derivative of the nitroaromatic. 
However, in the presence of oxygen the nitro anion radical species is converted back into the 
original nitro-based substrate, liberating the superoxide anion in a “futile cycle”. 
Consequently type II NTRs are known as “oxygen sensitive”. If the compound is reduced by 
a type I NTR (top reaction), the compound goes through a single step 2e
-
 reduction to the 5-
nitrosofuran derivative. Type I NTRs are thus deemed “oxygen insensitive”. The 5-
nitrosofuran derivative can be further metabolised by another type I NTR-mediated 2e
-
 
reduction to the 5-hydroxylaminofuran derivate. 
 
Based on oxygen sensitivity, flavin cofactor and the nitro reduction product, NTRs can be 
broadly divided into two classes, type I or type II NTRs (Figure 1.10.1). Type I NTRs, 
originally identified as factors that, once lost or expression is reduced, mediates resistance in 
prokaryotes to nitrofuran-based drugs (McCalla et al. 1978, Whiteway et al. 1998 and 
others), are “oxygen insensitive”, FMN-containing enzymes found predominantly in bacteria 
and absent from most eukaryotes, with several protozoan parasites, including trypanosomes, 
being major exceptions (Nixon et al. 2002, Muller et al. 2007, Wilkinson, Taylor et al. 2008, 
Pal et al. 2009). They mediate a series of 2-electron reduction events that convert the 
 46 
 
conserved nitro group to a hydroxylamine derivative via an unstable nitroso intermediate 
(Peterson et al. 1979). This conversion has a major effect on the electron distribution on the 
aromatic ring as nitro groups are electron withdrawing while hydroxylamine substituents are 
electron donating. Dependent on the ring structure, this electronic rearrangement promotes 
distinct fates to the newly formed reduction product. For example, the hydroxylaminofuran 
derivative generated from nitrofurans can be processed to either form a nitrenium ion that 
then promotes DNA adduct formation through esterification with guanine (McCalla et al. 
1971, Streeter et al. 1988, Corbett et al. 1995); generate DNA crosslinking adducts (McCalla, 
Reuvers et al. 1971, Denny 2003); or promote cleavage of the aromatic ring to yield toxic 
nitriles (Gavin et al. 1966, Peterson, Mason et al. 1979, Hall et al. 2011). In contrast, the 2-
hydroxylaminoimidazole derivative generated from 2-nitroimidazoles can rearrange to a 5-
hydroxyl-2-iminoimidazole derivatives via a nitrenium ion form in neutral conditions. 
Through the addition of water this 5-hydroxyl-2-iminoimidazole becomes a 2-amino-4,5-
dihydroxylimidazole intermediate, which can degrade to release glyoxal, a metabolite that 
readily forms adducts with a range of biological molecules, such as amino acid side chains 
and guanosine (Whitmore et al. 1986, Whitmore et al. 1986, Thornalley 2008, Hall et al. 
2012). 
 
In contrast, type II NTRs are ubiquitous, with examples being found across all life forms – 
for example human NADPH:cytochrome P450 reductase (Orna and Mason 1989) and the 
bacterial nitroaryl reductases (Angermaier et al. 1983). They use FAD or FMN as a cofactor, 
and mediate a 1-electron reduction of the conserved nitro group leading to the formation of 
an unstable nitro anion radical (Figure 1.10.1). In the presence of oxygen, type II NTR 
activity is said to be “oxygen sensitive”, the radical can undergo futile cycling to produce 
superoxide anions (O2
.-
) and regenerate the parental compound. This activation process 
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predominates in mammalian cells (Peterson, Mason et al. 1979, Moreno et al. 1982). Under 
hypoxic conditions, a nitroso form can be produced by either the interaction of two nitro 
anion radicals (which also regenerates the parent compound) or by a further 1-electron 
reduction of the nitro anion radical (Moreno, Docampo et al. 1982) (Figure 1.10.1). The 
nitroso form can then promote cellular damage directly or undergo reduction to the 
hydroxylamine derivative which then precipitates the pathways described above for type I 
NTRs (Kedderis et al. 1989, Leitsch et al. 2007). It is proposed that this anaerobic activation 
pathway underlies the basis of selective toxicity for antimicrobial nitroimidazoles such as 
metronidazole and prodrug activation in hypoxic tumours. 
 
Not all nitroreductases fall into these two groups, with several enzymes displaying features 
characteristic of both type I/II NTRs. For example, the mammalian thioredoxin reductase is a 
FAD-containing (type II characteristic) selenoprotein that can reduce nitroaromatic substrates 
by both 1- (type II characteristic) and 2- (type I characteristic) electron reductions; while the 
mammalian NAD(P)H:quinone reductase (NQO1; also known as DT-diaphorase) and 
xanthine oxidase are both FAD-containing (type II characteristic) enzymes that mediate the  
2- (type I characteristic) electron reduction of their target substrate (Knox et al. 1993; Croft 
and Coombs 2003; Cenas et al. 2006). Therefore, not all enzymes follow the above, relatively 
simple classification system. 
 
1.11 Activation of nitroaromatic compounds by trypanosomatids 
Before the report that trypanosomatids expressed type I NTRs, it had been assumed that the 
antiparasitic activity exhibited by the nitroaromatic compounds nifurtimox and benznidazole 
was primarily due to the action of type II NTRs, and thus involved induction of oxidative 
stress. This was supported by observations that trypanosomal extracts when treated with 
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nifurtimox generated superoxide anions and nitro anion radicals, although such findings were 
never noted for benznidazole (Docampo et al. 1979, Docampo et al. 1981, Viode, Bettache et 
al. 1999). Subsequent studies revealed that the 1-electron reduction of nifurtimox in vitro 
could be performed by a range of flavoproteins including trypanothione reductase, 
adrenodoxin reductase, lipoamide dehydrogenase and cytochrome P450 reductase 
(Blumenstiel et al. 1999, Viode, Bettache et al. 1999). This mode of action proved initially 
attractive given that trypanosomes were believed to have a limited enzymatic capacity to 
metabolise reactive oxygen species (Boveris et al. 1980, Fairlamb et al. 1992). However, it is 
now clear that these proposals were incorrect as trypanosomatids do express a range of 
superoxide and peroxide metabolising pathways, with these being distinct from those 
possessed by other eukaryotic organisms (Flohe et al. 1999, Wilkinson et al. 2002, Wilkinson 
et al. 2003, Irigoin et al. 2008). To date the only functional evidence for the involvement of 
the superoxide anion in nifurtimox toxicity is indirect, coming from studies on the superoxide 
dismutase B1 (SODB1) isoform where T. brucei TbSODB1 null mutants and T. cruzi 
TcSODB1 over expressers have been shown to be more susceptible to the nitrofuran than wild 
type cells (Temperton et al. 1998, Prathalingham et al. 2007). Genetic analysis of T. brucei or 
T. cruzi engineered to express altered levels of oxygen-sensitive NTRs activators, for 
example cytochrome P450 reductase or trypanothione reductase, or other components of the 
trypanosomal oxidative defence system, generate parasites that display the same 
susceptibility to nifurtimox as control cells (Kelly et al. 1993, Wilkinson et al. 2000, 
Wilkinson, Meyer et al. 2002, Wilkinson, Obado et al. 2002, Wilkinson et al. 2006, Hall, Bot 
et al. 2011, Hall and Wilkinson 2012). Therefore, as both trypanosomal and mammalian cells 
can undergo futile cycling leading to superoxide anion production, then induction of 
oxidative stress via activation by type II NTRs does not explain nifurtimox’s selectivity 
towards T. brucei or T. cruzi. 
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Based on flavin co-factor, oxygen-insensitive activity, substrate range and inhibition profiles 
it has now been shown that trypanosomes express a type I NTR that displays many of the 
characteristics of its bacterial counterparts (Wilkinson, Taylor et al. 2008). This 
mitochondrially targeted enzyme non-covalently binds FMN as cofactor , utilizes NADH as 
reductant and catalyzes the reduction of a wide range of nitroaromatic and quinone-based 
substrates via a ping-pong mechanism – an activity readily inhibited by dicoumarol 
(Wilkinson, Taylor et al. 2008, Bot et al. 2010, Hall et al. 2010, Hall, Bot et al. 2011, Hall 
and Wilkinson 2012, Mejia et al. 2012; Hall, Meredith and Wilkinson, unpublished). Using in 
vitro drug selection, gene manipulation, biochemical analysis and functional genomics 
approaches, it is now clear that this enzyme plays a key role in the nifurtimox and 
benznidazole activation within trypanosomes resulting in cleavage of the heterocyclic rings to 
produce an unsaturated open chain nitrile or glyoxal, respectively. (Wilkinson, Taylor et al. 
2008, Baker et al. 2011, Hall, Bot et al. 2011, Alsford et al. 2012, Hall and Wilkinson 2012, 
Mejia, Hall et al. 2012). Also, the type I NTR has been implicated in the antiparasitic activity 
of fexinidazole against T. brucei and L. donovani (Sokolova et al. 2010;Wyllie, Patterson et 
al. 2012) and exploited to evaluate whether other nitroaromatic compounds have potential as 
trypanocidal agents (Bot, Hall et al. 2010, Hall, Wu et al. 2010; Hu et al. 2011, 
Papadopoulou, Trunz et al. 2011, Papadopoulou et al. 2012). From such screens, certain 
aziridinyl nitrobenzamide (ANB), nitrobenzyl phosphoramide mustard (NBPM) and 
nitrotriazole derivatives show considerable promise against bloodstream-form T. brucei and 
T. cruzi amastigotes, the parasite stages present in the mammalian host, with many having 
superior selectivity against the pathogen as compared to nifurtimox. 
 
Although the biological function of the type I NTR has yet to be elucidated, its activity is 
essential to infective form trypanosomes: TbNTR cannot be deleted from the genome of 
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bloodstream-form T. brucei unless the cells express an ectopic copy of the gene, while T. 
cruzi epimastigotes TcNTR
-/-
 null mutant lines are unable to infect mammalian cells 
(Wilkinson, Taylor et al. 2008). Based on mitochondrial location and substrate preference it 
appears that the trypanosomal type I NTR may actually function as a NADH:ubiquinone 
oxidoreductase (Wilkinson, Taylor et al. 2008; Hall, Meredith and Wilkinson, unpublished). 
This hypothesis is supported by data obtained from deep sequence analysis of T. brucei 
populations selected for nifurtimox resistance using a whole genome loss of function screen 
which revealed that several “hits” were involved in ubiquinone-9 biosynthesis (Alsford, 
Eckert et al. 2012; Hall, Meredith and Wilkinson, unpublished). If this is the case then the 
trypanosomal type I NTR may be involved in helping to maintain the mitochondrial 
NAD
+
/NADH balance with reducing equivalents transferred onto ubiquinone. 
 
In addition to the above nitroreductase, trypanosomes and Leishmania also express an 
enzyme that shows both typeI/II characteristics. The prostaglandin F2α synthase (PGFS, also 
known as “old yellow enzyme”) from T. cruzi has been shown to mediate the 2-electron 
reduction of selected quinone and nitroaromatic substrates in vivo though only under 
anaerobic conditions (Claes et al. 2009). Intriguingly, this study reported that the enzyme was 
able to metabolise nifurtimox but not benznidazole and appears to contradict a finding which 
indicates that a laboratory selected benznidazole resistant T. cruzi cell line showed a 6-fold 
reduction in TcPGFS expression (Piscopo and Mallia 2006). Interestingly, the same study 
also reported that wild type T. cruzi strains which exhibited “natural” resistant to nifurtimox 
and/or benznidazole do not show this alteration (Piscopo and Mallia 2006). One possibility to 
account for these discrepancies could be a mix up of nifurtimox and benznidazole during the 
biochemical characterisation of TcPGFS. Alternatively the laboratory generated benznidazole 
resistant lines may have undergone significant genotypic alterations in comparison to the 
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initial parental line. This is evidenced as several other proteins/genes including 
cytosolic/mitochondrial tryparedoxin peroxidases, iron superoxide dismutase A, tyrosine 
aminotransferase and ascorbate peroxidase (and others) all show altered expression levels in 
this line (Nogueira et al. 2006, Andrade et al. 2008, Murta et al. 2008, Rego et al. 2008, 
Campos et al. 2009, Nogueira et al. 2012). This has led to confusion as to which event(s) 
actually cause benznidazole resistance and what has arisen as a consequence of the selection 
event. The propensity of T. cruzi to undergo large karyotypic changes has been well 
documented especially in relation to drug selection (Nozaki et al. 1996, Wilkinson, Taylor et 
al. 2008, Mejia, Hall et al. 2012). Therefore, the involvement of PGFS in mediating 
nitroheterocyclic drug resistance has not been adequately demonstrated. 
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2. Research Aim 
Nitroheterocyclic prodrugs such as nifurtimox and benznidazole are used to treat a number of 
parasitic infections. In a significant breakthrough, it has been shown that trypanosomes, 
pathogens related to Leishmania, activate these drugs using a bacterial-like, type-I 
nitroreductase. We now have the opportunity to extend these finding to investigate whether 
the nitroreductase activity can be exploited in the treatment of leishmaniasis.  
 
Our specific aims are to: 
 
1. Determine the biochemical properties of the type I nitroreductase expressed by 
Leishmania major (LmNTR). 
2. Investigate the importance of LmNTR during the parasite’s life cycle. 
3. Develop a reporter system for use in intracellular form Leishmania 
4. Conduct biochemical and phenotypic drug screens using an array of nitroaromatic 
compounds against the Leishmania promastigote and amastigotes. 
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3. Materials and Methods 
3.1 General stocks 
3.1.1 Organisms 
The organisms used in this study are listed in Table 3.1.1 
organism source 
Leishmania major MHOM/IL/80/Friedlin Prof D. Smith, University of York 
Human acute monocytic leukaemia line THP-1 Dr K. Seifert, LSHTM 
Escherichia coli XL-1Blue Laboratory stock 
Escherichia coli BL21+ Laboratory stock 
 
Table 3.1.1: Organisms used in this study 
 
3.1.2 Oligonucleotide primers  
All primers used in this study as listed in Appendix A. These were sourced from Sigma-
Genosys. 
 
3.1.3 Nitroaromatic compounds 
The structures of the nitroheterocyclic and nitrobenzyl compounds used in this study are 
listed in Appendix B. These were provided by Prof Longqin Hu (Rutger’s, The State 
University of New Jersey, USA), Dr Nuala Helsby (University of Auckland, New Zealand), 
Dr Nubia Boechat (Far Manguinhos, Brazil), Dr Priscille Brodin (Institute Pasteur Korea, 
Republic of Korea), Dr Maria Papadopoulou (NorthShore University Health System, USA) 
and Dr Adrian Dobbs (Queen Mary University of London, UK). 
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3.2 Cell culturing 
3.2.1 Maintenance of parasite lines 
The promastigote form of L. major MHOM/IL/80/Friedlin was cultured at 27C in M199 
medium (Invitrogen) supplemented with 20 % (v/v) tetracycline-free foetal bovine serum 
(Autogen Bioclear), 4 mM sodium bicarbonate, 40 mM HEPES pH7.4, 0.1 mM adenine, 
0.005 % (w/v) haemin, 25000 U L
-1
 penicillin and 25 mg L
-1
 streptomycin (all Sigma-
Aldrich). Once prepared with the appropriate supplements the medium was filter sterilised.  
In some experiments the growth medium was solidified with 1.0 % (w/v) Agar No.1 (Oxoid). 
Transformed parasites were grown in or on the above medium containing 20 (solid) or 40 
(liquid) mg L
-1
 G418, 10 mg L
-1
 blasticidin or 20 mg L
-1
 puromycin (all drugs from PAA 
Laboratories Ltd) as appropriate. 
 
The metacyclic promastigote-form of L. major MHOM/IL/80/Friedlin was harvested from 
stationary phase promastigote-form cultures (7-10 days old) using an agglutination technique 
(da Silva et al. 1987), Briefly, cultures were incubated at room temperature for 15 minutes in 
the presence of 50 mg L
-1 
peanut lectin (Sigma-Aldrich). Promastigote parasites were pelleted 
(100 g for 5 minutes) and the metacyclic-containing supernatant removed. 
 
The amastigote-form of L. major MHOM/IL/80/Friedlin was cultured as follows: L. major 
metacyclic promastigotes, harvested as described above, were transferred to a differentiated 
culture of THP-1 cells (Section 3.3.2) and allowed to infect the mammalian cells overnight at 
37°C under a 5 % (v/v) CO2 atmosphere: generally a ratio of 20 parasite cells per mammalian 
cell. The following day, free parasites were removed by extensively washing the monolayer 
(with fresh mammalian growth medium) and then placed in fresh mammalian growth 
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medium. Amastigote parasites were then grown at 37°C under a 5 % (v/v) CO2 atmosphere 
for between 4-6 days. 
 
3.2.2 Maintenance of mammalian lines 
The THP-1 cell line was grown at 37°C under a 5 % CO2 atmosphere in RPMI-1640 medium 
(PAA Laboratories Ltd.) supplemented with 2 mM pyruvate, 2 mM sodium glutamate, 25000 
U L
-1 
penicillin and 2.5 mg L
-1 
streptomycin, 20 mM HEPES (pH 8.0) (all Sigma-Aldrich) 
and 10% (v/v) tetracycline-free-fetal calf serum (Autogen Bioclear).  
 
3.2.3 Maintenance of bacterial strains 
E. coli strains were grown in NZCYM medium (10 g L
-1
 enzymatic casein digest, 1 g L
-1
 
Casamino acids, 5 g L
-1
 yeast extract, 5 g L
-1
 NaCl, 0.98 g L
-1
 MgSO4) (Sigma-Aldrich) 
supplemented with 100 mg L
-1
 ampicillin (Sigma-Aldrich) where appropriate. In some 
experiments, the growth medium was solidified with 1.5 % (w/v) Agar no.1 (Oxoid). 
 
3.2.4 Cell storage  
For long term storage, bacterial strains and Leishmania lines were deposited as frozen stocks 
in liquid nitrogen (parasite lines) or at -80
o
C (prokaryotic strains) in growth medium 
containing 20% (v/v) glycerol (Sigma-Aldrich). Bacterial strains were frozen directly at -
80
o
C in 1.2 mL cryogenic vials (Nunc). Leishmania lines, in 1.2 mL cryogenic vials (Nunc), 
were frozen slowly (1-2 days) to -80
o
C using a Cryo 1°C Freezing Container (Nalgene) 
containing isopropanol (VWR International), then transferred to liquid nitrogen for long-term 
storage. 
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Mammalian (THP-1) cells were frozen in fresh growth medium containing 20% (v/v) 
glycerol (Sigma-Aldrich) at a density of 1 x 10
5
 cells mL
-1
. Frozen stocks were generated as 
described for Leishmania lines using the Cryo 1°C Freezing Container (Nalgene). 
 
Eukaryotic cell lines were revived by quickly thawing the contents of the frozen vial. Thawed 
cells were pelleted by centrifugation for 5 minutes (parasites at 1640 g, mammalian cells at 
100 g) and washed in 10 mL of the appropriate medium. Cells were then re-suspended in 
fresh medium as per normal culturing. 
 
3.3 Anti-proliferation assays 
3.3.1 L. major promastigotes 
All growth inhibition assays were carried out in 96-well plates. L. major promastigotes in the 
logarithmic phase of growth were seeded at 5 x 10
5
 cells mL
-1
 in 200 μL growth medium 
containing different concentrations of drug. After incubation at 25
o
C for 6 days, resazurin 
(Sigma-Aldrich) was added to each well to a final concentration of 12.5 mg L
-1
 (or 2.5 μg per 
well). The plates were then incubated at 27
o
C and the degree of fluorescence noted at 24 hrs 
using a Gemini Fluorescent Plate reader (Molecular Devices) at λEX = 530 nm and λEM = 585 
nm with a filter cut-off set at 550 nm. The colour/fluorescence change resulting from the 
reduction of resazurin is proportional to the number of live cells. Control growth assays were 
also performed in the absence of compound (no drug control, 100 % parasite growth) and the 
absence of cells/compound (background, 0 % parasite growth). These were then used when 
determining the growth concentration of compounds that inhibited parasite growth by 50 % 
(IC50). 
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3.3.2 L. major amastigotes 
All growth inhibition assays were carried out in 96-well plates. THP-1 cells were seeded at 
2.5 x 10
4
 cells mL
-1
 in 200 μL mammalian cell growth medium and incubated at 37oC in a 5 
% (v/v) CO2 atmosphere for 3 days in the presence of 20 ng mL
-1
 phorbol 12-myristate 13-
acetate (PMA) (Sigma-Aldrich): PMA promotes differentiation to macrophage cells 
(Tsuchiya et al. 1980, Fleit et al. 1991). Freshly purified L. major metacyclic cells 
resuspended in mammalian growth medium (5 x 10
5
 cells mL
-1
) were added to twice-washed 
macrophage monolayers resulting in a parasite:macrophage cell ratio of ~20:1. Following 
overnight infection at 37°C in a 5 % (v/v) CO2 atmosphere, the cultures were washed twice in 
mammalian growth medium to remove non-internalized parasites, before addition of 200 μL 
fresh mammalian growth medium containing the compound to be tested. Drug-treated 
infections were incubated for a further 3 days at 37°C under a 5% (v/v) CO2 atmosphere. The 
growth medium was removed and the cells washed twice in fresh medium to remove any 
extracellular parasites. The cells were then lysed in 100 μL lysis buffer (Promega) and 10 μL 
aliquots transferred to a white 96-well plate. Alternatively, for early screening 50 μL aliquots 
of triplicate lysates were pooled into a separate well, and then 10 μL of the pooled lysate 
analysed. Luciferase activity was measured by adding 50 μL enzyme substrate reagent 
(Promega) to the lysed extract and light emission measured on a TopCount luminescence and 
β-plate counter (Perkin Elmer). Control growth assays were also performed in the absence of 
compound (no drug control, 100 % parasite growth) and the absence of cells/compound 
(background, 0 % parasite growth). These were then used when determining the IC50 value 
for each compound. 
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3.3.3 Mammalian cells 
All growth inhibition assays were carried out in 96-well plates. THP-1 cells were seeded at 
2.5 x 10
4
 cells mL
-1
 in 200 μL mammalian cell growth medium and incubated at 37oC in a 5 
% (v/v) CO2 atmosphere for 3 days in the presence of 20 ng mL
-1
 PMA. The THP-1 cells 
were then washed twice in fresh growth medium and incubated for a further 24 hrs. 
Following overnight incubation at 37°C in a 5 % (v/v) CO2 atmosphere, the cultures were 
washed twice in mammalian growth medium to replicate the amastigote proliferation assay, 
before addition of 200 μL fresh mammalian growth medium containing the compound to be 
tested. Drug-treated infections were incubated for a further 3 days at 37°C under a 5% (v/v) 
CO2 atmosphere. The growth medium was removed and the cells washed twice in fresh 
medium before the addition of resazurin (Sigma-Aldrich) in mammalian growth medium to a 
final concentration of 12.5 mg L
-1
 (or 2.5 μg per well). The plates were then incubated at 
37°C under a 5% (v/v) CO2 atmosphere and the degree of fluorescence noted after 24 hrs 
using a Gemini Fluorescent Plate reader (Molecular Devices) at λEX = 530 nm and λEM = 585 
nm with a filter cut-off set at 550 nm. The colour/fluorescence change resulting from the 
reduction of resazaurin is proportional to the number of live cells. Control growth assays 
were also performed in the absence of compound (no drug control, 100 % parasite growth) 
and the absence of cells/compound (background, 0 % parasite growth). These were then used 
when determining the concentration of compounds that inhibited parasite growth by 50 % 
(IC50). 
 
3.4 DNA extraction techniques 
3.4.1 Plasmid DNA extraction 
Small scale plasmid DNA preparations (5-20 μg) were extracted from Escherichia coli using 
the AccuPrep
®
 Nano-Plus Plasmid Mini Extraction Kit (Bioneer), according to the 
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manufacturer’s instructions. Briefly, 5 mL NZCYM containing 100 mg ampicillin L-1 was 
inoculated with the desired E. coli strain and incubated overnight at 37
o
C with vigorous 
aeration. The cells were pelleted (3000 g for 5 minutes), resuspended then lysed in an alkali 
buffer containing RNase A (Bioneer). The pH of the lysate was then adjusted by addition of 
neutralization buffer and the resultant chromosomal DNA/cell debris removed by 
centrifugation (16000 g for 10 minutes). The cleared lysate was passed through a nucleic 
acid-binding spin column such that DNA molecules bind to the silica membrane within the 
column. Salts and precipitates were then removed by a series of centrifugation and ethanol-
based wash steps, before eluting the DNA off the column into 50-100 μL low salt buffer  
(Bioneer) (10 mM Tris-HCl, 1 mM EDTA). Plasmid samples were then stored at -20C. 
 
For larger scale plasmids, DNA preparations (50-100μg DNA) were extracted from 
Escherichia coli using the Qiagen QIAfilter
® Midiprep kit, according to the manufacturer’s 
instructions. Briefly, 100 mL NZCYM containing 100 mg ampicillin L
-1
 was inoculated with 
the desired E. coli strain and incubated overnight at 37
o
C with vigorous aeration. The cells 
were pelleted (3000 g for 10 minutes) and the initial lysis stages performed as described for 
the small scale plasmid DNA extraction protocol. The lysate was then passed through a 
QIAfilter cartridge and the clear extract transferred into a nucleic acid-binding HiSpeedMidi-
Tip. The HiSpeedMidi-Tip contains a resin designed to operate by gravity flow such that it 
retains the plasmid DNA. The DNA was extensively washed in a high salt, isopropanol-based 
buffer maintained at a neutral pH, then eluted off the HiSpeedMidi-Tip using an alkali high 
salt, isopropanol-based buffer. The DNA was then concentrated and desalted by a series of 
isopropanol and ethanol precipitation steps before elution of the plasmid into 250-750 μL low 
salt buffer  (Qiagen) (10 mM Tris-HCl, 1 mM EDTA). Plasmid samples were then stored at -
20C. 
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3.4.2 Parasite genomic DNA extraction 
L. major genomic DNA was harvested using a SDS-based lysis/phenol:chloroform protocol 
adapted from Kelly et al. (1993). L. major cells from 10-50 mL promastigote-form cultures 
were pelleted (1000 g for 10 minutes), washed in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, pH 7.6) (Sigma-Aldrich) and then resuspended in TEN buffer 
(50 mM Tris-Cl pH 8.0, 50 mM EDTA, 50 mM NaCl) (all Sigma-Aldrich) containing 100μg 
mL
-1
 proteinase K  (Sigma-Aldrich). Sodium dodecyl sulphate (SDS) (Sigma-Aldrich) was 
then added to a final concentration of 1 % (w/v), and the mixture incubated at 37
o
C overnight 
or at 54
o
C for 2 hrs. The lysis solution was then gently mixed with an equal volume of phenol 
(Sigma-Aldrich). The aqueous/organic phases were partitioned by centrifugation (3555 g for 
10 minutes) and the aqueous phase collected. An equal volume of phenol:chloroform (1:1) 
(Sigma-Aldrich) was then added to the aqueous phase, mixed and partitioned as described 
above and the aqueous phase retained. If required, the phenol/chloroform step was repeated. 
The DNA containing aqueous phase was finally transferred to a fresh tube. A few drops (~20-
30 L) of 1 M MgCl2 (VWR International) were then added and the chromosomal DNA 
precipitated using an equal volume of isopropanol (VWR International). The resultant fibrous 
material was collected, transferred to a fresh 1.5 mL centrifuge tube, washed with 70 % (v/v) 
ethanol and left to air dry for ~5 minutes. Finally, the genomic DNA was dissolved in EB 
elution buffer (Qiagen) with a concentration of 30 μg mL-1 heat-treated (100oC for 10 
minutes) RNase A (Sigma-Aldrich). 
 
3.5 DNA manipulation techniques 
3.5.1 DNA purification 
DNA fragments (100 base pairs - 10 kilo base pairs) were purified from liquid or from 
agarose gel slices using the AccuPrep
®
 PCR Purification or the AccuPrep
®
 Gel Purification 
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Kits (both Bioneer), in accordance to manufacturer’s instructions. For DNA samples in 
liquid, a high salt buffer was applied to a DNA binding column (containing chaotropic salts). 
Under these conditions, the DNA binds to the silica membrane within the column. Salts and 
precipitates were then removed by a series of centrifugations and ethanol-based wash steps, 
before eluting DNA off the column into 30-50 μL low salt buffer (Bioneer) (10 mM Tris-
HCl, 1 mM EDTA). Samples were then stored at -20C. 
 
To purify a DNA fragment from an agarose gel slice the mass, hence volume, of that slice 
was determined. This was then solubilised in three volumes of Gel Binding Buffer (Bioneer) 
at 50C until the agarose had completely dissolved. One volume of isopropanol was added to 
the solution and the mixture applied to a DNA binding column. The sample was then treated 
as described above when purifying DNA fragments in solution. 
 
Additionally, to prepare for L. major transfection DNA was further purified from the eluents 
described above using ethanol precipitation. Samples were treated with sodium acetate (pH 
5.2) (Sigma-Aldrich) to a final concentration of 0.3M. After mixing, DNA was precipitated 
by adding 2 volumes of cold 100 % ethanol, followed by incubating at -20
o
C for 20 minutes. 
DNA was pelleted in a microcentrifuge at 20000 g for 10 minutes and washed in 70 % 
ethanol. The DNA was spun down again, the majority of supernatant removed, and the pellet 
air dried. The pellet was then dissolved in 5 μL (per transfection) of sterile distilled water. 
  
3.5.2 DNA amplification 
DNA fragments were amplified using polymerases and the associated buffers from New 
England Biolabs (NEB). Each 50μL reaction contained ThermoPol Reaction Buffer (20mM 
Tris-Cl pH8.8, 10mM (NH4)2SO4, 10mM KCl, 2mM MgSO4, 0.1% Triton X-100), 200μM 
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dNTPs, 0.1ng μL-1 template DNA, forward and reverse primers at (typically) 0.5 μM, and 
20U mL
-1
 Taq or VENT Pfu polymerase (depending on application). Additional MgSO4 
(NEB) was supplemented as necessary. 
 
Using a TC-412 thermal cycler (Techne), a standard DNA amplification programme 
consisted of one cycle at 96C for 1 minute (initial melting stage), then 30 cycles of the 
following: 96C for 30 seconds (denaturing stage), 55C for 30 seconds (annealing stage), 
72C for 60 seconds (extension stage). Based on the properties of the oligonucleotide 
primers, the annealing temperature and extension times were varied as necessary. 
 
3.5.3 DNA restriction digestion 
The restriction enzymes used (all from New England Biolabs), along with their relevant 
restriction buffers, are listed in Table 3.5.1. A typical restriction digestion was set up as 
follows. In a total volume of 50 μL, the DNA (5 μL) sample was mixed with 10X restriction 
buffer (5 μL), appropriate for particular enzyme under study, and sterile distilled water (39 
μl). When necessary, bovine serum albumin was supplemented into the reaction to a final 
concentration of 100 mg L
-1
 and the volume of sterile distilled water adjusted accordingly. 
Restriction enzyme (1 μL: 10-20 units) was added and the tube contents consolidated by 
centrifugation. The tube was then placed at an appropriate incubation temperature, generally 
37
o
C, for 1-3 hours. The reaction was halted by addition of a 1/10
th
 volume (5 μL) of loading 
dye (10 mM Tris-HCl pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% 
glycerol, 60 mM EDTA) (Fermentas) to the mixture. 
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restriction enzyme restriction site NEB buffer 
ApaI GGGCC^C 4 
AscI GG^CGCGCC 4 
BamHI G^GATCC 3 
HindIII A^AGCTT 2 
KpnI GGTAC^C 1 
SacI GAGCT^C 1 
SacII CCGC^GG 4 
SalI G^TCGAC 3 
SbfI CCTGCA^GG 4 
ScaI AGT^ACT 3 
XbaI T^CTAGA 4 
XhoI C^TCGAG 4 
 
Table 3.5.1: Restriction enzymes, their restriction sites and corresponding NEB buffer 
used in this study 
The “^” symbol denotes the DNA cleavage site on the single strand shown. 
 
3.5.4 DNA ligation 
A typical DNA ligation reaction was set up as follows. In a total volume of 20 μL, varying 
amounts of vector and insert DNA were mixed with 2 μL 10X T4 DNA ligation buffer (500 
mM Tris-HCl pH 7.5, 100 mM MgCl2, 10 mM ATP and 100 mM dithiothreitol) (New 
England Biolabs) and the volume adjusted to 19 μL with sterile distilled water. T4 DNA 
ligase (1 μL: 400 units) (New England Biolabs) was then added to the mixture and the 
reaction consolidated by centrifugation. The reaction was then incubated at room temperature 
for 2-4 hours, or in certain cases the reaction was placed at 4ºC overnight. The amount of 
vector and insert DNA used in ligation reactions was judged by visualisation on an ethidium 
bromide-stained agarose gel and a molar ratio of 5:1 (insert:vector) for “sticky-end” ligations 
and 10:1 for “blunt-end” ligations was applied. 
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3.5.5 Bacterial DNA transformation 
Competent bacteria were prepared the day of transformation. An overnight culture of E. coli 
was diluted 1:50 into NZCYM medium and grown for around 2 hours at 37ºC (optical 
density at 600 nm was judged between ~0.6-1.0). The cells (1 mL culture) were pelleted at 
3555 g for 5 minutes, re-suspended in 1 mL ice-cold 0.1 M CaCl2 (Sigma-Aldrich) and then 
incubated on ice for 10 minutes. Cells were harvested and the pellet re-suspended in 0.1 mL 
ice-cold 0.1 M CaCl2. The DNA to be transformed was then added to the competent cells: 15-
30 μL of a ligation or 1 μL of pure plasmid DNA. The bacteria/DNA mix was incubated on 
ice for 30 minutes, then heat shocked at 42ºC for 90 seconds before being placed back on ice 
for 2 minutes. Transformation mixes were then transferred on to NZCYM agar plates 
containing appropriate antibiotic selection. Agar plates were then incubated overnight at 37ºC 
to allow colonial growth. 
 
3.5.6 Parasite DNA transfection 
Early to mid-log phase L. major (2 x 10
7
 per transfection) were pelleted at 1000 g for 10 
minutes, washed in PBS, then resuspended in 1 mL PBS and transferred to a 1.5 mL 
microcentrifuge tube. Cells were then spun down at 2000 g for 5 minutes in a microcentrifuge 
and all supernatant removed. The pellet was then resuspended in 100 μL Human T-cell 
Nucleofector
® solution (Lonza), 5 μg of purified DNA (Section 3.5.1) added, and the mixture 
transferred to an Amaxa
®
 cuvette (Lonza), before electroporation in the Amaxa
®
 
nucleofection machine (Lonza) using the program U-033. The DNA/L. major mixture was 
then transferred to prewarmed M199, and incubated for 24 hrs at 27
o
C. 
 
The following day, plates were prepared containing M199 with 1% agar, 1.2 μg mL-1 
biopterin (Sigma-Aldrich) and the necessary selection drug (Section 3.2.1), and equilibrated 
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at 27
o
C for 2 hrs. Transfected parasites were then pelleted at 1000 g for 10 minutes, 
resuspended in 100 μL M199, and spread evenly across the M199-agar plates. The plates 
were sealed with Parafilm
®
 (VWR international) and incubated for 1-4 weeks at 27
o
C until 
colonies appear. Colonies were transferred to liquid M199 and cultured as described in 
Section 3.2.1 for analysis. 
 
3.5.7 DNA sequencing 
For Custom DNA Service sequencing (Eurofins MWG Operon), 0.75-2 μg of template DNA 
and 150 pmol in 15 μL of appropriate oligonucleotide primer were used for sequencing by 
the facility. 
 
3.5.8 Gel electrophoresis: DNA 
Conventional agarose gel electrophoresis was used to fractionate DNA molecules in the size 
range of 200 bp to 10 kbp. The agarose concentration, voltage and run times were altered to 
optimise separation in the desired range. A standard agarose gel was made by dissolving an 
appropriate amount of Molecular Grade Agarose (Bioline) in 1x TAE buffer (40 mM Tris 
base, 40 mM acetic acid, 1 mM EDTA) (Sigma-Aldrich) containing ethidium bromide (0.1 
mg L
-1
) (Sigma-Aldrich). Generally, an agarose concentration of 0.6-1.0% (w/v) was used. 
Following casting, the solidified gel was placed in electrophoresis buffer (1x TAE containing 
ethidium bromide), samples loaded into the wells, including a GeneRuler™ 1 kb DNA ladder 
marker (Fermentas), and a constant voltage applied across the gel. Generally, a run time of 1-
2 hours was employed when using a constant voltage of between 3-5 V cm
-1
. Migration of the 
sample through the agarose matrix was followed by monitoring the bromophenol blue/xylene 
cyanol dye fronts. When the DNA had migrated the desired distance, the gel was analysed on 
a UV transilluminator and documented (Syngene).  
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3.5.9 DNA blotting 
Agarose gels were depurinated for 15 minutes in 0.25 M HCl (VWR International), washed 
in distilled water, and then soaked in denaturation buffer (0.5 M NaOH, 1.5 M NaCl) (both 
Sigma-Aldrich) for 30 minutes. The gel was washed in distilled water, and soaked in 
neutralisation buffer (0.5 M Tris-HCl, 1.5 M NaCl, pH 7.2) for 60 minutes. Nucleic acids 
were transferred to a 0.22 μm MAGNA, nylon membrane (GE Water & Process 
Technologies) by capillary action (Southern 1975) using a 20X SSC solution (3 M NaCl, 0.3 
M Sodium Citrate, pH 7.0) (Sigma-Aldrich) drawn by layers of paper towels for 16-24 hours. 
The gel was placed on a 3MM filter paper ‘wick’ (GE Healthcare) wetted with 20X SSC, 
with the wick base submerged in a bath of 20X SSC. The nylon membrane was cut to the gel 
size and placed on top of the gel, then three sheets of 3MM filter paper again cut to the gel 
size, were placed on top. A pile of paper towels were placed on top of this construct and 
weighted down to compress the “sandwich”. The gel was lined with clingfilm to prevent 
short-circuit of the capillary action. Following transfer, the nucleic acid was cross-linked to 
the membrane using a UV cross-linker (Stratagene), using an auto-algorithm, with the DNA 
side of the membrane facing the UV bulbs. Membranes were stored at 4
o
C in aluminium foil. 
 
3.5.10 DNA probes 
Non-radioactive DNA probes were generated using the PCR DIG Probe Synthesis kit 
(Roche), in accordance to manufacturer’s instructions. Briefly, in a 50 μL reaction, 5 μL 10X 
Expand High Fidelity reaction buffer, containing 1.5 mM MgCl2, was combined with the 
forward and reverse primer (both between 0.1-1 μM), template DNA (approximately 10-100 
pg if using a plasmid) and 5 μL Probe Synthesis Mix containing 2 mM dATP, dCTP and 
dGTP plus 1.3 mM dTTP/0.7 mM DIG-labelled dUTP. The volume of the reaction was 
adjusted to 49.25 μL with sterile distilled water to which 0.75 μL (2.6 units) of DNA 
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polymerase was added. Using a TC-412 thermal cycler (Techne), a DNA amplification 
programme was used consisting of one cycle at 96C for 2 minute (initial melting stage), 30 
cycles of the following: 96C for 30 seconds (denaturing stage), 60C for 30 seconds 
(annealing stage), 72C for 60 seconds (extension stage). A single final elongation step at 
72C for 7 minutes was then carried out. Based on the properties of the oligonucleotide 
primers, the annealing temperature and extension times were varied as necessary. The 
resultant DIG-containing DNA fragment was analysed and purified following gel 
electrophoresis. 
 
3.5.11 DNA hybridisation 
Nylon membranes containing immobilised, single stranded DNA were pre-hybridised with 
5X SSC buffer containing 0.5 % (w/v) SDS, 1X Denhardts solution (200 mg L
-1
 Ficoll
®
 400, 
200 mg L
-1
 polyvinylpyrrolidone, 200 mg L
-1
 Bovine Serum Albumin) (all Sigma-Aldrich) 
and 0.2 mg ml
-1
 denatured, sheared salmon sperm DNA (Sigma-Aldrich) at 65C for 6 hours. 
The DNA probe was denatured (95C for 5 minutes), added immediately to the pre-
hybridisation solution and incubated at 65C overnight. The following morning, a series of 
stringency washes were performed firstly using 2X SSC/0.2% (w/v) SDS solution at 68
o
C for 
15 minutes and then in 0.2X SSC/0.2% (w/v) SDS at 68
o
C for 15 minutes. Hybridisation was 
detected using the DIG Luminescent Detection Kit (Roche) as per the manufacturer’s 
instructions. Briefly, the membrane was treated with an alkaline phosphatase-conjugated α-
DIG antibody, before washing. The membrane was then covered in a solution containing the 
dioxetane CSPD
®
, which is then (after incubation at 37
o
C for 10 minutes) metabolised by the 
alkaline phosphatase in a luminescent reaction. This luminescence is then detected and 
recorded using Amersham Hyperfilm ECL (GE Life Sciences). 
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3.6 Plasmid constructs 
3.6.1 Construction of vectors that facilitate heterologous expression of LmNTR in E. coli 
The LmNTR catalytic domain (residues 87-323) was amplified from the L. major Friedlin 
genome with the oligonucleotide primers LmNTR-1 (forward) and LmNTR-2 (reverse), 
generating a 717 bp fragment. The fragment was purified then digested with restriction 
enzyme combination BamHI+HindIII and cloned into the corresponding sites of the 
expression vector pTrcHis-C (Invitrogen), resulting in pTrcHis-C-ΔLmNTR. 
 
3.6.2 Construction of vectors that facilitate LmNTR gene deletion 
DNA fragments containing the flanks from LmNTR were amplified from L. major Friedlin 
genomic DNA using the oligonucleotide primer combinations LmNTR-9/LmNTR-10 for the 
5’ flank, and LmNTR-11/LmNTR-13 for the 3’ flank. This generated 731 and 1,076 bp 
fragments respectively that were digested with SacI+XbaI and ApaI+KpnI respectively. The 
fragments were gel purified and sequentially cloned on each side of a puromycin resistance 
cassette (PAC) from p5’TbNTRKO-PAC (Dr S. Wilkinson) to form pLmNTRKO-PAC. 
 
The vector pTbNTRKO-BSR (Dr S. Wilkinson) was digested with XbaI+ApaI releasing a 
DNA fragment containing the blasticidin-S deaminase gene plus T. brucei tubulin 5’ and 3’ 
UTRs (required for efficient expression of the drug resistance genes). This fragment was 
purified and cloned into the XbaI+ApaI sites of pLmNTRKO-PAC such that the puromycin 
N-acetyl-transferase-containing resistance cassette was replaced by the bsr-containing 
sequence, to form pLmNTRKO-BSR. 
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3.6.3 Construction of L. major episomal vectors that introduce ectopic copies of LmNTR 
The gene encoding LmNTR was amplified from L. major genomic DNA using VENT Pfu 
and the primers LmNTR-4/LmNTR-2. The 972 bp fragment generated was purified, digested 
with BamHI+HindIII then ligated into the corresponding sites of the trypanosomatid 
expression vector pTEX (Kelly, Ward et al. 1992) to form pTEX-LmNTR.  
 
3.6.4 Construction of constitutive L. major integrative luciferase expression vector 
A sequence corresponding to the L. major 5’ spacer/promoter ribosomal RNA was amplified 
from L. major Friedlin genomic DNA using the primer pairs LmrRNA-1/LmrRNA-2 
resulting in a 300 bp fragment. This was purified, digested with the SacI+BamHI enzyme 
combination and ligated into the corresponding sites of Trypanosoma cruzi reporter vector 
pRiboTEX-Luc (Bot, Hall et al. 2010) to form pLm5’RiboTEX-Luc. A sequence 
corresponding to the L. major 3’ spacer ribosomal RNA region was amplified from L. major 
Friedlin genomic DNA using the primer pairs LmrRNA-3/LmrRNA-4 resulting in a 850 bp 
fragment. This DNA was purified, digested with KpnI and cloned into the single KpnI site of 
pLm5’RiboTEX-Luc. Restriction mapping of the resultant plasmid with SbfI+AscI 
determined the orientation of the insert. Plasmids with the correct arrangement were called 
pLmRIX-Luc-0. 
 
A derivative of pLmRIX-Luc-0 was generated containing a polypyrimidine tract and splice 
leader addition site sequence upstream the T. cruzi MPX gene was inserted upstream of the 
luciferase reporter. Using the plasmid pTAG404 (Dr S. Wilkinson) as template, amplification 
reactions using primers LmrRNA-5/LmrRNA-6 were carried out, resulting in the generation 
of a 300 bp fragment. This DNA was purified, digested with BglII+BamHI and cloned into 
the unique BamHI site of pLmRIX-Luc. Restriction mapping of the resultant plasmids with 
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SacI+HindIII determined the orientation of the insert. The final construct was subsequently 
called pLmRIX-Luc 
 
3.6.5 Construction of constitutive L. major integrative LmNTR expression vector 
The gene encoding LmNTR was amplified from L. major genomic DNA using VENT Pfu 
and the primers LmNTR-4/LmNTR-18. The resultant 972 bp DNA fragment was digested 
with BamHI+XhoI and cloned into the BamHI+SalI sites of pLmRIX-Luc, replacing the 
luciferase gene. The construct was named pLmRIX-LmNTR. 
 
3.7 Protein analysis 
3.7.1 Heterologous expression of recombinant LmNTR  
An overnight culture (50 mL) of E. coli BL21(+) cells harbouring the plasmid pTrc-HisC-
ΔLmNTR was diluted into 2 L NZCYM broth containing 100 mg mL-1 ampicillin and grown 
for 4 hours at 37°C. The culture was transferred to 16
o
C an incubated with aeration for 30 
minutes before addition of isopropyl-β-d-thiogalactopyranoside to a final concentration of 1 
mM. The culture was then incubated overnight at 16
o
C. The cells were harvested by 
centrifugation (5000 g for 20 minutes) and the pellet stored at -20
o
C. 
 
3.7.2 Purification of recombinant LmNTR  
The E. coli pellet containing cells induced to express recombinant ΔLmNTR, stored at -20oC, 
was thawed then resuspended in 80 mL Lysis Buffer (50 mM NaH2PO4, pH 7.8; 500 mM 
NaCl; 8 protease inhibitor mix tablets (Roche)). This mixture was then supplemented with 
DNAse, RNAse, lysozyme, and 1 % (w/v) CHAPS (all Sigma-Aldrich) and incubated on ice 
for 30 minutes in order to lyse the cells. The extract was sonicated and cell debris removed by 
centrifugation (27000 g for 30 minutes at 4°C). The clarified supernatant was then applied to 
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a 2 mL pre-packed nickle-nitrilotriacetic acid (Ni-NTA) (Qiagen) column and the column 
copiously washed in 40 mL Wash Buffer 1 (50 mM NaH2PO4 pH7.8, 500 mM NaCl, 50 mM 
imidazole) then in 40 mL Wash Buffer 2 (50 mM NaH2PO4 pH7.8, 500 mM NaCl, 100 mM 
imidazole). Recombinant protein was eluted off the column using 10-20 x 0.5 mL aliquots of 
Elution Buffer (50 mM NaH2PO4 pH7.8, 500 mM NaCl, 500 mM imidazole, 1% (w/v) 
CHAPS). After elution, yellow fractions were collected and glycerol was added to a final 
volume of 20 % (v/v). This solution was then redistributed into 0.5 mL aliquots and frozen 
for future use at -80
o
C. 
 
3.7.3 Gel electrophoresis: protein 
Pre-cast gels (Biorad) were used for protein electrophoresis with a Mini-Protean III system 
(Biorad). Protein samples (10-20 L) were mixed with 5X Sample Buffer (10 % SDS (w/v); 
10 % β-mercaptoethanol (v/v); 20 % glycerol (v/v); 0.2 M Tris, pH 6.8; 0.05 % bromophenol 
blue (w/v)) (all Sigma-Aldrich) and denatured at 96
o
C for 5 minutes. The samples were 
separated on 12% polyacrylamide gels with 1X SDS-PAGE running buffer (25 mM Tris-
HCl, 200 mM glycine, 0.1 % (w/v) SDS) using a constant voltage 150 V for 60-90 minutes. 
Gels were stained for 2 hours in Coomassie Blue solution (0.2% (w/v) Coomassie brilliant 
blue, 7.5% (v/v) acetic acid, and 50% (v/v) ethanol) followed by de-staining in boiling 
distilled water. Samples were run alongside a PageRuler Prestained Protein ladder 
(Fermentas) as a marker.  
 
3.7.4 Flavin cofactor determination 
The flavin co-factor bound to trypanosomal NTRs was established by determining the 
fluorescence spectrum in acidic and neutral buffers (Faeder et al. 1973). Purified protein was 
desalted through a Zeba spin column (Thermo Scientific) and boiled for 5 min. In a total 
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volume of 100 μL, clarified supernatants (90 μL) containing 0.5 mg LmNTR were mixed 
with 10 μl 50 mM NaH2PO4 pH7.6 or 1 M HCl (final pH = 2.2). The fluorescence profile for 
each treatment was then determined using a Gemini Fluorescent Plate Reader (Molecular 
Devices (UK) Ltd, Wokingham, UK) with an λEX of 450 nm and a λEM of 480-600 nm. The 
resultant patterns were compared with profiles obtained using FMN and FAD standards. 
 
3.7.5 Nitroreductase assay 
ΔLmNTR activity was followed by monitoring the change in absorbance at 340 nm 
corresponding to NADH consumption using a Lambda 25 spectrophotometer (Perkin Elmer) 
(Wilkinson, Taylor et al. 2008). A standard reaction (1 mL) containing 50 mM Tris-Cl 
pH7.5, 100 μM NADH and 100 μM electron acceptor was incubated at room temperature for 
5 min from which the background reaction rate was determined. The assay initiated by 
addition of the LmNTR (35 μg) and the rate of NADH consumption recorded. The enzyme 
activity was then calculated using an ε value of 6,220 M-1 cm-1, giving values of enzyme 
activity in nmol NADH oxidised min
-1
 mg ΔLmNTR-1. The absorbance spectrum (320-
600nm) for each electron acceptor was determined previously and shown not to interfere with 
the analysis: at the concentrations used, no significant signal was detected at 340 nm for any 
of the compounds tested.  
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4. Developing a luciferase reporter cell line to screen compounds against 
amastigote L.major 
Several drug screening regimens are now in place for use with Leishmania, each with their 
own advantages and disadvantages (Sereno et al. 2007). The classical method involves 
visualising Giemsa stained intracellular Leishmania within tissue culture derived mammalian 
macrophages using light microscopy (Berman et al. 1980). This system although 
reproducible is laborious, subjective, and incompatible with a high throughput screening 
regimen, requiring a practised eye. To speed up drug discovery against these medically 
important organisms, recombinant Leishmania parasites expressing an array of reporter 
markers have been developed (see Section 1.8.4) (Sereno, Cordeiro da Silva et al. 2007). 
After reviewing the advantages and disadvantages of each of these systems, it was decided 
that the most suitable option for the development of an assay to be used in a multi-well plate 
format would involve the construction of luciferase expressing L. major cells, specifically 
one where the reporter gene had been integrated into the genome of the parasite. To this end, 
we obtained the published construct pGM-αNEOαLUC that targets the ribosomal DNA loci 
of both L. major and L. donovani (Roy, Dumas et al. 2000). However, following several 
failed attempts at transforming this DNA vector into E. coli, it was decided that we should 
develop our own luciferase expression construct. This would then be used to produce a L. 
major reporter cell line that could then be employed to rapidly screen various compounds 
against the intracellular, amastigote life cycle stage. 
 
4.1 Construction of a luciferase-expressing reporter cell line of L. major 
The first stage in the production of the luciferase-expressing L. major cell line is to create the 
DNA constructs needed to transfect into promastigote form parasites. Using the T. cruzi 
episomal expression pRiboTEX-Luc as a starting plasmid (Bot, Hall et al. 2010), a two step 
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cloning strategy was devised involving the introduction of DNA sequences from the L. major 
ribosomal DNA (rDNA) promoter/spacer region either side of a luciferase/neomycin 
phosphotransferase-containing cassette (Figure 4.1.1).  
 
Figure 4.1.1: Schematic representation outlining the two-step construction of pLmRIX-
Luc-0 
In the first step, the 5’ ribosomal DNA (rDNA) spacer/promoter region from L. major 
Friedlin was amplified from genomic DNA using VENT Pfu and the primers LmrRNA-
1/LmrRNA-2. The resultant DNA fragment (green box) was digested with SacI+BamHI and 
cloned into the corresponding sites of pRiboTEX-Luc (supplied by Dr C Bot) to form 
p5’LmRIX-Luc-0. In step 2, the 3’ rDNA spacer from L. major Friedlin was amplified from 
genomic DNA using VENT Pfu and the primers LmrRNA-3/LmrRNA-4. The resulting 
fragment (orange box) was digested with KpnI, and ligated into the corresponding site of 
p5’LmRIX-Luc-0 generating pLmRIX-Luc-0. The DNA sequences encoding for the ß-
lactamase (bla; grey), luciferase (luc; yellow) and neomycin phosphotransferase (npt; blue) 
genes are highlighted. The SacI (S), BamHI (B) and KpnI (K) restriction sites are also noted. 
 
In the first cloning step, the 5’ flank consisting of a 300 bp region centred on the rDNA array 
transcription initiation site (i.e. the ribosomal promoter), as identified by Martinez-Calvillo et 
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al. (2001), was amplified from L. major Friedlin genomic DNA using the primer combination 
LmrRNA-1/LmrRNA-2. The resultant DNA fragment was digested with SacI+BamHI and 
cloned into the corresponding sites of pRiboTEX-Luc (Bot, Hall et al. 2010), replacing the T. 
cruzi rRNA promoter sequence, to form p5’LmRIX-Luc-0. In the second cloning step, the 3’ 
flank, consisting of a ~850 bp DNA sequence derived from the 3’ end of the rDNA spacer, 
was amplified from L. major Friedlin genomic DNA using the primers LmrRNA-3/LmrRNA-
4. This fragment was digested with KpnI and ligated into the corresponding site of 
p5’LmRIX-Luc-0. The orientation of the 3’ flank was then determined by restriction 
digestion using SbfI+AscI which generated diagnostic 5.0 and 3.0 kbp fragments when the 
insert had been cloned as desired. The resultant ~8.0 kbp plasmid, called pLmRIX-Luc-0 
(Figure 4.1.2), was verified by restriction mapping and sequencing analysis. 
 
Figure 4.1.2: Restriction map of plasmid pLmRIX-Luc-0 
The L. major 5’ rDNA spacer/promoter (green) and 3’ rDNA spacer (orange) as described in 
Figure 4.1.1 are noted. The DNA sequences encoding for the β-lactamase (bla; grey), 
luciferase (luc; yellow) and neomycin phosphotransferase (npt; blue) genes are highlighted. 
The black boxes flanking the ntp gene correspond to the intergenic and 3’ untranslated region 
from T. cruzi GAPDH. These facilitate expression of the npt gene and, in the case of the 
intergenic sequence, provide a polyadenylation sequences used in the processing of the luc 
mRNA. 
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Before electroporation into L. major promastigotes, pLmRIX-Luc-0 was digested with the 
restriction enzymes SbfI+AscI, releasing a ~5.0 kbp DNA fragment containing the 
Leishmania rDNA/luciferase/neomycin phosphotransferase-containing sequences from the 
~3.0 kbp vector backbone. The larger fragment was gel purified and then introduced into the 
parasite by electroporation. Recombinant L. major cells were then selected on agar plates 
containing G418. After 3-4 weeks, colonies visible on the media surface were transferred into 
M199 medium containing G418 and cultured as described in Section 3.2.1. After two rounds 
of sub-culturing, equal aliquots of wild type L. major Friedlin and three independent LmRIX-
Luc-0 containing parasite clones in the stationary phase of growth were lysed and the 
luciferase activity determined (Figure 4.1.3). 
 
 
Figure 4.1.3: Luciferase expression by L. major promastigotes transfected with 
pLmRIX-Luc-0 
The luciferase activity, as measured in arbitrary light units (ALU), of extracts derived from 
recombinant  L. major promastigote clones transfected with pLmRIX-Luc-0 (Luc 0 clones 1, 
2 and 3) was determined and compared to that of the parental line (L. major Friedlin; wt). For 
all assays, cells in stationary phase of growth (~5x10
7
 cells mL
-1
) were lysed, and extracts 
from 1 x 10
6
 parasites analysed. The data are presented as (A) background corrected 
luminescence, and (B) luminescence relative to wild type. All readings were from one off 
experiments. The luminescence activities of all three recombinant parasite extracts was 
equivalent to that observed for wild type promastigotes. 
 
Comparison of the luminescence signal of recombinant parasite extracts with that displayed 
by the parental control revealed that all lystates had equivalent luciferase activities. This 
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strongly suggests that expression of the reporter was not occurring at a significant level. 
Analysis of the rDNA sequences present in pLmRIX-Luc-0 established that certain post-
transcriptional regulatory elements required for the correct expression of the luciferase within 
the trypanosomatids were missing from this construct. To rectify this oversight, a 270 bp 
sequence containing the polypyrimidine tract and spliced leader addition site located 
upstream of the T. cruzi mitochondrial tryparedoxin peroxidase gene was amplified from the 
plasmid pTAG404 (supplied by Dr Shane Wilkinson) using the primers LmrRNA-
5/LmrRNA-6. The resultant DNA fragment was digested with BglII+BamHI then cloned into 
a unique BamHI site present in pLmRIX-Luc-0 and located between the 5’ rDNA flank and 
the luciferase gene to form the ~8.3 kbp plasmid pLmRIX-Luc (Figures 4.1.4 and 4.1.5). 
Orientation of the insert was determined using a SacI+HindIII diagnostic digest. This plasmid 
was verified by restriction mapping and DNA sequencing. 
 
Figure 4.1.4: Schematic representation outlining the construction of the luciferase 
expression vector pLmRIX-Luc 
The polypyrimidine tract/splice leader addition site located upstream of the T. cruzi 
mitochondrial tryparedoxin peroxidase gene (red box) was amplified from the plasmid 
pTAG404 using VENT Pfu and the primers LmrRNA-5/LmrRNA-6. The resultant DNA 
fragment was doubly digested with BglII+BamHI and cloned into the BamHI site (B) of 
pLmRIX-Luc-0. DNA sequences encoding for the ampicillin (bla; grey) and neomycin (npt; 
blue) resistance cassettes, the luciferase reporter (luc; yellow), the L. major 5’ rDNA 
spacer/promoter (green) and the 3’ L. major rDNA spacer (orange) are all highlighted. 
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Figure 4.1.5: Restriction map of the luciferase expression vector pLmRIX-Luc 
The polypyrimidine tract and splice leader addition site located upstream of the T. cruzi 
mitochondrial tryparedoxin peroxidase gene (red) is highlighted. The DNA sequences 
encoding for the β-lactamase (bla; grey), luciferase (luc; yellow) and neomycin 
phosphotransferase (npt; blue) genes plus the L. major 5’ rDNA spacer + promoter (green) 
and 3’ rDNA spacer (orange) are also noted. 
 
As with pLmRIX-Luc-0, the plasmid pLmRIX-Luc was digested with SbfI+AscI, releasing a 
~5.3 kbp DNA fragment containing the expression cassette from the ~3.0 kbp vector 
backbone. The larger fragment was gel purified, electroporated into L. major promastigotes 
and G418 selection performed as described in Section 3.2.1. After several rounds of culturing 
the luciferase activity from 1 x 10
6
 clonal recombinant parasites and wild type cells was 
determined (Figure 4.1.6). In this case, comparison of the luminescence signal of extracts 
derived from L. major containing the luciferase expression construct were between 200 to 
1000-fold greater than that observed from wild type lysates. This clone-to-clone variation is 
believed to be dependent upon which rRNA array the construct integrated into, with certain 
rRNA arrays expressed at higher levels than others (Alsford et al. 2005, Alsford et al. 2008).  
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Figure 4.1.6: Luciferase expression by L. major promastigotes transfected with 
construct LmRIX-Luc 
The luciferase activity, as measured in arbitrary light units (ALU), of extracts derived from 
six recombinant  L. major promastigote (Luc 1-6) clones transfected with pLmRIX-Luc was 
determined and compared to that of the parental line (L. major Friedlin; wt). For all assays, 
cells in stationary phase of growth (~5x10
7
 cells mL
-1
) were lysed, and extracts from 1 x 10
6
 
parasites analysed. The luminescence activity was between 200 to 1000-fold higher in the six 
recombinant parasite extracts than wild type levels. 
 
4.2 Characterising luciferase-expressing L. major promastigotes 
As noted above, luciferase expression by the L. major clones varies (Figure 4.1.6). As one of 
the main uses for this reporter system is to develop a high throughput drug screening 
procedure, the culture exhibiting the highest reporter activity, namely LmRIX-Luc clone 1, 
was selected for further analysis – this particular clone had a relative luciferase level 
approximately three orders of magnitude greater than non-transformed parental cells. This 
clone was examined to determine how it relates to wild type cells in terms of its growth 
profiles, its ability to differentiate from one life cycle form to another, and also whether these 
recombinant parasites were infectious. Initially, assays were performed to monitor whether 
integration of the DNA into the L. major genome or subsequent expression of the reporter 
gene affected parasite growth (Figure 4.2.1). In these experiments, L. major LmRIX-Luc 
clone 1 and wild-type Friedlin cells were grown in parallel. Starting at density at 1 x 10
5
 
parasites mL
-1
 the culture was followed over the next 10 days and the growth curves of the 
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cell lines established. Over this time frame, the non-infectious promastigote recombinant 
parasites exhibited a similar growth profile to that displayed by the wild type culture with 
both cell lines having an approximate doubling time of around 18 hours. This indicates that 
integration of LmRIX-Luc into the L. major genome, and the resulting luciferase expression, 
has no effect on promastigote growth rates. This demonstrates that pLmRIX can be used as a 
general purpose integrative plasmid containing any required gene, without the plasmid 
components affecting parasite growth. 
 
Figure 4.2.1: Growth of L. major luciferase-expressing promastigotes 
The growth of luciferase-expressing (red) and wild type (blue) L. major promastigotes was 
monitored until cultures were in the stationary phase of growth. At day 0, both lines were 
seeded at 1x10
5
 cells mL
-1
, and parasite loads (expressed as promastigote number mL
-1
) 
determined every day over a 9 day period. The parasite lines used were L. major Friedlin 
(wild type) and L. major Friedlin LmRIX-Luc clone 1 (recombinant). Over the period 
examined, all L. major promastigote lines grew at equivalent rates. This experiment was 
repeated on two further occasions and the same profile was observed. 
 
Next, we evaluated whether there was a correlation between cell number and luciferase 
activity using two approaches, both giving similar results (Figure 4.2.2). In the first method, 
carried out while investigating the growth of recombinant parasites, equal volumes of culture 
were collected over the first 9 days and assayed for luminescence.  This clearly demonstrates 
that as the cell density increases so does the reporter signal. In the second procedure, the 
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luciferase activity was determined using fixed numbers of parasites (625 to 160,000). Again, 
a clear linear correlation between luminescence and cell number (over the range used here) 
was observed.  
 
 
Figure 4.2.2: Correlation between luciferase activity and L. major promastigote load 
(A) The growth of luciferase-expressing L. major (clone 1) was monitored over a 9 day 
period. At day 0, promastigote cells were seeded at 1x10
5
 cells mL
-1
 and every 20-24 hours, 
an aliquot (1 mL) was pelleted and the cells resuspended in 200 μL lysis buffer. A 20 μL 
aliquot of the lysate was then assayed for luciferase activity, as measured in arbitrary light 
units (ALU). The profile obtained directly reflects the growth pattern observed in Figure 
4.2.1. (B) The luciferase activity, as measured in arbitrary light units (ALU), from 625 to 
160,000 luciferase expressing L. major promastigotes was determined. Three independent 
readings were taken for each parasite load and the values are means ± standard deviation. 
Graphs A and B show a linear correlation between parasite load and luciferase activity. 
 
After showing that luciferase expression has no apparent adverse affects on promastigote 
growth, experiments were conducted to evaluate whether the transgenic parasites could be 
used in drug screening in a 96-well plate format. Recombinant parasites were grown in the 
presence of different concentration of nifurtimox for a period of 3 days at 27
o
C. After lysis 20 
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μL aliquots from each well were taken and the luciferase activity determined: all drug 
concentrations were assayed in triplicate. The luminescence signal obtained from drug treated 
extracts was then compared to no drug (100% growth) and no parasite (0% growth) controls 
and a dose response curve generated (Figure 4.2.3). From these plots, the concentration of 
nifurtimox that inhibited parasite growth by 50% (IC50) was calculated to be 7.5 ± 0.42 μM 
and is in line with the IC50 value (6.3 ± 0.1 μM) determined using the fluorescent vital dye 
resazurin (Meredith and Wilkinson, unpublished). 
 
Figure 4.2.3: Susceptibility of luciferase-expressing L. major promastigotes to 
nifurtimox 
Luciferase-expressing L. major promastigotes were seeded at 1 x 10
6
 cells mL
-1
 into a 96-
well microtitre plate with varying concentrations of nifurtimox. The cultures were then 
incubated for 3 days at 27
o
C before the addition of 50 μL lysis buffer. A 20 μL aliquot of the 
lysate was then assayed for luciferase activity. A dose response curve was presented as a 
percentage of the signal given by parasites incubated in the absence of nifurtimox. From this 
curve, the drug concentration that inhibited parasite growth by 50% (IC50) was established. 
The data are the means from 3 experiments ± standard deviations. 
 
After establishing that growth of L. major promastigote growth is not affected by luciferase 
expression, the ability of the LmRIX-Luc clone 1 to form infectious metacyclic 
promastigotes was studied. While determining the growth profile of non-infectious 
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promastigotes, parasite samples were collected and, using a well-characterised agglutination 
technique (da Silva and Sacks 1987), metacyclic parasites were quantified following 
purification (Figure 4.2.4). This shows that as the non-infectious promastigote culture reaches 
the stationary phase of growth (density of above 1 x 10
7
 cells mL
-1
) they start to differentiate 
into metacyclic parasites such that by day 8 there are approximately 2.5 x 10
5
 metacyclics 
present per mL of culture representing between 0.4 to 0.5% of the total number of cells. This 
is similar to results reported elsewhere in the literature (da Silva and Sacks 1987) and shows 
that integration of LmRIX-Luc into the L. major genome, and the resulting luciferase 
expression, has no effect on the ability of these parasites to differentiate from the non-
infectious to the infectious form. 
 
Figure 4.2.4: Growth curve and metacyclic production in LmRIX-Luc L. major (clone 1) 
The growth of luciferase-expressing L. major cells (blue diamonds, left axis) was monitored 
until cultures were in the stationary phase of growth as Figure 4.2.1. At day 5, 1 mL aliquots 
were taken from the cultures and metacyclics purified. The metacyclics were then counted 
and presented as a percentage of the overall number of L. major cells (red squares, right axis). 
This shows that LmRIX-Luc L. major are able to produce metacyclic cells, and these begin to 
develop from non-infective promastigotes when the culture reaches a density of around 1 x 
10
7
 cells mL
-1
. The data are the means from triplicate repeats ± standard deviations. 
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4.3 Characterising luciferase-expressing L. major amastigotes 
After demonstrating that luciferase expression does not affect the growth and differentiation 
of promastigote-form parasites, we then examined whether the reporter affected the 
intracellular mammalian stage. Using a human macrophage cell line (differentiated THP-1 
cells) and purified metacyclic, luciferase-expressing L. major, infection and subsequent 
amastigote growth experiments were carried out to determine the optimal ratio of parasite to 
mammalian cells needed to obtain reproducible luminescence (Figure 4.3.1). 
 
Figure 4.3.1: Correlation between luciferase activity and L. major metacyclic load 
Differentiated THP-1 cells seeded at 2.5 x 10
4
 cells mL
-1
 in a 96-well microtitre plate were 
infected overnight with varying numbers of purified luciferase-expressing L. major 
metacyclic parasites. The ratio of parasite to mammalian cell ranged from 0:1 to 80:1. Non-
internalised parasites were then removed by extensive washing in culture medium and the 
amastigote parasites grown for 3 days at 37
o
C in a 5% CO2 atmosphere. The growth medium 
was removed, the cells lysed (in 100 L lysis buffer) and the luciferase activity, as measured 
in arbitrary light units (ALU), for each extract (20 L) was determined. A linear correlation 
between the number of infectious metacyclic cells used in the initial infection and luciferase 
activity was observed throughout the range used. 
 
A linear correlation was observed such that when few metacyclic parasites were used to 
infect the THP-1 line (<20:1) a low luminescence signal (and hence pathogen load) was 
observed in cultures 3 days post-infection. In contrast, when a high pathogen to mammalian 
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cell ratio was used (>20:1) a readily detectible luciferase activity was observed. However, the 
numbers of purified metacyclic-form parasites needed to conduct further infection assays at 
parasite:mammalian cells ratios >20:1 (i.e. 40:1 and 80:1) was prohibitive. For example, the 
number of metacyclic cells required to conduct an 80:1 infection ratio within a single 96-well 
plate experiment would need 100 to 150 mL promastigote cells in the stationary phase. Based 
on luciferase activity and promastigote culture volumes we decided that a ratio of 20 
infectious L. major cells per macrophage was optimal for our needs.  
 
We next conducted a time course experiment to determine how the reporter activity of 
luciferase expressing L. major amastigotes varies with time post-infection. Using a 20:1 
parasite:mammalian cell ratio we carried out an infection and then at 24 hour intervals 
evaluated the luminescence signal, with all time points performed in triplicate (Figure 4.3.2). 
For the first 24 to 48 hours post-infection no significant difference was observed in luciferase 
activity in any of the replicate cultures. In the following 24-48 hours (i.e. 72 to 96 hours post-
infection) the reporter signal increased approximately 3-fold, indicating that amastigote 
replication was occurring. For the 72 hour post-infection time point, little difference in the 
luciferase activity was observed between the three triplicates whereas at the latter time point a 
pronounced difference was detected. When repeated and data taken at time points beyond 96 
hours, the luciferase activity fell back to levels equivalent to background (non-infected 
mammalian cells), similar to that observed for L. donovani (Roy, Dumas et al. 2000). Why 
there is this apparent drop in reporter activity is unclear. Based on our observations, all 
further studies involving infection of differentiated THP-1 cells and subsequent intracellular 
parasite growth were carried out for no longer than 72 hours post-infection. 
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Figure 4.3.2: Growth of in intracellular luciferase-expressing L. major amastigotes 
Differentiated THP-1 cells seeded at 2.5 x 10
4
 cells mL
-1
 in a 24-well microtitre plate were 
infected overnight with 5 x 10
5
 metacyclic cells mL
-1
. After infection, non-internalised 
parasites were then removed by extensive washing in culture medium and then on each day 
(up to the 4
th
 day post-infection), a subset of wells were lysed (in 100 L lysis buffer) and the 
luciferase activity, as measured in arbitrary light units (ALU), determined for each extract (20 
L).Following background correction, the luminescence signal was plotted against time. The 
data are the means from triplicate repeats ± standard deviations. 
 
After showing that the luciferase-expressing L. major line is infective to culture derived 
macrophages, we next determined whether it could infect a live animal model. Here, purified 
luciferase-expressing metacyclic promastigotes were inoculated into the footpad of BALB/c 
mice (three mice per cell line) and the ability of the pathogen to cause lesion pathology 
compared with wild type Friedlin controls assayed in parallel (Figure 4.3.3). By analysis of 
the size of the footpad wound it was clear that luciferase-expressing L. major cells retained 
their infectivity. However, the time taken for the pathology to appear was approximately 
twice that as compared to the wild type L. major: on average a lesion took 31 days to be 
detected in mice infected with wild type parasites while this was about 57 days for the 
recombinant line. This may suggest that in an animal system, luciferase expression by the 
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microbe may slightly reduce infectivity or could slow amastigote cell division. Alternatively, 
this difference could reflect an error in the initial metacyclic cell count such that fewer 
recombinant parasites were inoculated into the host organism, or inherent variation in this in 
vivo model. This issue can be addressed by increasing the sample size. Equally, differences in 
the time that each cell line has been in in vitro culture could also give rise to the observed 
profile. Interestingly, both cell lines generated a similar wound diameter (5 to 7 mm) before 
euthanisation. This would suggest that once an infection has become established the 
recombinant line behaves in the same way as wild type parasites, perhaps indicating that the 
problem identified above reflects an experimental error rather than a biological property. 
 
Figure 4.3.3 Luciferase-expressing L. major are infectious in a mouse model 
Purified luciferase-expressing (red) and wild type (blue) metacyclic parasites (2 x 10
6
) were 
inoculated into the footpad of BALB/c mice. Periodically, the size of the lesion was 
measured. All infections were done in triplicate and the data is expressed as the mean lesion 
size (in mm) ± standard deviation. Although a lag in lesion size was initially observed, by day 
60 onwards no significant difference was noted in the wound size generated by wild type and 
luciferase-expressing L. major. All in vivo work was performed at the London School of 
Hygiene and Tropical Medicine by Dr Karin Seifert. 
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4.4 Validating the luciferase-based drug screening assay for use with L. major 
amastigotes 
Following the demonstration that luciferase-expressing L. major are infectious in both in 
vitro and in vivo models, we next evaluated whether this recombinant line could be used in 
96-well plate drug assay. Using the parameters determined above, we infected differentiated 
THP-1 cells with recombinant parasites (20 parasites per mammalian cell) and then cultured 
the intracellular amastigote cells in the presence of different concentrations of nifurtimox 
(Figure 4.4.1). After 72 hours growth post-infection, the medium was removed, the cells 
lysed and the luciferase activity for each culture determined: all growth assays at each drug 
concentration were conducted in triplicate (Section 3.3.2). 
 
Figure 4.4.1: Susceptibility of luciferase-expressing L. major amastigotes to nifurtimox 
In a 96-well plate format, differentiated THP-1 cells seeded at 2.5 x 10
4
 cells mL
-1
 were 
infected overnight with 5 x 10
5
 cells mL
-1
 purified luciferase-expressing L. major metacyclic 
parasites (giving a ratio of 20 parasites per mammalian cell). Non-internalised parasites were 
removed by extensive washing in culture medium and the amastigote parasites grown for 3 
days at 37
o
C in a 5% CO2 atmosphere in the presence of different concentrations of 
nifurtimox. Cells were then lysed (in 50 L lysis buffer) and the luciferase activity, as 
measured in arbitrary light units, for each extract (10 L) determined. Data, expressed as a 
dose response curve, is shown as a percentage of the luminescence signal generated by 
parasites grown in the absence of nifurtimox. For the curve, the concentration of nifurtimox 
that inhibited parasite growth by 50% was established. The data are the means from 3 
experiments ± standard deviations. 
 
In these experiments, the controls consisted of mammalian cells infected with L. major grown 
in the absence of drug (100% parasite growth); and uninfected mammalian cells that gave a 
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background luciferase activity (0% parasite growth). The signals generated by drug-treated 
extracts were then compared against the infected/non-infected controls and a dose response 
curve generated (Figure 4.4.1). Additionally, comparing the luminescence values and 
deviations of the positive and negative controls, gives a Z factor score of 0.790, labelling this 
assay as “excellent” (Zhang et al. 1999). From these plots, the IC50 value for nifurtimox was 
calculated to be 0.58 ± 0.06 μM (Table 4.4.1). This is significantly lower than the 
promastigote IC50 noted above. Interestingly, mammalian intracellular stage T. cruzi is also 
more susceptible to nifurtimox than their insect stage counterparts (Bot, Hall et al. 
2010).Why this is the case is unclear given that the bloodstream and procyclic forms of T. 
brucei have similar IC50 values, though this could reflect a contrast between intracellular and 
extracellular parasites (Table 4.4.1, Enanga, Ariyanayagam et al. 2003).  When the 
susceptibility of differentiated THP-1 cells to nifurtimox was determined, the IC50 value was 
calculated to be >100 M (Table 4.4.1). This indicates that this nitrofuran has a selective 
toxicity (The ratio of IC50 against mammalian cells/IC50 against the parasite) of >170. 
Therefore based on our data nifurtimox shows selective killing of the L. major amastigotes 
within an intracellular milieu and that the observed leishmanicidal activity is not due to death 
of the mammalian cell. 
L. major T. cruzi T. brucei THP-1 
promast amast epimast amast PCF BSF  
7.5 ± 0.42 0.58 ± 0.06 2.78  ± 0.20 0.24 ± 0.04 4.89 ± 0.12 5.58 ± 0.86 >100 
 
Table 4.4.1: Susceptibility of L. major, T. cruzi, T. brucei and THP-1 cells to nifurtimox 
All data are average IC50 values ± standard deviations given in M. The growth inhibition 
data for T. cruzi epimastigotes (epimast) and amastigotes (amast) taken from Wilkinson, 
Taylor et al. 2008 and Bot, Hall et al. 2010, respectively, T. brucei procyclic (PCF) and 
bloodstream (BSF) forms from Enanga, Ariyanayagam et al. 2003. The L. major 
promastigote (promast) and amastigote (amast) were generated using the luciferase-
expressing line reported here. The cytotoxicity of nifurtimox to differentiated THP-1 cells 
was also examined. 
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4.5 Chapter summary 
The development of a luciferase reporter system in L. major has demonstrated that: 
1. The construct pLmRIX-Luc contains all the mRNA processing elements (including 
splice leader and polypyrimidine tract addition sites) required to express the luciferase 
within L. major promastigote and amastigote cells. 
2. Expression of luciferase at levels ~1000 times that of wild type appears not to impair 
the ability of the parasites to grow or produce infective metacyclic cells.  
3. Luciferase activity shows a linear relationship to cell number, with luminescent 
signals detectable down to 625 promastigote cells. 
4. Using this recombinant line, promastigote and amastigote drug screening protocols 
have been developed and validated using nifurtimox. Reliable dose-dependent growth 
response curves were generated from which accurate IC50 values with low variation 
were determined. 
5. A pilot study has shown that the LmRIX-Luc parasites are able to infect and 
proliferate in a mouse model causing lesion pathology. This opens up the possibility 
for using these cells in in vivo imaging. 
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5. Evaluating the role of a L. major type I nitroreductase 
5.1 Identification of a L. major type I nitroreductase 
Type 1 nitroreductases are a group of enzymes that mediate the reduction of a wide range of 
nitroaromatic and quinone-based substrates. They were originally believed to be restricted to 
prokaryotes and absent from eukaryotes. However, recent studies have shown that this is not 
the case with several eukaryotic microorganisms, including Giardia, Entamoeba, 
trypanosomes and yeast containing type I NTRs (Nixon, Wang et al. 2002, Muller, Wastling 
et al. 2007, Wilkinson, Taylor et al. 2008, Pal, Banerjee et al. 2009, Bang et al. 2012). 
Furthermore, this enzyme has been implicated in the activation of a series of nitroaromatic 
prodrugs in trypanosomes (Hu et al. 2003, Wilkinson, Taylor et al. 2008, Bot, Hall et al. 
2010, Hall, Wu et al. 2010, Baker, Alsford et al. 2011, Hall, Bot et al. 2011, Hall and 
Wilkinson 2012, Mejia, Hall et al. 2012). Consequently this oxidoreductase was investigated 
in L. major. BLASTP searches using the T. cruzi and T. brucei NTR (TcNTR and TbNTR; 
Gene ID Tc00.1047053510611.60 and Tb427.07.7230 respectively) amino acid sequences, 
coupled with text searches using the string “nitroreductase” on the L. major GeneDB 
(http://www.genedb.org/genedb/leish) webpage, identified a NTR homologue within this 
leishmanial parasite. Similar searches of the TryTriDB website has identified sequences 
encoding orthologous oxidoreductive enzymes found in a range of other Leishmania species 
(http://tritrypdb.org/tritrypdb/). The single copy, putative L. major NTR gene designated 
LmNTR (Gene ID LmjF05.0660) consists of a 972 bp open reading frame localised to 
chromosome 5 in the genome of the parasite (Figure 5.1.1 A). Comparison of the Leishmania 
and Trypanosoma NTR genomic loci reveals a high degree of synteny with the adjacent genes 
being conserved through millions of years of evolution. LmNTR encodes for a 323 amino acid 
protein with a predicted size of 34.7 kDa and an isoelectric point of 8.84. The full length 
protein is ~90% identical to NTRs from L. mexicana (Gene ID LmxM.05.0660) and L. 
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infantum (Gene ID LinJ.05.0660), ~75% identical to the enzyme from L. braziliensis (Gene 
ID LbrM.05.0650) and has ~50% identity to TcNTR and TbNTR. When compared to the 
bacterial counterparts such as E. coli nfsB and Bacillus cereus NAD(P)H nitroreductase 
(GenBank Accession numbers NP_415110 and NP_832770, respectively) the highest levels 
of sequence identity is around 20% 
(A) 
atgcttcgccgcagcccccgcttgctattggttgcagcaggggcccgccctgccgcctcc 
 M  L  R  R  S  P  R  L  L  L  V  A  A  G  A  R  P  A  A  S  
acccctcgagccagcgaggccgccggcacctgtggcaacgaggagcgccacagcaacacc 
 T  P  R  A  S  E  A  A  G  T  C  G  N  E  E  R  H  S  N  T  
agcagtggccatggtggttttctagccacactgcgccatctcgtggcgtggaaccgcacg 
 S  S  G  H  G  G  F  L  A  T  L  R  H  L  V  A  W  N  R  T  
aacgcggcggccgccgcatcgtcgtcatccgtgtcgtgcgcagaaaccccagcatgcgtc 
 N  A  A  A  A  A  S  S  S  S  V  S  C  A  E  T  P  A  C  V  
agcagcagcgcagcactcgacgccgtcgaggccgtcgtgcgcgaccggtggacgtgccgg 
 S  S  S  A  A  L  D  A  V  E  A  V  V  R  D  R  W  T  C  R  
cagttcgacacggcgaagccgatagacctcgacactctcaagcgcgtcttggcggcgacg 
 Q  F  D  T  A  K  P  I  D  L  D  T  L  K  R  V  L  A  A  T  
acccgcgccccgactggtttcaaccttcaggggtggcacgcggtcgtcgtcaccaatgag 
 T  R  A  P  T  G  F  N  L  Q  G  W  H  A  V  V  V  T  N  E  
gcggtgcgggagcagctcttcaaggcagcgctcggccagccgcaggtgctgcaggcgccg 
 A  V  R  E  Q  L  F  K  A  A  L  G  Q  P  Q  V  L  Q  A  P  
gcaactgtcgtcttcgttggggacacagagccggagcggaacgcgccgcaggcgcttgag 
 A  T  V  V  F  V  G  D  T  E  P  E  R  N  A  P  Q  A  L  E  
atgggtctcgagacgggctactacagccccctctacggtgccacctacctccgcaacatc 
 M  G  L  E  T  G  Y  Y  S  P  L  Y  G  A  T  Y  L  R  N  I  
tactacctcatgcacggcggtcctatgcagtcgatggccgccgtaaagtcggtcgtgagt 
 Y  Y  L  M  H  G  G  P  M  Q  S  M  A  A  V  K  S  V  V  S  
gcgtggtacagccgggcggctggcacgccgctcatctccgtcccggtgagccgcaccggc 
 A  W  Y  S  R  A  A  G  T  P  L  I  S  V  P  V  S  R  T  G  
tacgcgtggaagcagacgatgattccggcgacgacgttcgtgaatctctgcaccgccgcc 
 Y  A  W  K  Q  T  M  I  P  A  T  T  F  V  N  L  C  T  A  A  
ggctgggagacttgcatgatggagggcatcgacgaagatgccgtgaagcgcgcgttggga 
 G  W  E  T  C  M  M  E  G  I  D  E  D  A  V  K  R  A  L  G  
gtgccggcggaacgatacactgtgccggtcatcatcagcgtcggctacgcgaccgccacg 
 V  P  A  E  R  Y  T  V  P  V  I  I  S  V  G  Y  A  T  A  T  
gaggccgagaaacgtcaggtgtgcagctcgcgcttcgcgacgccacacaccgtgcggtgg 
 E  A  E  K  R  Q  V  C  S  S  R  F  A  T  P  H  T  V  R  W  
aacaagttctag 
 N  K  F  -   
(B) 
 
Figure 5.1.1: Domain structure of LmNTR 
(A) The nucleic and deduced amino acid sequence of LmNTR is shown. (B) The LmNTR 
protein sequences can be divided into two distinct domains. The region highlighted in grey 
represents a putative amino terminal leader sequence absent from the bacterial sequences. 
The region highlighted in green corresponds to the catalytic domain and represents the 
sequence cloned into the pTrcHis-C expression vector 
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Analysis of the LmNTR revealed that the protein sequence can be divided into two distinct 
domains (Figure 5.1.1 B). By comparison to the bacterial sequences (Figure 5.1.2), residues 
1-85 appear to represent an amino terminal extension. This is borne out using the SignalP 
(http://www.cbs.dtu.dk/services/SignalP) (Petersen et al. 2011) algorithm which indicates 
that this region possess a cleavage site between amino acids 20 and 21. Further analysis using 
PSORT II (http://psort.hgc.jp/form2.html) suggests that this protein may be mitochondrial 
(~40% probability) with the iPSORT (http://ipsort.hgc.jp/) algorithm indicating that the first 
nine amino acids (MLRRSPRLL), characterized by the presence of hydrophobic and basic 
amino acids and a lack of acidic residues, make up a mitochondrial targeting peptide. As 
TbNTR is located in the mitochondrion of bloodstream-form T. brucei, it is tempting to 
speculate that this region performs the same targeting role for LmNTR.  
 
Residues 93-296 of LmNTR correspond to a nitroreductase catalytic domain (Pfam 
PF00881). Comparison of the region from bacterial, trypanosomal and leishmanial type I 
NTRs demonstrate that it is highly variable, possessing several key conserved residues 
involved in FMN co-factor binding (Figure 5.1.2) (Parkinson et al. 2000, Wilkinson, Taylor 
et al. 2008, Mejia, Hall et al. 2012). Based on charge and hydrophobicity, other sites do share 
some similarity with these postulated to be involved with substrate binding, particularly in 
relation to the electron donor, NAD(P)H (Parkinson, Skelly et al. 2000). Below we describe 
the characterisation of the nitroreductase domain following heterologous expression in E. coli 
and purification of the recombinant protein. 
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T.cruziA            MRRNDIKRR-LLDSLISYWRWNR------ENLSRNFSAFVENGR---HVIGMDGPVEAGSEKDMGRGNSSMPPFFSSMPPS-SSSSLPLDAMKRVVHERRSCKRFDPTKSIDLDVVSDLL 109 
T.cruziB            MKRNGIKRG-LWDSLILYWRWNR------ENLLRNVSTFAENGR---HVIGMDGPVEAGSEKDVGRGNSYMPPIFSSMPPSPSSSSLPLDTMKRVVHERRSCKRFDPTKPIDLDVVSDLL 110 
T.brucei            MNVSRCRWQGVIKSLRSYWKWNAGAALSATNSQNSTSPYETWGSGISRFFTFLRSSIAATAQEVPREPDRIPPTYYSKASR-----KSLDAFIRVVERRHSSKRFDSSRPVDHTLIARLL 115 
L.major             MLRRSPRLLLVAAGARPAASTPRASEAAGTCGNEERHSNTSSGHG--GFLATLRHLVAWNRTNAAAAASSSSVSCAETPAC-VSSSAALDAVEAVVRDRWTCRQFDTAKPIDLDTLKRVL 117 
L.infantum          MLRRSRRLLLAAAGARPAAFTPRAREAAGTCGNEERDSNTSSGHG--GFLATLRHLVAWNRTNAAAAASSSSASCAETPAC-VSNNAALDAVEAVVRARWTCRQFDTAKPIDLDTLKRVL 117 
L.mexicana          MLCHSRRLLLIAAGAPPADPVPRARE--------ERHSNASSGYG--GFLATLRHLMAWNCTNVAAASSSSSASCAAIPAC-VNDNAALDAVEAAVRNRWTCRQFDTAKPIDLDTLQRVL 109 
L.braziliensis      MFRHSR-------------CSNKARN------------GTSS-----GFLATLRSLVTWGRASATVASSSSPASCGRTAGC-ISAGVALDAVEAAVRNRWTCRQFDTAKTIDLDTLRRVL 89 
E.coli              -----------------------------------------------------------------------------------------MDIISVALKRHSTKAFDASKKLTPEQAEQIK 31 
S.dysenteriae       -----------------------------------------------------------------------------------------MDIISVALKRHSTKAFDASKKLTPEQAEQIK 31 
S.enterica          -----------------------------------------------------------------------------------------MDIVSVALKRYSTKAFDPSKKLTAEEADKIK 31 
B.cereus            ----------------------------------------------------------------------------------MTNSVKTNDFNEILTGRRSIRKYDPSVKISKEEMTEIL 38 
                                                                                                               .      * : : :*.:  :       :  
 
T.cruziA            AMTVRAPTALNLQPWVAVVIHEEEQRETLSRAALGQPQPRDAPVTVVFAGDMEPESNAPAALEMGLESGYYHSLYGAAYLRHAYYLLHGGPCEVMSHVKAIVSAWYSESTGNAMLSVPRN 229 
T.cruziB            AMTVRAPTALNLQPWVAVVIHEEEQRETLSRAALGQPQPRDAPVTVVFAGDMEPESNAPAALEMGLESGYYHSLYGAAYLRHAYYLLHGGPCEAMSHVKAIVSAWYSESTGNAMLSVPRN 230 
T.brucei            EATTRAPTAFNLQPWVAIVVHETSQRGALSHAALDQPQPREAPVTVVFAGDMEPEWRAPAALELGLNSGYYHPLYGAAYLRLVYYHLHGGPFGSMAKAKSCISSWYSNATGTPLLSVPTT 235 
L.major             AATTRAPTGFNLQGWHAVVVTNEAVREQLFKAALGQPQVLQAPATVVFVGDTEPERNAPQALEMGLETGYYSPLYGATYLRNIYYLMHGGPMQSMAAVKSVVSAWYSRAAGTPLISVPVS 237 
L.infantum          AATTRAPTGFNLQGWHAVVVTNTAVREQLFKAALGQPQVLQAPATVVFVGDTEPERNAPQALEMGLETGYYSPLYGAAYLRNIYYFMHGGPMQSMAAVKSVVSAWYSQAAGTPLISVPVS 237 
L.mexicana          AATTRAPTGFNLQGWHAVVVTNTAVREQLYKAALGQPQVLQAPATVVFVGDTEPERNAPQALEMGLETGYYRPLYGAAYLRNIYYFMHGGPMQSMAAVKSVVSAWYSRAAGTPLISVPVS 229 
L.braziliensis      TATTRAPTGFNLQGWHAVVVTSTAVREQLVKAALGQPQVLQAPATVVFVGDMEPERNAPQTLEMGLETGYYDPLYGSAYLRNVYYFLHGGPMQSMAAVKSAVSAWYSRAAGTPLVSVPVS 209 
E.coli              TLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGN-----------YVFNERKMLDASHVVVFCAKT-----AMDDVWLKLVVDQEDADGRFATPEAKAANDKGRKFFADMHRKDLH-D 134 
S.dysenteriae       TLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGN-----------YVFNERKILDASHVVVFCAKT-----AMDDAWLKLVVDQEDADSRFATPEAKAANDKGRKFFADMHRKDLH-D 134 
S.enterica          TLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGN-----------YTFNERKMLDASHVVVFCAKT-----AMDDAWLQRVVDQEDADGRFATPEAKAANDKGRRFFADMHRVSLK-D 134 
B.cereus            TEATLAPSSVNMQPWRFVVIESDEAKATLAPLAKFN----------------QSQVETSSAMIA---------LFGDLNNFDNAEEIYGTAVERGLMPAEVKEDQMKKLSAYFSMVTPEV 133 
                         :*:. * * *  :*      :  :   *  :                .    :. .:             .            .             .      :           
 
T.cruziA            KQAYAWKQVMIPATTFLYLATAAGFDTAILEGFDEAQVRRVAGLP-PRFTVPVIISVGHGAKN--GFHSVRSPRFPTKHLVRWGKF 312 
T.cruziB            KQAYAWKQVMIPATTFLYLATAAGFDTAILEGFDEAQVRRVAGLP-PRFTVPVIISVGHGAKN--GFHSVRSPRFPTKHLVRWGKF 313 
T.brucei            MQGYAWKQAMIPATTFIYAATAAGLDTAILEGFDEAKVREVVGLP-ERYTVPVIISVGYKKADEQGKPPVRSPRFSTGSLVRWNRF 320 
L.major             RTGYAWKQTMIPATTFVNLCTAAGWETCMMEGIDEDAVKRALGVPAERYTVPVIISVGYATATEAEKRQVCSSRFATPHTVRWNKF 323 
L.infantum          RAGYAWKQTMIPATTFVNLCAAAGWDTCMMEGIDEDAVKRALGVPAERYTVPVIISVGYATAAEAEKRQVGSSRFATPHTVRWNKF 323 
L.mexicana          RTGYAWKQTMIPATTFVSLCTAAGWDTCMMEGIDEDAVKRALGVPAERYTVPVIISVGYATAAEAEKRQVCSSRFATPHTVRWNKF 315 
L.braziliensis      RAGYAWKQTLIPATTFVQLCTAAGWDTCMMEGIDEEAVKQVLGVPAERYTVPVIVSVGYATAAEAEKRQVRSPRFATSHTVRWNKF 295 
E.coli              DAEWMAKQVYLNVGNFLLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVVVPVGHHSVEDFNATLPKS-RLPQNITLTEV-- 217 
S.dysenteriae       DAEWMAKQVYLNVGNFLLGVAALGLDAVPIEGFDAAILDAEFGLKEKGYTSLVVVPVGHHSVEDFNATLPKS-RLPQNITLTEV-- 217 
S.enterica          DHQWMAKQVYLNVGNFLLGVAAMGLDAVPIEGFDAEVLDAEFGLKEKGYTSLVVVPVGHHSVEDFNAGLPKS-RLPLETTLTEV-- 217 
B.cereus            MKDTVLIDGGLVAMQFMLAARAHGYDTCPIGGFEKDQIAEAFGLDKESYVPVMLISIGKAADSG-----YQSVRLPIEKVAEWK-- 212 
                           :  : .  *:    * * ::  : *::   :    *:    :.  :::.:*             * *:.           
Figure 5.1.2: ClustalW2 analysis of type 1 nitroreductases across a selection of trypanosomatid and bacterial species 
Amino acid sequence alignment of the type 1 nitroreductases from the trypanosomes T. cruzi CL Brenner (both genes due to the hybrid nature of 
the genome of this strain, TcCLB.510611.60 and TcCLB.506791.70) and T. brucei (Tb927.7.7230); Leishmania species L. major 
(LmjF.05.0660) L. infantum (LinJ.05.0660), L. mexicana (LmxM.05.0660) and L. brazilienesis (LbrM.05.0650); and the bacteria Escherichia 
coli (NP_415110), Shigella dysenteriae (EIQ63968), Salmonella enterica (ZP_03221487) and Bacillus cereus (NP_832770). Amino acids that 
may interact with the flavin co-factor (bold and red) and consist of the putative targeting signal (yellow box, using the iPSORT algorithm) are all 
highlighted. Residues that are common to all eleven sequences are shown with an asterix. 
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5.2 Heterologous expression and purification of recombinant LmNTR 
To investigate the function of LmNTR, a region (residues 87-323, Figure 5.1.1) containing 
the catalytic domain was amplified from L. major Friedlin genomic DNA using the primers 
LmNTR-1/LmNTR-2. The resultant 717 bp fragment (designated LmNTR) was digested 
with BamHI+HindIII and cloned into the corresponding sites of the expression vector 
pTrcHis-C (schematic representation shown in Figure 5.2.1). This generated the plasmid 
pTrcHisC-LmNTR (Figure 5.2.2). 
 
Figure 5.2.1: Schematic representation outlining the construction of the E. coli 
expression vector pTrcHisC-ΔLmNTR  
A DNA fragment containing the LmNTR catalytic domain (ΔLmNTR; dark green) was 
amplified from L. major genomic DNA using VENT Pfu and the primers LmNTR-
1/LmNTR-2. This fragment was digested with BamHI+HindIII and cloned into the 
corresponding sites of pTrcHisC (Invitrogen) to form pTrcHisC-ΔLmNTR. DNA sequences 
encoding for β-lactamase (bla; grey), the LmNTR leader sequence (LS; light grey) and the 
expression vector’s promoter machinery (PM), multiple cloning site (MCS) and polyhistidine 
tag (His6) are all highlighted. The BamHI (B) and HindIII (H) restriction sites are also noted. 
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In the pTrcHis system, recombinant LmNTR is tagged at its amino terminal with a histidine-
rich motif (His6) and the Xpress™ epitope (Invitrogen), sequences that facilitate purification 
and detection of the protein following expression in a suitable E. coli strain. Sequencing 
confirmed that the L. major gene had be cloned in-frame with these ancillary regions. 
 
Figure 5.2.2: Restriction map of the E. coli expression vector pTrcHisC-ΔLmNTR 
The gene encoding LmNTR, minus the gene leader sequence (ΔLmNTR), is highlighted in 
dark green. The DNA sequences encoding for β-lactamase (bla; grey), the ATG start codon, 
polyhistidine tag (His6), Xpress
TM
 epitope and an enterokinase cleavage site (ECl) are also 
noted. 
 
The plasmid pTrcHisC-LmNTR was then transformed into E. coli BL21(+), a strain used for 
expressing proteins from this system. Based on conditions used to purify trypanosomal type I 
NTRs (Hall et al., 2010) a pilot expression study was carried out. This involved diluting an 
overnight E. coli [pTrcHisC-LmNTR] culture 1:50 fold and growing the bacteria at 37°C for 
4 hours. The culture was transferred to 16
o
C and incubated with aeration for 30 minutes. 
IPTG was then added to a final concentration of 1 mM and the cells incubated overnight at 
16
o
C. Extracts were generated and a ~30 kDa band was detected by Western-blot analysis 
using a monoclonal antibody that recognises the Xpress™ epitope in the soluble fraction of 
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lysates (results not shown). Use of other bacterial growth medium other than NZCYM (e.g. 
Luria-Bertani broth) failed to generate sufficient levels of soluble protein. Once these 
conditions had been established the culture volume was scaled up to 2 L and the expression 
experiments repeated. The resultant clarified extract (generated as described in Section 3.7.1) 
was then applied to an Ni-NTA column and recombinant LmNTR readily purified by one 
round of affinity chromatography, with all elutions being yellow in colour (Figure 5.2.3). 
This expression and purification protocol routinely generated 10-50 mg recombinant LmNTR 
per litre of bacterial culture. Elution of this column was carried out using a 50 mM NaHPO4 
pH7.8/500 mM NaCl buffer containing 500 mM imidazole and 1% (w/v) CHAPS. If the 
detergent was omitted from the elution buffer then most of the His6-tagged protein remained 
bound to the column. This suggests that the recombinant LmNTR may not solely be binding 
to nickel present in the resin via the poly-histidine tag and could be binding to the matrix 
support.  
 
 
Figure 5.2.3: Purification of recombinant LmNTR 
Fractions collected at various stages of His6-tagged LmNTR purification were fractionated 
on a 12% polyacrylamide gel and visualised by Coomassie-staining. The clarified supernatant 
of an E. coli (pTrcHic-LmNTR) cell lysate (SN) was loaded onto a Ni-NTA column and the 
flow through collected (B1), and then reapplied (B2). The column was washed extensively 
with 50 mM (W1) and 100 mM (W2) imidazole-containing solutions (see Section 3.7.1).  
His6-tagged LmNTR was eluted off the column using a solution containing 500 mM 
imidazole; 1% CHAPS (E1-E7). A band of approximately 30 kDa was observed in all wash 
and elution fractions and corresponds to recombinant LmNTR. The Prestained Protein 
Marker (M) is indicated. 
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5.3 Unravelling the biochemical properties of LmNTR 
A characteristic feature of all type I NTRs relates to their ability to bind FMN as co-factor 
(Roldan, Perez-Reinado et al. 2008). During purification it was noticeable that all elution 
fractions containing recombinant LmNTR were yellow suggesting that this parasite enzyme 
was a flavoprotein. To confirm that this was the case and also identify the nature of the flavin 
a fluorescence-based assay was employed (Faeder and Siegel 1973) (Figure 5.3.1). 
 
Figure 5.3.1: Evaluating the co-factor in recombinant ΔLmNTR 
Fluorescence spectra of FMN, FAD (both 50 μM) and supernatant from boiled purified, 
recombinant LmNTR (0.5 mg) at pH 7.6 (blue line) and pH 2.2 (red line) was determined 
using an excitation λ at 450 nm and emission λ between 480-600 nm. All the fluorescence 
analyses were carried out in triplicate and the profiles are derived from the mean values. 
 
Purified recombinant protein was passed through a desalting spin column and the flow 
through collected. The protein (0.5 mg) was boiled and sample clarified. The fluorescence 
profile of the yellow supernatant was then evaluated under neutral and acidic pHs using an 
excitation wavelength of 450 nm and excitation spectrum of 480 to 600 nm. FAD and FMN 
were treated in parallel and acted as reference standards. Under these conditions, the NTR-
derived sample and FMN exhibited maximal fluorescence in a pH 7.5 buffer having a peak 
emission around 560 nm. Under acidic conditions (pH 2.2) this signal was quenched. For 
FAD, the fluorescence observed under neutral pH conditions is enhanced in acidic buffers. 
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Based on the fluorescence characteristics and release of the flavin from the protein backbone 
following boiling, the data strongly suggest that LmNTR non-covalently bind FMN as co-
factor, in agreement with observations made with the two trypanosomal enzymes (Hall & 
Wilkinson, unpublished). 
 
Type I NTRs can metabolise a wide range of nitroaromatic and quinone-based substrates 
using NADPH and/or NADH as electron donor. In the presence of an appropriate electron 
acceptor, reactions involving the oxidation of these two reductants can be readily followed in 
a spectrophotometer by following the change in absorbance at 340 nm (Figure 5.3.2 A). 
Using NADH as electron donor and benznidazole as electron acceptor, we evaluated whether 
this reaction was pH dependant (Figure 5.3.2 B).  Several Trizma
®
 base buffers ranging in pH 
from 7 to 9 were tested.  From these results, high activity levels were observed between pHs 
7 to 8, with maximal activity recorded at pH 7.5. At pH 8.5 and 9, enzyme activity was 
approximately 1/3
rd
 that at pH 7.5. Importantly, these reactions take place under normoxic 
conditions and indicate that LmNTR activity towards benznidazole is oxygen-insensitive. 
  
Using benznidazole as a substrate and in pH 7.5 buffer, we next examined which of the 
reduced nicotinamide adenine dinucleotides LmNTR had preference for: both TcNTR and 
TbNTR favour NADH as electron donor with TcNTR not interacting with NADPH at all 
(Wilkinson, Taylor et al. 2008; Hall & Wilkinson, unpublished). Under these aerobic 
conditions LmNTR could readily metabolise this nitroimidazole using NADH, with only 
minimal oxidation occurring when using NADPH (Figure 5.3.2 C). In the presence of 100μM 
NADH and 100μM benznidazole, the rate of change in absorbance at 340 nm can be readily 
followed as a steady deflection. The gradient of the resultant slope can be determined from 
which the enzyme activity calculated in nmol NADH consumed mg
-1
 ΔLmNTR min-1. In the 
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case of Figure 5.3.2 C for example, this reveals a difference in enzyme activity of 110 nmol 
NADH consumed mg
-1
 ΔLmNTR min-1 in blue, against 50 nmol NADPH consumed mg-1 
ΔLmNTR min-1 in red. 
 
Figure 5.3.2: Formation of a NADH consumption assay using recombinant ΔLmNTR to 
screen nitroaromatic compounds as possible substrates. 
(A) Schematic representation for the reduction of quinone and nitroaromatic based substrates 
by NTRs using NADH as electron donor; ‘red’ represents the reduced and ‘oxid’ the oxidized 
form of the substrate (figure modified from Wilkinson, Taylor et al. 2008). (B) The 
metabolism of benznidazole (100 μM) by LmNTR (35 μg) was monitored in buffers with 
different pH values (pH 7.0-9.0), using NADH (100 μM) as electron donor. LmNTR activity 
was expressed as μmol NADH oxidised min-1 mg LmNTR-1. (C) NTR activity was monitored 
by following the oxidation of NADH (100 μM, blue line) or NADPH (100 μM, red line) in 
the presence of LmNTR (35 μg) and benznidazole (100 M). The curve shows the rate of 
change in absorbance at 340 nm which corresponds to the oxidation of NAD(P)H to 
NAD(P)
+
, and highlights the increased enzyme activity when using NADH as electron donor. 
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To further investigate the type of kinetics that LmNTR displays toward NADH, assays were 
carried out using various concentrations of reductant against a fixed concentration of 
benznidazole (Figure 5.3.3 A). For this substrate, double reciprocal plots were linear at all 
concentrations of electron acceptor with the slopes remaining roughly parallel, a pattern 
characteristic of a ping-pong mechanism. Likewise, reciprocal assays using a fixed 
concentration of NADH and varying amounts of benznidazole generated a similar pattern of 
parallel slopes (Figure 5.3.3 B). The slope profiles observed only occurred over a limited 
concentration range, with noncompetitive substrate inhibition detected when the NADH or 
benznidazole level was above 200 M (Figure 5.3.3 C and D respectively). 
 
After establishing the enzyme assay and determining that LmNTR displays typical 
oxidoreductase ping-pong type kinetics (at least towards benznidazole), we next evaluated the 
substrate range displayed by the parasite enzyme. A series of nitroaromatic and quinone-
based compounds were assayed to determine whether these could drive LmNTR activity. 
Such assays were carried out using a fixed concentration of electron donor (NADH), a fixed 
amount of enzyme and varying concentrations of the electron acceptor. In many cases 
(benznidazole, metronidazole, LH32, LH33, LH37, duroquinone and coenzyme Q1) the 
oxidation of NADH was followed although for others (nifurtimox, nitrofurazone and 
nitrofurantoin) the direct reduction of substrate was monitored (such electron acceptors 
usually had a prohibitively high absorbance at 340 nm). Analysis of the resulting slopes (see 
Figure 5.3.2 A as example), the enzyme activities were determined and double reciprocal 
(Lineweaver-Burk) plots generated. From this graphs, kinetic data (apparent KM, apparent 
VMAX and kCAT/KM) was calculated (Table 5.3.1). 
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Figure 5.3.3: Ping pong kinetics of recombinant ΔLmNTR 
Lineweaver-Burk reciprocal plots showing parallel best fit lines indicative of ping-pong 
kinetics. (A) Enzyme activity in nmol NADH consumed min
-1 mg ΔLmNTR-1 while varying 
NADH concentration at three set benznidazole concentrations: 100μM (blue diamonds), 
75μM (red squares) and 50μM (green triangles). (B) Enzyme activity in nmol NADH 
consumed min
-1 mg ΔLmNTR-1 while varying benznidazole concentration at three set NADH 
concentrations: 100μM (blue diamonds), 80μM (red squares) and 75μM (green triangles). (C) 
Noncompetitive substrate inhibition caused by high levels of NADH causing the enzyme 
activity to rapidly drop. (D) Noncompetitive substrate inhibition caused by high levels of 
benznidazole causing the enzyme activity to rapidly drop. 
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The analysis of these assays (Table 5.3.1) shows that LmNTR has a wide substrate range. 
Additionally, by observing the kCAT/KM (a measure of enzyme efficiency) it appears that 
LmNTR has a substrate preference for quinone compounds (particularly coenzyme Q1), 
which possibly hints towards the biological function of this enzyme within the parasite. 
compound class 
compound 
name 
apparent KM 
(μM) 
apparent VMAX 
(nmol min
-1
 mg
-1
) 
kCAT/KM 
(M
-1
 s
-1
) 
nitroimidazole 
benznidazole 22.0 78.7 2.5 x 10
3
 
metronidazole 2.4 17.9 5.2 x 10
3
 
nitrofuran 
nifurtimox 9.7 50.9 3.7 x 10
3
 
nitrofurazone 4.7 68.3 1.0 x 10
4
 
nitrofurantoin 3.9 56.7 1.0 x 10
4
 
nitrobenzyl 
compounds 
CB1954 13.1 85.9 4.6 x 10
3
 
LH32 28.8 100.7 2.5 x 10
3
 
LH33 8.2 114.2 9.8 x 10
3
 
LH37 7.1 71.7 7.1 x 10
3
 
quinones 
duroquinone 9.8 140.6 1.0 x 10
4
 
coenzyme Q1 5.1 145.2 2.0 x 10
4
 
 
Table 5.3.1: Activity of recombinant LmNTR towards a range of nitroaromatic and 
quinone-based substrates 
The apparent VMAX and KM values of LmNTR (35 μg) toward various nitroaromatic and 
quinone-based substrates (0-100 μM) were determined in the presence of NADH (100 μM). 
For benznidazole, metronidazole, LH32, LH33, LH37, duroquinone and coenzyme Q1, 
activity was followed by monitoring the rate of NADH oxidation (Abs340nm) and the kinetic 
values calculated using a ε = 6,220 M-1 cm-1. For nitrofurans, assays were carried out by 
following the direct reduction of the nitroheterocycle. Kinetic values were calculated using ε 
= 18,000, 12,000 or 15,000 M
-1 
cm
-1
 for nifurtimox (Abs435nm), nitrofurazone or 
nitrofurantoin (both Abs400nm), respectively from which the amount of reductant consumed 
per reaction was determined, assuming that 4 molecules of NADH are oxidized per molecule 
of nitrofuran reduced (Hall, Bot et al. 2011). For CB1954, activity was monitored by 
detecting production of the hydroxylamine (Abs425nm). Kinetic values were determined 
using a ε = 1,200 M-1 cm-1 from which the amount of NADH oxidized per reaction was 
determined, assuming that 4 molecules of reductant are turned over per molecule of CB1954 
reduced (Race et al. 2007, Bot, Hall et al. 2010). The apparent VMAX values are expressed as 
nmol NADH oxidized min
-1
 mg
-1
 and apparent KM value in μM. The specificity constant 
(kcat/KM), expressed in M
-1
 s
-1
, was determined and assumed one catalytic site per 30 kDa 
monomer. 
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5.4 Functional analysis of LmNTR within L. major 
The application of reverse genetics has been routinely used for several decades to study gene 
function in a variety of different organisms. In the case of Leishmania, this approach has been 
facilitated by development of reliable DNA transfection protocols, a series of genetic tools 
that permit the functional analysis of a gene/protein of interest within the parasite itself and 
free access to a well organised genome sequence database. Below, the efforts made to alter 
the level of LmNTR in L. major by introducing ectopic copies of the gene on episomal or 
integration expression vectors, or by deleting one or both LmNTR alleles from the nuclear 
genome are described. 
 
5.4.1 Expression of elevated levels of LmNTR 
A series of attempts to construct cell lines expressing elevated levels of LmNTR (and tagged 
derivatives) through the introduction of ectopic copies of LmNTR into the parasite were 
carried out. Initial efforts involved amplifying the complete LmNTR open reading frame (plus 
the STOP codon) from L. major Friedlin genomic DNA using the primers LmNTR-
4/LmNTR-2. The resultant ~970 bp DNA fragment was digested with BamHI+HindIII and 
cloned into the corresponding sites pTEX-TcGPXI (Wilkinson, Meyer et al. 2002) such that 
the TcGPXI gene was replaced by LmNTR to form pTEX-LmNTR (Figure 5.4.1). This 
episomal construct was confirmed through restriction digest mapping (restriction map shown 
in Figure 5.4.2) and DNA sequencing.  
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Figure 5.4.1: Schematic representation outlining the construction of the episomal 
Leishmania expression vector pTEX-LmNTR  
The gene encoding LmNTR (LmNTR; dark green) was amplified from L. major genomic 
DNA using VENT Pfu and the primers LmNTR-4/LmNTR-2. The resultant DNA fragment 
was digested with BamHI+HindIII and cloned into the corresponding sites of pTEX-TcGPXI 
(Wilkinson, Meyer et al. 2002), replacing the TcGPXI gene, to form pTEX-LmNTR. The 
DNA sequences encoding for ampicillin (bla; grey) and neomycin (npt; blue) resistance, and 
TcGPXI (black) are all highlighted. The BamHI (B) and HindIII (H) restriction sites are also 
noted. 
 
 
Figure 5.4.2: Restriction map of the episomal Leishmania expression vector pTEX-
LmNTR 
The DNA sequences encoding for LmNTR (LmNTR; dark green), β-lactamase (bla; grey), 
and neomycin phosphotransferase (npt; blue) are highlighted. The black boxes flanking 
LmNTR and npt genes correspond to the 5' UTR, intergenic and 3' UTR regions from T. cruzi 
GAPDH and facilitate gene expression. 
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This plasmid was then used in multiple (11) transfections of L. major Friedlin promastigotes 
on numerous (7) occasions. In all cases no stable G418-resistant parasite colonies were 
observed after 4 weeks of selection. However, positive controls (transfecting the heterozygote 
cell lines with an episomal GFP expression plasmid, pTEX-GFP, in parallel) did result in 
G418-resistant promastigotes. A derivative of pTEX-LmNTR was generated designed to 
facilitate expression of a c-myc (9E10) epitope-tagged version of the oxidoreductase (pTEX-
LmNTR-9E10). As with the untagged protein, repeated electroporation of this episomal 
vector into L. major promastigotes failed to generate recombinant parasites. 
 
To determine whether elevated LmNTR expression could be facilitated using an integrative 
system, the full length gene (plus STOP codon) was amplified from L. major Friedlin 
genomic DNA using the primers LmNTR-4/LmNTR-18. The resultant ~970 bp DNA 
fragment was digested with BamHI+SalI and cloned into the BamHI+XhoI sites of pLmRIX-
Luc such that the luciferase gene was replaced by LmNTR to form pLmRIX-LmNTR (Figure 
5.4.3). 
 
Following restriction mapping and DNA sequencing to confirm the nature of this construct 
(Figure 5.4.4), the plasmid was digested with SbfI+AscI to liberate an LmNTR-containing 
fragment of ~4.6 kbp, which was then purified and transfected into L. major promastigotes 
using the Amaxa
®
 Nucleofector
®
 system. As for the pTEX-based constructs, multiple (5) 
transfections carried out on 3 separate occasions using pLmRIX-LmNTR failed to generate 
G418-resistant cells. However, positive controls (transfecting the heterozygote cell lines with 
the pLmRIX-Luc construct, in parallel) did result in G418-resistant promastigotes. 
Electroporation of a c-myc (9E10) tagged version of LmNTR using this integration system 
also did not generate transformants.  
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Figure 5.4.3: Schematic representation outlining the construction of the integrative 
Leishmania expression vector pLmRIX-LmNTR  
The gene encoding LmNTR (LmNTR; dark green) was amplified from L. major genomic 
DNA using VENT Pfu and the primers LmNTR-4/LmNTR-18. The resultant DNA fragment 
was digested with BamHI+XhoI and cloned into the BamHI+SalI sites of pLmRIX-Luc, 
replacing the luciferase gene. The DNA sequences encoding for ampicillin (bla; grey) and 
neomycin phosphotransferase (npt; blue) resistance, luciferase (luc; yellow), the L. major 5’ 
rDNA spacer/promoter (green), 3’ L. major rDNA spacer (orange), and the T. cruzi 
mitochondrial tryparedoxin peroxidase polypyrimidine tract/splice leader addition site (red) 
are all highlighted. The BamHI (B), and XhoI (X) restriction sites are also noted. 
 
 
Figure 5.4.4: Restriction map of the integrative Leishmania expression vector pLmRIX-
LmNTR  
The DNA sequences encoding for β-lactamase (bla; grey), LmNTR (LmNTR; dark green) and 
neomycin phosphotransferase (npt; blue) are all highlighted. The T. cruzi mitochondrial 
tryparedoxin peroxidase polypyrimidine tract/splice leader addition site (red), L. major 5’ 
rDNA spacer/promoter (light green) and L. major 3’ rDNA spacer (orange) are also noted. 
Additionally, the black boxes flanking npt correspond to the intergenic and 3’ UTR from T. 
cruzi GAPDH and facilitate expression of LmNTR and neomycin phosphotransferase genes. 
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From our data it appears that introducing an ectopic copy of LmNTR (and thus possibly 
increasing the expression of LmNTR) into L. major promastigotes is deleterious to these 
cells. A similar property has been observed using T. cruzi epimastigotes where over 
expression of TcNTR (wild type and tagged versions) could also not be carried out 
(Wilkinson, unpublished results). 
 
5.4.2 LmNTR gene deletion studies 
An alternative way to alter the copy number of LmNTR (and thus, theoretically, the levels of 
LmNTR) is to remove one or both genes from the wild type L. major genome to create 
heterozygous or null mutant lines. The phenotypic effect of such an event can then be 
elucidated. To achieve this, two gene deletion constructs were designed to replace each allelic 
copy of LmNTR by homologous recombination with antibiotic resistance cassettes. To 
construct the first vector, based around the gene encoding for puromycin N-acetyl-transferase 
(pac), a two step cloning strategy was used (Figure 5.4.7). Initially, primers (LmNTR-
9/LmNTR-10) to the DNA sequence immediately upstream of LmNTR were designed to 
facilitate amplification of a ~700 bp fragment (designated 5’ LmNTR UTR) using L. major 
Friedlin genomic DNA as template. The resultant fragment was digested with SacI+XbaI and 
cloned into the corresponding sites of the pac-containing vector p5’TbNTRKO-PAC 
(supplied by Dr S Wilkinson). In this cloning event, the 5’ TbNTR UTR sequence was 
replaced with the 5’ LmNTR UTR fragment to form p5’LmNTRKO-PAC. In the second 
cloning step, primers (LmNTR-11/LmNTR-13) to the DNA sequence immediately 
downstream of LmNTR were designed to facilitate amplification of a ~1 kbp fragment 
(designated 3’ LmNTR UTR) using L. major Friedlin genomic DNA as template. This 
fragment was digested with ApaI+KpnI and cloned into the corresponding sites of 
p5’LmNTRKO-PAC to generate pLmNTRKO-PAC (Figure 5.4.8). At each stage the 
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constructs (p5’LmNTRKO-PAC and pLmNTRKO-PAC) were confirmed by restriction 
mapping and DNA sequencing. 
 
 
Figure 5.4.7: Schematic representation outlining the two-step construction of 
pLmNTRKO-PAC 
In the first step, the 5’ UTR of LmNTR (blue) was amplified from L. major Friedlin genomic 
DNA using VENT Pfu and the primers LmNTR-9/LmNTR-10. The resultant DNA fragment 
was digested with SacI+XbaI and cloned into the corresponding sites of p5’TbNTRKO-PAC 
(supplied by Dr S Wilkinson), replacing the 5' UTR from TbNTR (black), to form 
p5’LmNTRKO-PAC. In step 2, the 3’ UTR of LmNTR (red) was amplified from L. major 
Friedlin genomic DNA using VENT Pfu and the primers LmNTR-11/LmNTR-13. The 
resulting fragment was digested with ApaI+KpnI, and ligated into the corresponding site of 
p5’LmNTRKO-PAC generating pLmNTRKO-PAC. The DNA sequences encoding for β-
lactamase (bla; grey) and puromycin N-acetyl-transferase (pac; yellow) are highlighted. The 
SacI (S), XbaI (X), ApaI (A) and KpnI (K) restriction sites are also noted. 
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Figure 5.4.8: Restriction map of the LmNTR gene deletion vector pLmNTRKO-PAC 
The DNA sequences encoding for puromycin N-acetyl-transferase (pac; yellow) and β-
lactamase (bla; grey) are highlighted while the 5' (blue) and 3' (red) UTRs from LmNTR are 
also noted. The black boxes flanking the pac gene correspond to the UTRs from T. brucei 
tubulin repeats and these facilitate expression of this resistance marker in the parasite. 
 
 
Once the pLmNTRKO-PAC construct had been made, a second gene deletion vector based 
around the gene encoding for blasticidin-S deaminase (bsr) was constructed (Figure 5.4.9). A 
bsr-containing resistance cassette was excised from the vector pTbNTRKO-BSR (supplied by 
Dr S Wilkinson) following digestion with XbaI+ApaI. The resultant fragment (~970 bp) was 
then cloned the corresponding sites of pLmNTRKO-PAC such that the pac-containing 
resistance cassette was replaced with the bsr counterpart. This generated the plasmid 
pLmNTRKO-BSR (Figure 5.4.10). This construct was confirmed by restriction mapping and 
DNA sequencing. 
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Figure 5.4.9: Schematic representation outlining the construction of pLmNTRKO-BSR  
The vector pTbNTRKO-BSR (Wilkinson, Taylor et al. 2008) was digested with XbaI+ApaI 
releasing a DNA fragment containing the blasticidin-S deaminase (bsr; light green) gene plus 
T. brucei tubulin 5’ and 3’ UTRs (black bars). This fragment was purified and cloned into the 
XbaI+ApaI sites of pLmNTRKO-PAC such that the puromycin N-acetyl-transferase-
containing resistance cassette (pac; yellow + T. brucei tubulin 5’ / 3’ UTRs designated as 
flanking black bars) was replaced by the bsr-containing sequence, to form pLmNTRKO-
BSR. The DNA sequence encoding for ampicillin resistance (bla; grey) as well as the 5’ 
(blue) and 3’ (red) UTR from LmNTR, are also highlighted. X and A correspond to XbaI and 
ApaI restriction sites, respectively. 
 
 
Figure 5.4.10: Restriction map of the LmNTR gene deletion vector pLmNTRKO-BSR 
The DNA sequences encoding for blasticidin-S deaminase (bsr, light green) and the β-
lactamase (bla; grey) are highlighted while the 5' (blue) and 3' (red) UTRs from LmNTR are 
also noted. The black boxes flanking the bsr gene correspond to the T. brucei tubulin 5’/3’ 
UTRs and facilitate expression of this resistance marker in the parasite. 
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Prior to their introduction into L. major promastigotes, both deletion constructs were 
processed to release the gene targeting fragment from the plasmid backbone. For the pac-
containing vector, restriction digestion using SacI+KpnI resulted in two bands: one of ~3.0 
kbp, corresponding to the LmNTR targeting fragment, and the second at ~2.8 kbp which 
corresponds to the vector backbone. The ~3.0 kbp band was gel purified. For the bsr-
containing vector, the plasmid was digested with ScaI and the single ~5.6 kbp fragment 
purified: this particular enzyme cleaves the plasmid within the sequence encoding for β-
lactamase (bla) present in the vector backbone. This purified ~5.6 kbp fragment was then 
subject to a second round of restriction digestion using SacII+KpnI. This produced three 
bands, two of which correspond to the unwanted plasmid backbone. The third ~2.8 kbp 
fragment that corresponds to the bsr-containing LmNTR targeting fragment was gel purified. 
 
Both the pac and bsr-containing LmNTR targeting fragments (~3.0 and ~2.8 kbp, 
respectively) were introduced into L. major promastigotes using the Amaxa
®
 Nucleofector
®
 
system. Recombinant L. major cells were then selected on agar plates containing the 
appropriate antibiotic. After 3-4 weeks, colonies visible on the media surface were transferred 
into M199 medium containing either puromycin or blasticidin as applicable and cultured as 
described in Section 3.2.1. After two rounds of sub-culturing, genomic DNA from several 
putative pac and bsr-containing heterozygote clones (designated as LmNTR
+/-
 PAC or 
LmNTR
+/-
 BSR) was extracted and digested with the restriction enzyme ApaI. Following size 
fractionation, the agarose gel was transferred onto nylon membrane and used in Southern 
hybridisation, using the 5’ LmNTR UTR as probe. This particular restriction enzyme (ApaI) 
was chosen for such an analysis following in silico restriction mapping using DNA sequences 
around the LmNTR loci, downloaded from the L. major genome database. Based on this, we 
predicted that an ApaI band of ~1.7 kbp was detected in digested L. major Friedlin genomic 
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DNA when using the 5’ LmNTR UTR as probe (Figure 5.4.11 A) with one of the ApaI 
restriction sites in the 5’ region of LmNTR itself, and the other being upstream within the 
intergenic region. Integration of the pac or bsr-containing constructs at the LmNTR loci 
results in the complete deletion of the oxidoreductase gene and loss of the associated ApaI 
restriction site. However, both constructs do introduce an alternative ApaI site as part of their 
resistance cassette (Figures 5.4.8 and 5.4.10). As such, Southern hybridization of ApaI-
digested LmNTR
+/-
 PAC or LmNTR
+/-
 BSR genomic DNAs using the 5’ LmNTR UTR probe 
is predicted to detect diagnostic bands at ~2.9 or ~2.7 kbp, respectively (Figure 5.4.11 A). 
When the actual hybridisations were performed, the above expected bands sizes were 
detected indicating that LmNTR heterozygote clones had been produced (Figure 5.4.11 B). It 
is interesting to note that the stoichiometry of the bands shown by the LmNTR
+/-
 PAC clone 
indicates trisomy, with an extra copy of wild type LmNTR (Figure 5.4.11 B, lane 2). 
 
 
 
Figure 5.4.11: Disruption of NTR in L. major 
(A) Schematic representation outlining the LmNTR allele (dark green) and the effects of gene 
disruption with vectors based around the puromycin N-acetyl-transferase (pac; yellow) or 
blasticidin-S (bsr; light green) resistance cassettes. The 5' (blue) and 3' (red) UTRs of LmNTR 
are highlighted. The restriction sites for the enzyme ApaI and the expected fragment sizes (in 
kbp) following ApaI digestion of L. major genomic DNA are shown. (B) Autoradiographs of 
ApaI digested genomic DNA from wild type L. major Friedlin (lane 1) and LmNTR
+/-
 PAC 
and BLA heterozygous clones (lanes 2 and 3, respectively). Southern blots were hybridised 
with labelled 5' LmNTR UTR probe. Sizes given are in kbp. 
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We next attempted to generate L. major LmNTR null mutant lines. Despite multiple (16) 
electroporations performed on 7 separate occasions, no double drug resistant parasites were 
obtained. However, positive controls (transfecting the heterozygote cell lines with an 
episomal GFP expression plasmid, pTEX-GFP, in parallel) resulted in double drug resistant 
promastigotes. In these experiments, the pac-containing LmNTR targeting vector was 
transfected into the LmNTR
+/-
 BSR line and vice versa, all to no avail. This inability to 
generate LmNTR null mutants strongly suggests that the function of this enzyme is essential 
for the growth of L. major promastigotes. Unfortunately, rescue experiments were deemed 
unfeasible based on our previous finding that expression of ectopic copies of LmNTR 
promastigotes is deleterious in this parasite life cycle stage. 
 
To help evaluate the phenotypic properties displayed by heterozygote line, the L. major 
LmNTR
+/-
 BSR cells were electroporated with the ~5.3 kbp SbfI/AscI DNA fragment that 
contains the integrative luciferase expression system (LmRIX-Luc). Selection on agar plates 
yielded a number of drug (G418) resistant clones. The luciferase activity in extracts derived 
from these lines was shown to be comparable with that generated from the lysates described 
previously in Section 4.2 (data not shown).  
 
5.4.3 Characterisation of the L. major LmNTR
+/-
 heterozygote parasites 
To assess the effect of a single LmNTR gene replacement we established the growth 
properties of promastigote-form parasites with respected to wild type cells. Starting at a 
density of 1 x 10
5
 parasites mL
-1
 the growth of a LmNTR
+/-
 BSR clone (clone 2) was followed 
over the next 10 days and growth curves of the cultures established (Figure 5.4.12). This was 
performed in triplicate. Over this time frame, the promastigote recombinant parasites 
exhibited a similar growth profile to that displayed by the wild type culture with both cell 
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lines having an approximate doubling time of around 18 hours. Similar experiments were 
performed using a LmNTR
+/-
 PAC clone and no growth defect was recorded using this line 
either (data not shown). This indicates that loss of a single LmNTR allele has no effect on the 
promastigote growth rate. 
 
 
Figure 5.4.12: Growth of LmNTR
+/-
 heterozygote promastigotes parasites 
The growth of L. major LmNTR
+/-
 (BSR) heterozygote clone (red squares) and wild type L. 
major Friedlin (blue diamonds) promastigote parasites was monitored until cultures were in 
the stationary phase of growth. At day 0, both lines were seeded at 1x10
5
 cells mL
-1
, and 
parasite loads (log10 number of parasites mL
-1
) determined every day over a 10 day period. 
Three independently derived growth curves for each cell line are shown. 
 
Previous work using T. cruzi and T. brucei lines with reduced NTR expression has shown 
that these cells display resistance to nitroheterocyclic compounds (Wilkinson, Taylor et al. 
2008). To determine whether this is the case for L. major promastigotes, the susceptibility of 
the LmNTR
+/-
 heterozygote lines to nifurtimox was determined and compared to controls 
performed in parallel (Figure 5.4.13). From the resultant dose response curves, the IC50 
values of wild type parasites was calculated to be 4.07 ± 0.21 M while that recorded for the 
recombinant line was almost 3-fold higher at 11.49 ± 0.59 M. 
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Figure 5.4.13: Susceptibility of L. major Friedlin wild type and LmNTR heterozygous 
parasites to nifurtimox 
(A) Dose response curves of L. major cells expressing lower levels of LmNTR (LmNTR
+/-
 
heterozygote; red) to nifurtimox was compared to L. major Friedlin wild type (in blue) 
parasites. The data points are averages derived from experiments performed in quadruplicate. 
(B) From the dose response curves, the IC50 values of L. major Friedlin and LmNTR 
heterozygote cells were determined. The data points are averages ± standard deviation 
derived from experiments performed in quadruplicate. 
 
While determining the above growth profiles, parasite samples were collected from day 5 
onward and, using a well-characterised agglutination technique (da Silva and Sacks 1987), 
metacyclic parasites were purified then quantified (Figure 5.4.14). Assessment of the 
numbers of metacyclics as a percentage of the total cell populations indicated that the 
LmNTR
+/-
 heterozygote promastigotes differentiate into the infectious-form cells at levels 
equivalent to wild type parasites when they reach the stationary phase of growth (density of 
above 1 x 10
7
 cells mL
-1
). Therefore, loss of a single LmNTR allele has no effect on the 
differentiation of promastigote parasites in to metacyclic-form cells. 
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Figure 5.4.14: Metacyclic production in LmNTR
+/-
 (BSR) L. major 
The growth of L. major LmNTR
+/-
 (BSR) heterozygote clone 2 (red squares) and wild type L. 
major Friedlin (blue diamonds) promastigotes was monitored until cultures were in the 
stationary phase of growth (see Figure 5.4.12). At day 5 (and every day until day 10), an 
aliquot (1 mL) of each culture was taken and metacyclic parasites purified following 
agglutination of promastigotes using peanut lectin (see Section 3.2.1). The number of 
metacyclic parasites was then determined. For each cell line, metacyclic loads from three 
independent cultures were evaluated. The data is expressed as a % metacyclics load in the 
total L. major population. 
 
Next, we assessed the ability of LmNTR heterozygote cells to infect mammalian cells using 
an in vitro tissue culture protocol or animals. For the former experiments we made use of the 
luciferase expressing LmNTR
+/-
 BSR line (see Section 5.4.2): these cells were shown to 
exhibit a promastigote growth and metacyclogenesis at levels equivalent to wild type/non-
luciferase expressing LmNTR heterozygotes (data not shown). A series of mammalian 
differentiated THP-1 cultures were infected with purified luciferase-expressing L. major 
Friedlin or LmNTR
+/-
 BSR metacyclic parasites under the conditions previously noted 
(Section 4.3). At time intervals, extracts were generated from cultures and the luciferase 
activity determined over a 4 day post-infection period (Figure 5.4.15). After correcting for 
background luminescence (lysed, uninfected macrophages), the reporter signal generated 
from LmNTR
+/+
 homozygote amastigotes increased appearing to plateau by day 4 post-
infection. In contrast, LmNTR
+/-
 heterozygote cultures exhibited luminescence values 
equivalent to background, giving a highly statistically significant difference between the two 
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cell lines by day 3 (Student’s t-test, p < 0.01). Based on these data it appears that disruption 
of one LmNTR allele results in haploid insufficiency such that L. major amastigotes are 
unable to grow. 
 
 
Figure 5.4.15: Growth of LmNTR
+/-
 heterozygote amastigote parasites in tissue cultured 
mammalian cells 
In a 24-well plate, differentiated THP-1 cells (2.5 x 10
4
 cells per well) were infected 
overnight with purified metacyclic L. major (5 x 10
5
 cells per well, giving a ratio of 20 
parasites per mammalian cell). The following day, non-internalised parasites were removed 
by extensive washing before growing the cells at 37
o
C in a 5% CO2 atmosphere in fresh 
medium. On days 1, 2, 3 and 4 post-infection, cells were lysed (in 100 μL lysis buffer) and 
the luciferase activity, as measured in arbitrary light units (ALU), for 20 μL of each extract 
was determined. The background corrected luciferase activity, used as a measure of 
amastigote load, was plotted against time. The cell lines used were a luciferase-expressing L. 
major LmNTR
+/-
 (BSR) heterozygote clone (red squares) and luciferase-expressing L. major 
Friedlin (blue diamonds), with three independent cultures per cell line evaluated at each time 
point. The data are means from the replicate counts ± standard deviations. 
 
To determine whether the in vitro amastigote proliferation defect translates to problems with 
in vivo infectivity, BALB/c mice were infected with wild type or LmNTR
+/-
 heterozygote L. 
major metacyclic cells, through injection into their footpad. Over a period of 80 days, the 
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mice were studied and measurements taken of any footpad lesion that developed. Over an 80 
day period, the presence and size of any footpad lesions was monitored. For mice infected 
with wild type parasites, a wound was detected by day 31 that gradually increased in size to 
give lesions that ranged in size from 5.5 to 9.5 mm diameter. By day 75 these mice were 
euthanized. Interestingly, the three mice infected with LmNTR
+/-
 heterozygote cells presented 
no signs of lesion by day 80 (Figure 5.4.16). This strongly indicates that the function of 
LmNTR is important in establishing and expansion of a L. major infection. 
 
 
 
Figure 5.4.16 LmNTR
+/-
 heterozygote L. major are not infectious to mice 
Purified LmNTR
+/-
 (BSR) heterozygote clone (red squares) and wild type L. major Friedlin 
(blue diamonds) metacyclic parasites (2 x 10
6
) were inoculated into the footpad of BALB/c 
mice. Periodically, the size of the lesion was measured. For each cell line, three mice were 
infected and the data is expressed as the mean lesion size (in mm) ± standard deviation. All in 
vivo work was performed at the London School of Hygiene and Tropical Medicine by Dr 
Karin Seifert. 
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5.5 Chapter summary 
Characterisation of LmNTR has shown that: 
1. The L. major genome contains a single gene encoding for a type 1 nitroreductase, 
designated as LmNTR. 
2. The catalytic domain of LmNTR can be heterologously expressed in E. coli and 
readily purified as a His6-tagged recombinant protein. 
3. The purified recombinant protein non-covalently binds FMN as a cofactor. 
4. The purified recombinant protein mediates the metabolism of a wide range of 
nitroaromatic and quinone-based compounds, preferentially using NADH as source of 
reductant. 
5. Metabolism of nitroaromatic and quinone-based substrates occurs in the presence of 
oxygen via a ping-pong kinetic mechanism. 
6. Expression of elevated levels of LmNTR in L. major promastigotes appears to be 
deleterious to cell growth. 
7. In promastigote-form parasites, a single LmNTR allele can be readily deleted from the 
L. major genome indicating that reduction in levels of this enzyme does not affect 
promastigote growth or metacyclogenesis. 
8. In promastigote-form parasites, both allelic copies of LmNTR cannot be deleted from 
the L. major genome, indicating that complete absence of this enzyme is lethal to 
promastigotes. 
9. LmNTR+/- heterozygotes are unable to replicate in the intracellular amastigote-form 
parasites in tissue culture or animal model systems indicating haploid insufficiency.  
10. The above data demonstrate that LmNTR levels play a crucial role in the parasite 
growth of the two replicative stages tested here. 
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6. Evaluating nitroaromatic compounds as leishmanicidal prodrugs 
Current treatments used against the various forms of leishmaniasis are problematic (Croft and 
Olliaro 2012). Several cause unwanted toxic side effects, resistance in a clinical context has 
been reported for others while most require medical supervision for administration. 
Additionally, many of the drugs that have recently come onto the market are expensive and 
their use is restricted. Against this backdrop, there is an urgent requirement for new, safe and 
cost effective therapies that can ideally be given as an oral dose. One group of compounds 
that meets many of these prerequisites are the nitroaromatics. Although concerns about the 
toxicity and mutagenic activity of some chemicals in this class have been raised, a number of 
the most commonly prescribed antibiotics belong to this grouping, for example 
metronidazole, tinidazole, furazolidone, nitrofurazone etc. Here, we report the biochemical 
and leishmanicidal screens of a range of novel nitroaromatic compounds aimed at evaluating 
their potential as antiparasitic agents, and examine the role played by LmNTR in these 
activities. A total of 52 structures across 4 distinct compound classes were analysed 
consisting of 22 nitrobenzyl phosphoramide mustards (NBPMs), 13 aziridinyl 
nitrobenzamides (ANBs), 8 nitrofurans and 9 nitrobenzamides. Below, the 
biochemical/cytotoxicity screens performed for each of these classes are described. 
 
6.1 Biochemical and toxicity screening of nitrobenzyl phosphoramide mustards 
Phosphoramide mustards such as cyclophosphamide and ifosfamide have been used as 
anticancer agents since the late 1950s (Arnold et al. 1958, Colvin 1999, Carli et al. 2003). 
These structures have recently been combined with a nitrobenzyl substituent group to 
generate a series of nitroreductase activated prodrugs . In mammalian cell lines engineered to 
express the E. coli type I nitroreductase, such compounds exhibit significant levels of 
cytotoxicity while certain variants display trypanocidal properties (Hu, Yu et al. 2003, Hall, 
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Wu et al. 2010, Hu, Wu et al. 2011). Using compounds supplied by Prof Lonqin Hu (Rutgers, 
the State University of New Jersey), we evaluated their potential against L. major then tested 
investigated their toxicity toward mammalian cells. 
 
Initially, biochemical screens were conducted using purified recombinant LmNTR and a 
range of NBPMs to determine whether these compounds functioned as substrate for the 
parasite enzyme, and to elucidate any structure-activity relationships. In the presence of 35 μg  
LmNTR, assays were performed using fixed concentrations of nitroaromatic (100 μM) and 
reductant (NADH; 100 μM) and the rate of oxidation of NADH followed by monitoring the 
change in absorbance at 340 nm (Section 3.7.5) with each compound analysed in triplicate. 
From the resulting slopes, the enzyme activity was calculated and expressed as nmol NADH 
oxidised min
-1
 mg ΔLmNTR-1 as a bar chart (Figure 6.1.1). 
 
Figure 6.1.1: Evaluating nitrobenzyl phosphoramide mustards as LmNTR substrates 
A series of NBPMs were assayed to determine whether they could drive LmNTR activity. 
Enzyme assays were performed using a 50 mM Tris-Cl pH 7.5 buffer, 100 μM NADH and 
100 μM electron acceptor. The assay mixture was incubated at room temperature for 5 min 
from which the background reaction rate was determined. The assay was then initiated by 
addition of recombinant LmNTR (35 μg), and the rate of NADH consumption was recorded 
by following the change in absorbance at 340 nm. From the resultant graphs, the enzyme 
activity was then calculated using an ε value of 6,220 M-1 cm-1, giving values of enzyme 
activity in nmol NADH min
-1
 mg ΔLmNTR-1. The values shown are the means of data from 
three experiments ± standard deviations. 
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Of the 22 compounds analysed, 8 structures (designated as cyclic NBPMs) consisted of a 
nitrobenzyl group attached either directly or through a carbamate linker to a 
cyclophosphamide grouping with 14 structures (designated as acyclic NBPMs) containing the 
phosphoramide mustard as part of a linear arrangement linked to the a nitrobenzyl group 
containing various substituents (Appendix B). Based on this preliminary biochemical screen, 
the compounds could be divided into those that were not LmNTR substrates (activity <20 
nmol NADH oxidised min
-1
 mg ΔLmNTR-1), those that stimulated a moderate activity 
(between 20-60 nmol NADH oxidised min
-1
 mg ΔLmNTR-1) and those that were readily 
metabolised by the parasite enzyme (>60 nmol NADH oxidised min
-1
 mg ΔLmNTR-1). Using 
this as a crude measure, 3 cyclic NBPMs (LH5, 6 and 12) were evaluated as moderate 
substrates while 5 showed little or no LmNTR activity. In contrast, most (11) of the cyclical 
structures were metabolised by LmNTR with 4 (LH27, 31, 33 and 37) showing high levels of 
activity. Of those substrates driving the higher activities, 3 contain halogen groups attached to 
the nitrobenzyl ring. 
 
We next evaluated the growth inhibitory properties of the NBPMs towards L. major 
promastigotes and amastigotes using resazurin or luciferase as reporter, respectively (Section 
3.3). An initial screen with all 22 compounds was conducted using a fixed concentration of 
30 μM against the promastigote and 10 μM against the amastigote, due to the apparent 
difference in susceptibilities between these two life cycle forms mentioned in Section 4.4. For 
the compounds that exhibited leishmanicidal properties in the initial assays, secondary 
screens were performed using a range of drug concentrations: 0, 0.3, 1, 3, 10 and 30 μM 
against L .major promastigotes and 0, 0.1, 0.3, 1, 3 and 10 μM against L .major amastigotes. 
From the resultant growth inhibition data, dose response curves for each agent were plotted 
(Figure 6.1.2) and the IC50 values determined (Table 6.1.1).  
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Figure 6.1.2: Dose response curves of L. major and THP-1 cells to nitrobenzyl 
phosphoramide mustards 
Various concentrations of leishmanicidal NBPMs were tested against L. major and THP-1 
cells. The growth inhibitory effect of each treatment was evaluated and dose response curves 
constructed for promastigotes (blue line), amastigotes (red line) and THP-1 cells (green line). 
In all cases the drug treatments were performed in triplicate and the plots shown represent the 
average growth inhibition obtained at each concentration. The curves for compounds LH32, 
LH34 and LH37 are shown. 
 
compounds 
L. major IC50 (M) differentiated THP-1 
IC50 (M) 
selective 
toxicity promastigotes amastigotes 
LH3-9 LH12-15; 
LH17-18; LH24 
>30 >10 nd nd 
LH16 15.6 ± 1.13 2.75 ± 0.40 >100 >36 
LH19 >30 4.72 ± 0.55 >100 >21 
LH27 16.23 ± 0.29 4.65 ± 0.15 >100 >22 
LH31 9.05 ± 0.56 7.00 ± 0.40 >100 >14 
LH32 4.72 ± 0.23 1.09 ± 0.21 >100 >92 
LH33 5.88 ± 0.28 0.21 ± 0.07 >100 >476 
LH34 3.10 ± 0.28 0.77 ± 0.12 >100 >143 
LH37 1.29 ± 0.08 2.17 ± 0.27 >100 >46 
 
Table 6.1.1: Susceptibility of L. major and THP-1 cells to nitrobenzyl phosphoramide 
mustards 
For all data, the IC50 values are averages ± standard deviation (where appropriate) derived 
from experiments performed in triplicate. The selective toxicity compares a compound’s IC50 
value against the mammalian line with that recorded against L. major amastigotes. nd is not 
determined. 
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We then determined the growth inhibitory properties displayed by all the leishmanicidal 
NBPMs towards differentiated THP-1 cells using resazurin as reporter (Figure 6.1.2; Table 
6.1.1). Under these conditions none of the compounds showed significant in vitro toxicity. 
Comparison of the mammalian toxicity IC50 value with that determined against the L. major 
amastigote for a given compound gives a crude measure of its selectivity (Table 6.1.1). For 3 
compounds (LH32, 33 and 34), selective toxicity values of around 100 or greater were 
observed. 
 
To demonstrate that NTR plays a role in NBPM prodrug activation within the parasite itself, 
the susceptibility of L. major LmNTR
+/-
 heterozygote promastigotes to LH33 and LH34 was 
investigated (Figure 6.1.3). For both compounds, cells with reduced levels of the 
nitroreductase were more resistant to the agent than wild type controls. For LH33, wild type 
L. major had an IC50 value of 4.73 ± 0.29 M while L. major LmNTR
+/-
 heterozygote cells 
had an IC50 value of 7.66 ± 0.23 M; and for LH34, wild type L. major had an IC50 value of 
3.70 ± 0.40 M while L. major LmNTR+/- heterozygote cells had an IC50 value of 12.14 ± 
0.84 M (Figure 6.1.4). 
 
Figure 6.1.3: Dose response curves of L. major Friedlin wild type and LmNTR 
heterozygous parasites to LH33 and LH34 
Dose response curves of L. major cells having lower levels of LmNTR (LmNTR 
heterozygote; red) to LH33 and LH34 was compared to L. major Friedlin wild type (in blue) 
parasites. The data points are averages derived from experiments performed in quadruplicate.  
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Figure 6.1.4: IC50 values of L. major Friedlin wild type and LmNTR
+/-
 heterozygous 
parasites to LH33 and LH34 
From the dose response curves shown in Figure 6.1.3, the IC50 values of L. major Friedlin 
and LmNTR heterozygote cells was determined. The data points are averages ± standard 
deviation derived from experiments performed in quadruplicate. 
 
Based on our findings, NBPMs that contain the phosphoramide mustard as part of an acyclic 
structure and have halogen substituents on the nitrobenzyl ring are the most readily 
metabolised by the LmNTR enzyme and represent the most potent agents against both L. 
major promastigotes and amastigotes. Some (LH32, 33 and 33) have IC50 values of 1 μM or 
less against the intracellular stage without inducing mammalian cell toxicity. 
 
6.2 Biochemical and toxicity screening of aziridinyl nitrobenzamides 
The ANB class of nitroaromatic compounds are derived from the lead CB1954 (also called 
tretazicar). This structure was initially developed as an anticancer agent and is undergoing 
clinical evaluation in two distinct regimes, involving either a bacterial type I NTR-based gene 
therapy approach or in partnership with caricotamide in the Prolarix™ combinatorial treatment 
(Chung-Faye et al. 2001, Patel et al. 2009). CB1954 and several derivatives are trypanocidal, 
an activity that is dependent on type I NTR expression by the parasites (Bot, Hall et al. 2010). 
As with the NBPMs, we evaluated whether 13 ANBs, supplied by Dr Nuala Helsby 
(University of Auckland) and Developmental Therapeutics Program/National Cancer 
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Institute, were substrates for the LmNTR enzyme before assessing their toxicity towards L. 
major and mammalian cells. 
 
As described previously, biochemical tests using fixed amounts of electron donor (NADH; 
100 μM) and acceptor (ANB; 100 μM) were performed in the presence of purified 
recombinant ΔLmNTR (35 μg). However, examination of the absorbance spectrum of 
CB1954 and its derivatives revealed that during reduction they exhibit considerable changes 
in absorbance at 340 nm themselves. This precluded following NADH oxidation as a means 
of monitoring enzyme activity. Consequently, these compounds were assayed at 425 nm, the 
peak absorbance of the hydroxylamine derivative of this class of compounds (Race, Lovering 
et al. 2007, Bot, Hall et al. 2010) (Figure 6.2.1). 
 
 
Figure 6.2.1: Biochemical screens of aziridinyl nitrobenzamides 
Recombinant LmNTR activity assays across a series of ANBs. Enzyme assays were 
performed using a 50 mM Tris-Cl pH 7.5 buffer, 100 μM NADH and 100 μM electron 
acceptor. The assay mixture was incubated at room temperature for 5 min from which the 
background reaction rate was determined. The assay was then initiated by addition of 
recombinant LmNTR (35 μg). The rate of ANB consumption was recorded by determining 
the rate of increase in absorption at 425 nm that corresponds to the production of the 
hydroxylamine derivative from the parent compound. The enzyme activity was then 
calculated using an ε value of 1,220 M-1 cm-1 and assuming that 4 molecules of NADH are 
oxidised per molecule of ANB reduced (Race, Lovering et al. 2007, Bot, Hall et al. 2010), 
expressed in nmol NADH mg ΔLmNTR-1 min-1. 
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This class of compounds, like the NBPMs, show a range of ΔLmNTR activities, with 9 
compounds, including CB1954, displaying enzyme activities greater than 50 nmol NADH 
min
-1
 mg ΔLmNTR-1. It is interesting to note that NH3-5 exhibit low enzyme activities. 
These compounds represent a sub-class of ANBs that contain only one nitro substituent at the 
2-position on the benzyl ring with in respect to the aziridinyl moiety: all other compounds 
contain two nitro groups on the benzyl ring at both the 2 and 4-positions. 
  
The growth inhibitory properties of the ANBs towards L. major promastigotes and 
amastigotes were then determined (Section 3.3). As with the NBPMs, an initial screen was 
conducted against both life cycle stages using the fixed concentrations of nitroaromatic (10 
μM against both parasite forms). The structures NH3-5 and NH7-8 had no effect on either 
parasite form with NH9 and NH12 having no activity against promastigote cells. Secondary 
screens were then conducted for the leishmanicidal compounds identified from the initial test 
using a variety of different drug ranges. The resultant growth inhibition data was then used to 
generate dose response curves for each agent tested (Figure 6.2.2) from which the IC50 values 
were determined (Table 6.2.1).  
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Figure 6.2.2: Dose response curves of L. major and THP-1 cells to aziridinyl 
nitrobenzamides 
Various concentrations of leishmanicidal ANBs were tested against L. major and THP-1 
cells. The growth inhibitory effect of each treatment was evaluated and dose response curves 
constructed for promastigotes (blue line), amastigotes (red line) and THP-1 cells (green line). 
In all cases the drug treatments were performed in triplicate and the plots shown represent the 
average growth inhibition obtained for each concentration. The curves for compounds 
CB1954, NH6 and NH10 are shown. 
 
compounds 
L. major IC50 (M) differentiated 
THP-1 IC50 (M) 
selective 
toxicity promastigotes amastigotes 
NH3-5; NH7-8 >10 >10 nd nd 
CB1954 0.42 ± 0.01 0.05 ± 0.02 >100 >2000 
NH1 7.32 ± 0.63 11.15 ± 2.01 >100 >9 
NH2 1.48 ± 0.18 2.95 ± 1.14 >100 >34 
NH6 6.85 ± 0.18 2.10 ± 0.22 >100 >48 
NH9 >10 0.67 ± 0.05 >100 >149 
NH10 0.49 ± 0.04 0.56 ± 0.05 >100 >178 
NH11 0.91 ± 0.07 0.06 ± 0.01 >100 >1667 
NH12 >10 1.32 ± 0.02 >100 >76 
 
Table 6.2.1: Susceptibility of L. major and THP-1 cells to aziridinyl nitrobenzamides  
For all data, the IC50 values are averages ± standard deviation (where appropriate) derived 
from experiments performed in triplicate. The selective toxicity compares the IC50 value 
against the mammalian line with that recorded against L. major amastigotes for a given 
compound. nd is not determined. 
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The cytotoxicity screens against differentiated THP-1 cells revealed that none of the tested 
compounds displayed significant inhibitory activity towards this mammalian line (Figure 
6.2.2; Table 6.2.1). Comparisons of the IC50 data indicated that several compounds (CB1954, 
NH9, NH10 and NH11) all show significant selectivity against L. major amastigotes with two 
recording selective toxicity values in excess of 1500-fold. As such these compounds warrant 
further attention with regards to drug development targeting cutaneous leishmaniasis and 
possibly against other forms of this disease.  
 
6.3 Susceptibility screening of other nitroaromatic compounds 
In addition to the aziridinyl containing nitrobenzamides, several non-aziridinyl based 
antimycobacterial nitrobenzamide structures, developed by Dr Priscille Brodin (Institute 
Pasteur, Korea) (Christophe et al. 2009), were evaluated as potential leishmanicidal agents. 
Initial biochemical screens using purified ΔLmNTR and a range of these compounds were 
performed, aimed at determining whether any of these structures functioned as substrate for 
the parasite enzyme. All assays were conducted using fixed concentrations of nitroaromatic 
(100 μM) and reductant (NADH; 100 μM) and the rate of oxidation of NADH followed by 
monitoring the change in absorbance at 340 nm (Section 3.7.5). Purified recombinant 
LmNTR (35 μg) was then added to the reaction and the NADH oxidation monitored. From 
the resulting slopes, the enzyme activity was calculated and expressed as nmol NADH 
oxidised min
-1
 mg ΔLmNTR-1 as a bar chart (Figure 6.3.1). Most nitrobenzamide compounds 
tested generated a reasonable level of NADH oxidation indicating that these compounds are 
effectively metabolised by LmNTR. The only substrate that failed to generate an enzymatic 
response was IPK2 with two further chemicals (IPK6 and IPK9) omitted from these assays 
due to solubility problems. 
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Figure 6.3.1: Evaluating nitrobenzamides as substrates for LmNTR 
The enzymatic activity of LmNTR towards IPK compounds was investigated. Using an assay 
buffer containing 50 mM Tris-Cl pH 7.5 buffer, 100 μM NADH and 100 μM electron 
acceptor the background rate of NADH oxidation was followed for 5 min at room 
temperature by monitoring the change in absorbance at 340 nm: no compound exhibited 
significant absorbance properties at this wavelength.  The assay was then initiated by addition 
of recombinant LmNTR (35 μg), and the rate of NADH oxidation monitored. From the 
resultant graphs, the enzyme activity was then calculated using an ε value of 6,220 M-1 cm-1, 
giving values of enzyme activity in nmol NADH min
-1
 mg ΔLmNTR-1. The values shown are 
from single assays conducted by Ms Carissa Chu, an undergraduate student. IPK6 and IPK9 
were not analysed due to precipitation of substrates during the assay. 
 
Next, the leishmanicidal activities of all 9 nitrobenzamides were evaluated against 
promastigote and amastigote form parasites (Section 3.3). As with the other nitroaromatics, 
preliminary screens were conducted using the fixed concentrations of nitroaromatic (30 μM 
against the promastigote and 10 μM against the amastigote). This demonstrated that all 
structures had antimicrobial activity against intracellular parasites with only two (IPK1 and 8) 
effective against the insect stage. Secondary screens on the leishmanicidal compounds were 
then performed using a variety of different drug concentrations and from the resultant growth 
inhibition data, dose response curves were generated (Figure 6.3.2) from which the IC50 
values were determined (Table 6.3.1).  
 132 
 
 
Figure 6.3.2: Dose response curves of L. major and THP-1 cells to nitrobenzamides 
Various concentrations of leishmanicidal nitrobenzamide were tested against L. major and 
THP-1 cells. The growth inhibitory effect of each treatment was evaluated and dose response 
curves constructed for promastigotes (blue line), amastigotes (red line) and THP-1 cells 
(green line). In all cases the drug treatments were performed in triplicate and the plots shown 
represent the average growth inhibition obtained at each concentration. The curves for 
compounds IPK1 and IPK8 are shown. 
 
To evaluate cytotoxicity, growth inhibition studies at concentrations up to 100 M were then 
carried out on differentiated THP-1 cells. As for the anti-parasitic experiments, dose response 
curves were generated (see Figure 6.3.2 as an example) from which the IC50 values for 
particular compounds were determined (Table 6.3.1). For most compounds, toxicity was 
observed at the highest concentration (100 M) but even at this drug level all cultures 
displayed more than 50% growth.  Comparisons of mammalian and amastigote IC50 data 
indicated that all showed significant selectivity toward intracellular L. major, with one (IPK6) 
recording a selective toxicity value in excess of 1500-fold and several others (IPK3 and 
IPK7) around 500. 
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compounds 
L. major IC50 (M) differentiated 
THP-1 IC50 (M) 
selective 
toxicity promastigotes amastigotes 
IPK1 1.34 ± 0.40 0.20 >100 >500 
IPK2 >10 0.86 >100 >116 
IPK3 >10 0.20 >100 >500 
IPK4 >10 1.00 >100 >100 
IPK5 >10 1.05 >100 >95 
IPK6 >10 0.06 >100 >1667 
IPK7 >10 0.21 >100 >476 
IPK8 1.79 ± 0.21 0.35 >100 >286 
IPK9 >10 0.61 >100 >164 
 
Table 6.3.1: Susceptibility of L. major and THP-1 cells to nitrobenzamides 
For promastigote and THP-1 data, the IC50 values are averages ± standard deviation (where 
appropriate) derived from experiments performed in triplicate. For the amastigote data, the 
IC50 values are derived from three independent lysates that were pooled prior to luminescence 
detection and appear without standard deviations. The selective toxicity compares a 
compound’s IC50 value against the mammalian line with that recorded against L. major 
amastigotes. nd is not determined. 
 
To conclusively demonstrate that the leishmanial type I NTR plays a key role in 
nitrobenzamide activation in the parasite itself, the susceptibility of L. major LmNTR
+/-
 
heterozygote promastigotes was investigated. For IPK1 (Figure 6.3.3 A), one of the two 
compounds effective against this particular life cycle stage, cells with reduced levels of the 
nitroreductase were approximately 2-fold more resistant to the compound than controls: wild 
type L. major had an IC50 value of 2.85 ± 0.31 M to IPK1 while L. major LmNTR 
heterozygote cells had an IC50 value of 5.30 ± 0.83 M (Figure 6.3.3 B).  
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Figure 6.3.3: Susceptibility of L. major Friedlin wild type and LmNTR
+/-
 heterozygous 
parasites to IPK1 
(A) Dose response curves of L. major cells expressing lower levels of LmNTR (LmNTR 
heterozygote; red) to IPK1 was compared to L. major Friedlin wild type (in blue) parasites. 
The data points are averages derived from experiments performed in quadruplicate. (B) From 
the dose response curves, the IC50 values of L. major Friedlin and LmNTR
+/-
 heterozygote 
cells were determined. The data points are averages ± standard deviation derived from 
experiments performed in quadruplicate. 
 
The final class of nitroaromatic tested were a series of nitrofurans synthesized by Dr Adrian 
Dobbs (Queen Mary University of London).  Due to time constraints, only toxicity screens 
were conducted targeting the L. major replicative forms and THP-1 cells. In growth 
inhibition assays, all compounds displayed potency against promastigote and amastigote 
parasites with several displaying significant cytotoxicity toward the mammalian cell line 
(Figure 6.3.4; Table 6.3.2). Despite this, some structures showed selectivity against the 
intracellular parasite, generating reasonable selective toxicity ratios – for example MNG5a 
and MNG10a are 153- and 234-fold more effective against the parasite than the mammalian 
cell respectively.  
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Figure 6.3.4: Dose response curves of L. major and THP-1 cells to nitrofurans 
Various concentrations of leishmanicidal nitrofuran were tested against L. major and THP-1 
cells. The growth inhibitory effect of each treatment was evaluated and dose response curves 
constructed for promastigotes (blue line), amastigotes (red line) and THP-1 cells (green line). 
In all cases the drug treatments were performed in triplicate and the plots shown represent the 
average growth inhibition obtained at each concentration. The curves for compounds AD3 
and MNG11a are shown. 
 
compounds 
L. major IC50 (M) differentiated 
THP-1 IC50 (M) 
selective 
toxicity promastigotes amastigotes 
nifurtimox 6.28 ± 0.04 2.15 ± 0.01 >100 >47 
AD1 4.60 ± 2.55 9.75 nd nd 
AD2 0.43 ± 0.02 1.50 15.90 ± 0.50 11 
AD3 1.23 ± 0.21 5.15 >100 >19 
MNG5a 2.13 ± 0.12 0.65 99.50 ± 8.38 153 
MNG7a 3.35 ± 0.4 1.80 >100 >56 
MNG10a 0.22 ± 0.01 0.35 81.88 ± 13.09 234 
MNG11a 1.08 ± 0.15 1.45 93.82 ± 2.01 65 
 
Table 6.3.2: Susceptibility of L. major and THP-1 cells to nitrofuran-based compounds 
For promastigote and THP-1 data, the IC50 values are averages ± standard deviation (where 
appropriate) derived from experiments performed in triplicate. For the amastigote data, the 
IC50 values are derived from three independent lysates that were pooled prior to luminescence 
detection and appear without standard deviations. The selective toxicity compares the IC50 
value against the mammalian line with that recorded against L. major amastigotes for a given 
compound. nd is not determined. 
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The above screens against L. major amastigotes using 52 nitroaromatic compounds identified 
15 compounds that show selective growth inhibition (selectivity toxicity ratios of >100).  
Some of these structures are shown in Figure 6.3.5. This represents a hit rate of just below 
30% and clearly demonstrates how understanding the basic biology behind prodrug activation 
can aided in identifying new lead compounds that warrant further evaluation to treat 
leishmaniasis. 
 
 
 
Figure 6.3.5: Structures of the several effective compounds identified in the L. major 
amastigote screens 
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6.4 Chapter summary 
By assaying several classes of nitroaromatic compound as potential ΔLmNTR substrates, as 
well as inhibitors of L. major growth in both life cycle stages, we have demonstrated that: 
1. Halogenated acyclic NBPMs show significant activity using recombinant, purified 
ΔLmNTR. 
2. Halogenated acyclic NBPMs also show strong antiparasitic properties and high 
selectivity against mammalian cells. LH33 and LH34 show IC50 values against 
amastigote L. major in the nano molar range. 
3. ANB compounds lacking a second nitro group on the 4-position of the aromatic ring 
in respect to the aziridinyl moiety (sub-class Ib) exhibited little to no ΔLmNTR 
activity, unlike the other ANBs which drive significant NADH turnover. 
4. ANB compounds that exhibit activity in the biochemical screen show strong 
antiparasitic behaviour (with the exception of NH7) and high selectivity. Most 
promising are CB1954 and NH11, which exhibit IC50 values against amastigote L. 
major of 0.05 ± 0.02 μM and 0.06 ± 0.01 μM respectively. 
5. The nitrobenzamides tested show great promise as potential future leishmaniasis 
therapies, as all 9 compounds show IC50 values against amastigote L. major of around 
or below 1 μM, with all exhibiting high selectivity.  
6. The nitrofuran compounds tested show reasonable parasite killing properties, however 
4 of the 9 compounds tested unfortunately show cytotoxicity against mammalian 
cells, with IC50 values against differentiated THP-1s lower than 100 μM. 
7. Loss of an allele of LmNTR causes (~2 to 3-fold) resistance to a number of these 
nitroaromatics, suggesting that cytotoxicity is mediated via LmNTR activation. 
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7. Discussion 
To facilitate the identification of novel leishmanicidal compounds, here we report the 
construction of an integrative DNA vector containing the gene encoding for luciferase and 
the characterisation of recombinant L. major lines expressing this reporter. This system has 
allowed us to: 
1. Establish a high-throughput, 96-well plate based drug screening assay. 
2. Identify several nitroaromatic compounds that exhibit significant growth inhibitory 
activities against the parasite with little cytotoxicity towards mammalian cells. 
3. Evaluate the phenotype of intracellular L. major with a reduced type I 
nitroreductase gene copy number  
 
For several decades, the “gold-standard” method used to screen for leishmanicidal 
compounds involved directly counting Giemsa stained Leishmania cells within infected 
macrophages. Although giving reproducible results, this has proven to be extremely laborious 
and incompatible with a high throughput screening process. This type of intact, whole cell 
analysis has been improved upon using a computer-based cell counting algorithm pioneered 
for use in T. cruzi (Engel et al. 2010) and recently applied to L. donovani (De Muylder et al. 
2011). This kind of approach involves fixing parasite-infected mammalian cells after 
treatment with a given compound, staining the pathogen/host cell’s DNA with an appropriate 
dye (such as DAPI) and then capturing the resultant images. The algorithm then distinguishes 
between mammalian and pathogen cells simply on the genome size making use of the large 
cell nucleus in the former as compared to the relatively small kinetoplast (mitochondrial 
genome) in the parasites. One of the key advantages of this method, as with the Giemsa 
staining method, is that wild type parasites can be used, allowing the analysis of clinical 
relevant strains. However, the drawbacks of this method is that it requires proprietary image 
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capturing equipment and analysis software coupled with the fact that it cannot be applied to 
in vivo animal models. Consequently, most other alternatives to the classical DNA stain 
approaches involve the creation of genetically modified parasite lines. Cell lines expressing 
ectopic copies of β-galactosidase, first produced to validate transfection protocols (LeBowitz, 
Coburn et al. 1991), were applied to compound screening regimens in 2003 (Okuno, Goto et 
al. 2003). This method, although not particularly sensitive and suffering from background 
issues, did establish that such procedures could be employed in drug development. Attempts 
to improve this system using other colorimetric reporters, e.g. the β-lactamase gene, also 
suffered with sensitivity problems (Buckner and Wilson 2005) and have generally been 
superseded by other genetically modified parasite lines. One such approach taken has been to 
label recombinant Leishmania with a fluorescent protein such as RFP, GFP or eGFP (Kamau, 
Grimm et al. 2001, Singh and Dube 2004, Singh, Gupta et al. 2009, Bolhassani, Taheri et al. 
2011, Pulido, Muñoz et al. 2012; Okuno, Goto et al. 2003). Although these systems are 
relatively easy to implement and allow for easy kinetic monitoring, they often experience 
sensitivity problems. For example, the signal emitted by the “standard” GFP is too low for 
use in a 96-well microtitre format although implementation of a multimeric form of this 
fluorescent protein has been shown to overcome this problem (Chan, Bulinski et al. 2003). 
Additionally, many lines expressing fluorescent proteins do so via episomal vectors. Such 
expression systems are flawed, given that the copy number of such plasmids varies between 
cells within the same population, resulting in highly variable fluorescence signals. Moreover, 
without appropriate drug selection such genetic elements can be readily lost. However, the 
presence of a drug required to maintain plasmid selection could lead to interactions with the 
compound(s) of interest. As a consequence, cell lines containing a stably-integrated GFP are 
now available (Singh, Gupta et al. 2009, Bolhassani, Taheri et al. 2011). 
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Perhaps the most reliable and versatile Leishmania reporter system developed to date 
involves the use of luciferase. Both episomal and integrative vectors have been constructed 
and used to indirectly monitor cell numbers as a function of luminescence (Roy et al. 2000; 
Sereno et al. 2001; Gupta et al. 2005; Lang et al. 2005; Thalhofer et al. 2010; Michel et al. 
2011). Although this system requires relatively expensive luciferin-containing buffers, it is 
sensitive, rapid, and reproducible and can be applied to multiple parasite life cycle stages. 
Additionally, using luciferase-expressing cell lines is compatible with high throughput 
screening and in vivo imaging in a mammalian model. 
 
After evaluating all the different reporter systems available at the start of the project, we 
decided to construct our own luciferase vector system and after transfection, generate our 
own recombinant parasite cells. To this end, we modified an existing T. cruzi integration 
expression vector and made it compatible for use in L. major (Figure 4.1.5). The resultant 
recombinant lines were shown to behave similarly to wild type L. major Friedlin with regards 
promastigote growth, ability to undergo metacyclogenesis and proliferation in the 
intracellular amastigote form (Sections 4.2 and 4.3). This extended to an in vivo animal 
model situation where the luciferase expressing cells were able to infect and cause cutaneous 
pathology in BALB/c mice (Figure 4.3.3). Interestingly, standard firefly luciferase systems 
have recently been applied to combine in vivo and ex vivo methods for drug screening and 
monitoring of Leishmania in a real time infection (de La Llave et al. 2011, Michel, Ferrua et 
al. 2011), with the LmRIX-Luc cell lines now available for similar applications. However, it 
may be advantageous to use red-shifted variants of the reporter as the luminescence signal 
derived from these modified proteins show better tissue penetration in whole animals models 
than standard firefly luciferase (Lewis and Kelly, unpublished). Additionally, studies using 
luciferase-expressing T. brucei showed that in vivo imaging is not without its problems. 
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Assumptions are made that the luciferase substrate luciferin is distributed evenly throughout 
the animal after administration, and that any luminescence signals are visualised equally 
irrespective of the infected organ. However, it is apparent that this is not the case with 
luminescence readings from extracted organs not necessarily agreeing with the signals 
detected in the live animal (Claes, Vodnala et al. 2009). 
 
Once it had been established that luciferase expression by L. major did not affect the growth 
of the replicative stages, we next determined whether these recombinant cells could be used 
in drug screening. Initially, we conducted a series of assays using nifurtimox as selective 
agent against promastigote and amastigote parasites. For the promastigotes, we adapted a 96-
well plate format growth inhibition protocol that used resazurin (in the form of 
alamarBlue™) as reporter of cell density (Mikus et al. 2000 – modified by Chu & Wilkinson, 
unpublished). When these conditions were applied to the luciferase-based assay, an IC50 
value of 7.5 ± 0.42 μM was determined, comparable with the value obtained by other 
methods (e.g. using resazurin). For the amastigote drug assay, the optimal conditions for 
mammalian cell infection and time course of an infection in a 96-well plate assay were 
determined (Section 4.3). Using a ratio of 20 infectious-form metacyclic L. major (purified 
from promastigote cultures in the stationary phase of growth) to each mammalian cell, an 
overnight infection and a 3 day post infection incubation period in the presence of nifurtimox, 
the IC50 was determined to be 0.58 ± 0.06 μM, similar to the value recorded for the related, 
intracellular parasite T. cruzi (Bot, Hall et al. 2010). This indicates that amastigote cells are 
(13-fold) more susceptible to this particular 5-nitrofuran than promastigotes, with nifurtimox 
displaying little/no cytotoxicity to the mammalian cell line used in the infection (IC50 value 
>100 μM). Why there is a difference in the IC50 values is unclear but may reflect variations 
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between the two parasite forms in relation to prodrug uptake, prodrug activation and/or the 
availability of molecules targeted by any toxic metabolites generated following activation.  
 
After demonstrating that the luciferase-expressing amastigotes could be used in a 96-well 
plate drug screening assay we extended these tests to encompass a range of other 
nitroaromatic compounds, specifically the nitrobenzyl phosphoramide mustards (NBPMs), 
aziridinyl nitrobenzamides (ANBs), non-aziridinyl nitrobenzamides and nitrofurans. This 
identified a series of lead structures whose growth inhibition data was then compared to the 
IC50 values obtained against promastigotes and differentiated mammalian THP-1 cells – the 
promastigote and mammalian IC50 values were collected using the vital dye resazurin. For the 
NBPM series, 8 compounds were shown to affect amastigote parasite growth at a 
concentration >10 M, with 7 of these displaying activity against the promastigote form at 
concentration >30 M (Table 6.1.1). In parallel, we also evaluated whether the NBPMs 
functioned as substrates for LmNTR. This demonstrated that all of the leishmanicidal 
compounds were metabolised by the parasite enzyme with 6 of the most potent anti-parasitic 
agents eliciting the highest enzymatic activities out of the entire chemical series (Figure 
6.1.1). Comparison of the NBPM structures revealed that compounds in this small library 
could be broadly divided into two sub-classes with the potent leishmanicidal/biochemical 
substrate data being associated with one of these groups. In general, one class of NBPMs 
where the phosphoramide linker is part of a cyclical arrangement (Appendix B), did not 
function as substrates for the parasite enzyme, with 3 showing low to moderate enzyme 
activity. None of these cyclical compounds affected parasite (promastigote or amastigote) 
growth. For the other compounds where the phosphoramide linker is part of a linear 
arrangement connecting the nitrobenzyl moiety to the mustard component, 11 out of 14 were 
metabolised by LmNTR. The compounds that elicited the highest enzymatic activities were 
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all related in that they contained an electron-withdrawing halogen substituent located on the 
nitro-containing aromatic ring. Intriguingly, those structures that were preferentially 
metabolised by ΔLmNTR displayed the highest potency towards the promastigote and 
amastigote parasites and had little/no associated mammalian cell cytotoxicity (Table 6.1.1). 
Previous biochemical and anti-parasitic studies using T. brucei/TbNTR or T. cruzi/TcNTR 
generated a similar structure activity relationship (Hall, Wu et al. 2010, Hu, Wu et al. 2011). 
Interestingly, comparison of the enzymatic data indicates that TbNTR metabolises the most 
active compounds at a level 10-100 times greater than that of TcNTR and LmNTR. This may 
reflect different metabolic requirements of the intracellular parasites T. cruzi and L. major as 
compared to T. brucei which lives extracellularly in the bloodstream. The involvement of 
LmNTR in prodrug activation within the parasite itself was demonstrated using LH33 and 
LH34 as L. major LmNTR
+/-
 heterozygote cells (Figures 6.1.3 and 6.1.4) are more resistant 
(1.6-fold and 3.3-fold respectively) to the NBPMs than wild type controls. Again this is in 
keeping with observations made using T. brucei (Hall, Wu et al. 2010). 
 
The mechanism of NPBM activation by NTR as posited by Hall et al. (2010) may account for 
their anti-parasitic behaviour.  By analogy with other type I NTRs, the LmNTR-mediated 
reduction of the electron-withdrawing nitro-group present on the benzyl ring is believed to 
generate an electron-donating hydroxylamine. This causes an electronic rearrangement along 
the NBPM backbone, ultimately promoting cleavage of a C-O bond found in the acyclic 
phosphoramide linker. Fragmentation of the compound then occurs resulting in release of a 
toxic mustard moiety (Hall, Wu et al. 2010, Wilkinson et al. 2011). The presence of a second 
electron-withdrawing group (e.g. a halogen) on the benzyl ring adjacent to the 
phosphoramide leaving group exacerbates this electronic “switch” by making the nitro group 
more prone to reduction. As a consequence, such NBPMs are more likely to become 
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“activated” and thus release the cytotoxic metabolites more readily into the cell. As this type 
of nitroreductase is absent from mammalian cells, it is the expression of type I NTR by the 
parasite itself that underlies the selectivity of such nitroaromatic prodrugs. When tested 
against differentiated THP-1 cells, none of the potent leishmanicidal NBPMs identified here 
displayed cytotoxicity, allowing us to calculate a selective toxicity (ST) value (the ratio 
between differentiated THP-1 IC50 values versus amastigote L. major). From this crude 
measurement, ST values of >143 and >476 were determined for LH34 and LH33 
respectively, the 2 most effective anti-L. major compounds from this chemical series. 
Similarly, such compounds displayed significant potency against bloodstream-form T. brucei, 
with LH34 having an IC50 value of 8 nM (Hall, Wu et al. 2010). However, this study also 
noted that LH34 did display significant cytotoxicity towards undifferentiated THP-1 cells 
(LH34 yielded an IC50 value of 10 μM) although other reports indicate little effect on other 
cell lines such as V79 (Chinese hamster fibroblasts) and SKOV3 (human ovarian carcinoma) 
cells (Hall, Wu et al. 2010, Hu, Wu et al. 2011). Why these halogenated NBPMs are more 
effective against T. brucei as compared with L. major has yet to be fully determined but may 
reflect that these compounds are more readily metabolised by TbNTR as compared to its 
leishmanial (and T. cruzi) counterpart. However, it must be noted that other factors may also 
account for this difference. For example, the halogenated NBPMs may be able to access the 
cell or site where Lm/TbNTR is located more readily in T. brucei than in L. major 
(mitochondria in the case of T. brucei), or could reflect how readily toxic metabolites are 
released from this site. Why different mammalian lines display varying susceptibilities to the 
halogenated NBPMs is again unclear. One possibility may involve the expression profiles of 
potential nitroaromatic activators in the mammalian cell itself. Although not investigated 
here, certain FAD-containing mammalian enzymes such as NAD(P)H:quinone 
oxidoreductase 1 (also known as NQO1 or DT-diaphorase) and NAD(P)H:quinone 
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oxidoreductase 2 (NQO2), can catalyse the two electron reduction of quinone and 
nitroaromatic-based agents (having a preference for the former), analogous to the 
bacterial/protozoal type I NTRs (Ernster et al. 1958; Knox et al. 1988, Hajos et al. 1991; 
Jaiswal 1994; Miseviciene et al. 2006). Expression of such proteins is generally up-regulated 
under oxidative stress conditions and in cancer lines (Schor et al. 1977, Sharp et al. 2000). 
Therefore, the different susceptibilities displayed by the various mammalian lines (THP-1, 
V79 and SKOV3) where cytotoxicity has been determined may reflect differing expression 
levels of these potential activators. 
 
The next set of compounds to be analysed using biochemical screening (purified recombinant 
ΔLmNTR) and anti-proliferative (against promastigote and amastigote L. major and 
differentiated THP-1 cells) assays were the ANBs, based on the CB1954. These compounds 
have shown promise as anticancer agents using a procedure known as GDEPT (Denny 2003). 
In this therapy, mammalian cells expressing the E. coli NfsB are more susceptible to CB1954  
without any significant cytotoxic effects against the NTR-lacking controls (Helsby et al. 
2004). Initially, we determined whether the ANBs could function as substrates for purified 
recombinant LmNTR (Figure 6.2.1). These biochemical screens established that out of the 13 
compounds tested, only 3 (NH3-5) were not metabolised by the parasite enzyme. When these 
studies were extended to look at their anti-parasitic activities, 4 compounds including NH3-5, 
had no affect on L. major amastigote growth with screens against promastigotes 
demonstrating that a total of 6 compounds, including the 4 agents lacking anti-amastigote 
activity, having no affect on this insect stage (Table 6.2.1). For those compounds that did 
affect amastigote growth, some generated very low IC50 values in the nanomolar range: 
CB1954 and NH11 yielding IC50 values of 50 and 60 nM respectively. None of these 
leishmanicidal ANBs displayed cytotoxicity towards differentiated THP-1 cells yielding 
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encouraging ST values: >200 for CB1954 and >1667 for NH11 (Table 6.2.1). When a 
structure-activity analysis was performed, some interesting trends were observed. Based on 
the number and positioning of nitro-groups on the benzyl ring and presence/position of other 
substituent groups on this ring, the ANBs studied here can be broadly divided into three 
groups. The so-called group Ia compounds, as typified by CB1954, all contain two nitro 
groups located at the 2- and 4- positions on the benzyl ring relative to an aziridinyl ring plus a 
side chain at the 5- position (CB1954, NH1-2 and NH9-12). All of these functioned as 
substrates for LmNTR and had the highest potency towards the parasite. The second group, 
designated as group Ib, contain an alteration to the group Ia backbone, where the 4-nitro 
group relative to the aziridinyl ring had been replaced with either a hydrogen or SO2Me 
substituent (NH3-5). These are the compounds that were inactive in enzyme and anti-
parasitic assays. The final group, called group II, all resemble group Ia compounds but have 
the side chain at the 6-position (NH6-8). These did function as LmNTR substrates (Figure 
6.2.1) but only one (NH6) displayed leishmanicidal properties. One possible reason for the 
lack of group Ib activity in both enzyme and parasite screens could be due to the structure of 
LmNTR’s active site. Our data suggests that only the 4-nitro group can be reduced (group Ib 
compounds lack this) with reduction of the 2-nitro group possibly being hindered by the 
adjacent aziridinyl moiety. All other compounds tested (group Ia and II) contain the second 
reducible nitro group at the exposed 4- position. However, while TbNTR is also unable to use 
Ib ANBs as a substrate, it has been demonstrated that, like E. coli type I NTRs, either nitro-
groups can be readily reduced, though not both on the same molecule (Knox et al. 1992, Bot, 
Hall et al. 2010). Taken together this implies that the configuration of electrons around the 
aromatic ring when featuring one or two nitro groups in relation to the 2- or 4-nitro moieties 
is the important factor. 
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Further screens using other nitroaromatic compound classes such as the non-aziridinyl 
nitrobenzamides and 5-nitrofurans were also performed. While a number of the nitrofuran 
compounds exhibited potential cytotoxicity problems against differentiated THP-1 cells, 
MNG10a and MNG5a were still able to give selective toxicity values of 234 and 153 
respectively due to their potency against amastigote L. major (Table 6.3.2). To put these in 
context, nifurtimox currently represents one of the partner drugs in the NECT formulation 
used against African sleeping sickness, and exhibits a low ST of 36 when comparing the IC50 
values against T. brucei and THP-1 cells (Hall, Wu et al. 2010). It is worth noting, however, 
that this previous study uses undifferentiated THP-1 cells, which could be misleadingly low 
for reasons detailed earlier in this section. A possible source for this toxic effect on 
mammalian cells could be activation by the aldehyde dehydrogenase 2 (ALDH2), which has 
been shown to mediate 5-nitrofuran toxicity in several species, including yeast, zebrafish and 
human cells (Zhou et al. 2012). When we evaluated the IC50 of nifurtimox towards 
differentiated THP-1 cells, no toxicity issues were observed at concentrations up to 100 M. 
In vitro, the metabolites generated following reduction of nifurtimox by trypanosomal NTRs 
have been purified (Hall, Bot et al. 2011). These products, in particular an unsaturated open-
chain nitrile derivative, are cytotoxic and are equally lethal to both trypanosomal and 
mammalian cells. This suggests that the downstream target(s) of this nitrile derivative is 
common to both host and parasite cells with proposals indicating that non-specific adduct 
formation with a range of biological molecules may occur (Hall et al 2011; Wilkinson et al 
2011). Whether the leishmanicidal nitrofurans identified here function via an open-chain 
nitrile intermediate was not determined. 
 
In the case of the non-aziridinyl nitrobenzamide compounds, all exhibited activity against L. 
major amastigotes with no toxicity displayed against mammalian cells. Many of these anti-
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parasitic agents yielded IC50 values in the nano molar range – 7 out of the 9 compounds 
analysed (Table 6.3.1). As a result several members of this class of nitroaromatic have 
respectable ST values of >500. In contrast, only 2 of the compounds (IPK1 and 8) were 
active against the promastigote form. Why there is such a difference in the potency of the 
non-aziridinyl nitrobenzamide toward the amastigote and promastigote-forms is again unclear 
but reflects the distinct biological and biochemical properties exhibited between these two 
life cycle stages as exemplified by proteomic and genomic studies (Cohen-Freue et al. 2007; 
Pescher et al. 2011). Out of those compounds biochemically screened, only one (IPK2) was 
not metabolised by the parasite enzyme (Figure 6.3.1). Intriguingly this compound does have 
leishmanicidal properties, though presumably not by a type I NTR activation mechanism (not 
investigated further). For IPK1, LmNTR activity was manifested within the promastigote cell 
as LmNTR
+/-
 heterozygote parasites were approximately 2-fold more resistant to this 
compound than wild type controls (Figure 6.3.3). 
  
This project also set out to characterise and investigate the functional role played by a type I 
nitroreductase expressed by L. major. Following searches of the L. major genome for 
orthologues of Tb and TcNTR, the DNA sequence of LmNTR was elucidated. By aligning the 
predicted protein sequence with other NTRs of bacterial and kinetoplastid origins several 
conserved residues theorised to be important in substrate and flavin cofactor binding were 
identified (Figure 5.1.2) (Mejia, Hall et al. 2012; Hall et al., unpublished). Additionally, as 
previously noted with the trypanosomal sequences, LmNTR contains an (approximately) 80 
residue amino-terminal extension as compared to its bacterial counterparts (Wilkinson, 
Taylor et al. 2008). When analysed further using protein prediction algorithms, this region 
has the potential to function as a mitochondrial targeting sequence. This was not investigated 
here (see Section 8) but has been studied in T. brucei where epitope tagging of the TbNTR 
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leader sequence fused to GFP demonstrated that this protein is located in the mitochondrion 
(Wilkinson, Taylor et al. 2008). As a general rule trypanosomatid mitochondrial leader 
sequences are small and correspond to the first (approximately) 10 amino acids of the protein. 
If this is the case for LmNTR (and its trypanosomal counterparts) then there are 
approximately 70 residues of the protein from the end of the putative targeting signal to the 
start of the catalytic domain whose function still remains unknown. 
 
To confirm that LmNTR does actually function as a type I NTR, the catalytic region was 
expressed in E. coli as an amino terminal His6-tagged fusion protein. This recombinant 
enzyme could be readily purified by one round of affinity chromatography on a Ni-NTA 
column, with LmNTR-containing elutions appearing yellow in colour. This is suggestive that 
LmNTR has a flavin co-factor. Using a fluorescence-based assay (Faeder and Siegel 1973), it 
was subsequently shown that recombinant LmNTR non-covalently bound FMN, a 
characteristic feature of all type I NTRs (Figure 5.3.1) (Zenno et al. 1996, Watanabe et al. 
1998; Hall et al., unpublished). As bacterial type I NTRs can use NAD(P)H, the electron 
donor preference of LmNTR was studied. This revealed that both NADH and NADPH could 
supply reducing equivalents to the parasite enzyme with NADH being the preferred option 
(Figure 5.3.2 C). This is in agreement with observations made using the trypanosomal 
enzymes (Wilkinson, Taylor et al. 2008; Hall et al., unpublished).  
 
Once the optimal source for reducing equivalents had been established, the range of electron 
acceptor structures was analysed. Using spectrophotometric-based assays, it was shown that 
recombinant ΔLmNTR could metabolise a wide range of compounds including several 
classes of nitroaromatics (e.g. nitrofurans, nitroimidazoles, nitrobenzyls) and 1,4-
benzoquinones (Table 5.3.1). By calculating the apparent VMAX and kCAT/KM values, the 
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preferred substrate of LmNTR appear to be quinone-based, similar to observations made 
using trypanosomal NTRs (Hall et al., unpublished). This finding could be indicative of the 
as yet unknown endogenous function of LmNTR. Trypanosomal NTRs are similar to NADH 
dehydrogenases, that metabolise NADH and in doing so transfer electrons over to ubiquinone 
to generate ubiquinol (Brandt 2006). It is interesting to note that the highest kCAT/KM value 
recorded here for LmNTR was for coenzyme Q1, a synthetic member of the ubiquinone 
family. In trypanosomes, NADH dehydrogenase activities have been recorded from several 
distinct proteins (Fang et al. 2001, Fang et al. 2002, Fang et al. 2003). It is indeed tempting to 
speculate that the kinetoplastid NTR is in fact the 33 kDa FMN-containing, mitochondrial 
NADH dehydrogenase isolated from T. brucei in 2002 (Fang and Beattie 2002). In the case 
of benznidazole, a detailed kinetic analysis was carried out to investigate how this electron 
acceptor and NADH interact with LmNTR (Figure 5.3.3). As with other oxidoreductase 
systems, this was shown to occur via a ping-pong mechanism. This interaction was shown to 
be subject to noncompetitive substrate inhibition indicating that the relative ratios of electron 
donor to acceptor are critical for the function of this enzyme. Again, this pattern is typical for 
many oxidoreductase and has been observed in studies using TbNTR and TcNTR (Hall and 
Wilkinson 2012). 
  
To address the role and importance of LmNTR to L. major, attempts to alter expression levels 
of this enzyme were made by genetically manipulating the copy number of the corresponding 
gene within the parasite itself. In T. brucei and T. cruzi, such studies have categorically 
implicated the type I NTR in the activation of nitroaromatic prodrugs, with loss of TbNTR or 
TcNTR leading to resistance while cells expressing elevated levels of the oxidoreductase were 
more susceptible to these compounds (Wilkinson, Taylor et al. 2008). Additionally, this work 
also showed that the type I NTR activity was essential to the parasite forms present in the 
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mammalian host, indicating that inhibition of this enzyme can also be targeted for drug 
development. 
 
When attempts were made to express LmNTR within L. major promastigotes using several 
different vector systems with either wild type or epitope-tagged versions of the gene, no 
stable recombinant parasites were selected. Consequently, it appears that introducing ectopic 
copies of LmNTR (and thus increasing LmNTR expression) has an adverse effect on the 
growth of L. major promastigotes. This is reminiscent of the situation in T. cruzi 
epimastigotes where TcNTR could not be readily over expressed (Wilkinson, unpublished). 
The only case where an ectopic copy of TcNTR has been expressed within T. cruzi employed 
a parasite line selected for benznidazole resistance, cells shown to be TcNTR
+/-
 heterozygotes 
(Mejia, Hall et al. 2012). Furthermore, following electroporation of pTEX-TcNTR, Southern 
hybridisation demonstrated that these recombinant trypanosomes contained only a single 
copy of the episome. Interestingly, when investigating the effects of the antiparasitic 
compound fexinidazole, Wyllie et al. (2012) was able to over express LmNTR in L. donovani 
using a vector containing an amastigote-specific expression site. When this plasmid was 
electroporated into promastigote cells, LmNTR expression is repressed and then following 
differentiation into amastigotes forms up-regulated. These recombinant cells were then 
shown to be more susceptible to fexinidazole than controls, indicating successful over 
expression of the oxidoreductase. However, it is important to note that the L. major protein 
was being expressed in L. donovani, which may also account for the apparent contrast to our 
data.  
 
When the converse approach was taken, aimed at reducing the copy number of LmNTR by 
targeted gene deletion, we could readily generate two heterozygote lines (Figure 5.4.11). 
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However, repeated attempts to a construct LmNTR
-/-
 null mutant cells failed. Based on our 
previous findings relating to failed over expression of the nitroreductase within the insect 
stage, we did not introduce an ectopic copy of LmNTR into the heterozygote parasite line. 
Together this data strongly suggests that LmNTR is essential to L. major promastigote 
viability. Interestingly, repeated attempts to establish LmNTR
+/-
 heterozygote parasites within 
cultured macrophages (differentiated THP-1 cells) and in a mouse model failed despite the 
appropriate controls working (Figures 5.4.15 and 5.4.16). This indicates that LmNTR activity 
is important, if not essential, to the intracellular amastigote form, even in an animal. Certain 
aspects of these observations bear some similarity and some differences to the situation noted 
with other trypanosomastids. For T. cruzi, both allelic copies of TcNTR could readily be 
deleted from epimastigote (insect-form) parasites to construct null mutant lines (Wilkinson, 
Taylor et al. 2008). However, these cells could not be cultured in mammalian cells and in a 
mouse model. This suggests that NTR activity is important, if not essential, to intracellular-
form trypanosomes, as we observed with L. major. In the case of the bloodstream-form of T. 
brucei, TbNTR could not be deleted unless an ectopic copy was expressed, again implying 
that NTR activity is important to the viability of extracellular parasites also (Wilkinson, 
Taylor et al. 2008). This finding is backed up by a series of studies on T. brucei using RNAi 
(Wilkinson, Taylor et al. 2008, Hall, Wu et al. 2010, Sokolova, Wyllie et al. 2010, Baker, 
Alsford et al. 2011, Alsford, Eckert et al. 2012). In a number of these experiments, whole 
genome loss-of-function assays performed at different resolutions, using nifurtimox as 
selective agent, repeatedly identify TbNTR as the key factor that interacts with this 5-
nitrofuran. These studies also implicated several enzymes involved in ubiquinone synthesis 
and FMN formation as minor factors whose reduction in function also leads to nifurtimox 
resistance, all of which appears to again demonstrate the importance of TbNTR in mediating 
nifurtimox activation. 
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The fact that this oxidoreductase preferentially metabolises quinone-based substrates and is 
located in the mitochondrion adds further weight to the argument that the biological function 
of NTRs in trypanosomatids involves the regeneration of NAD
+
 in this particular organelle 
(Wilkinson et al. 2008; Wilkinson, Taylor et al. 2008, Hall, Wu et al. 2010, Sokolova, Wyllie 
et al. 2010, Baker, Alsford et al. 2011, Alsford, Eckert et al. 2012). The reducing equivalents 
are subsequently transferred to ubiquinone Q9 (Martin et al. 1979, Martin et al. 1979, 
Ranganathan et al. 1995) molecules to form the corresponding ubiquinol that then drives 
different types of redox cascades dependent upon the trypanosomatid parasite. For 
bloodstream-form T. brucei, ubiquinone Q9 is regenerated via a trypanosomal alternative 
oxidase and TbNTR may represent the “enigmatic” NADH:ubiquinone oxidoreductase 
activity previously noted (Clarkson et al. 1989, Bienen et al. 1993, Chaudhuri et al. 2006, 
Surve et al. 2012). The situation in intracellular trypanosomes or Leishmania is unclear as the 
gene encoding for the trypanosomal alternative oxidase is not present in the T. cruzi and L. 
major genomes, although they do possess a gene that has potential to encode for a 
mitochondrially targeted alternative oxidase-like protein (GenBank accession number 
EAN97989). However, this enzyme lacks certain key features that typify this class of oxidase 
and its activity has yet to be confirmed. 
 
Taken together all of our data and the published material relating to the function of NTR in L. 
major, T. cruzi and T. brucei strongly indicate that NTR is essential to parasite forms that 
replicate in the mammalian host and therefore represents a genetically validated target, prime 
for exploitation for drug development. These data also make the potential for using 
nitroaromatic compounds as future antileishmanial prodrugs particularly encouraging. There 
is mounting data showing that by mutating/silencing/deleting a single allele of Tb or TcNTR 
in laboratory trypanosomal cell lines, cross resistance to nitroaromatic compounds occurs as 
 154 
 
the prodrugs can no longer be activated (Wilkinson, Taylor et al. 2008, Hall, Wu et al. 2010, 
Sokolova, Wyllie et al. 2010, Baker, Alsford et al. 2011, Alsford, Eckert et al. 2012). This 
has also been reported in clinical T. cruzi cell lines (Mejia, Hall et al. 2012). In this case, it 
would then be feasible to then treat the patient using a different compound to inhibit the 
remaining levels of NTR, resulting in parasites unable to survive/infect. However, this 
approach would also require an extra, accompanying development cycle for an NTR 
inhibitor-based drug. However if, as is the case in L. major, by decreasing the quantity of the 
parasite NTR the cell is then already prevented from establishing a mammalian infection, the 
concern of resistance to nitroaromatic treatments (and the cost in developing NTR inhibitors 
in this case) is then defunct. This, together with the highly selective antileishmanial 
properties exhibited by some of the compounds reported here makes the nitroaromatics a 
highly promising class of compounds that warrant increased attention and research in the 
field of leishmaniasis treatment. 
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8. Future work 
This project has described the production of a luciferase-expressing L. major reporter cell 
line, which was then used in a nitroaromatic compound screening program. Additionally, we 
have investigated the function of a type I NTR expressed by L. major (LmNTR), a potential 
activator of these prodrugs, in vitro, in vivo and within a BALB/c mouse infection model. 
 
The LmRIX-Luc cell line developed here was used to screen 4 distinct classes of 
nitroaromatics. This identified several structures with significant potency against amastigote 
parasites and little/no cytotoxicity to cultured mammalian cells, as judged by their IC50 
values. This screening program, initially validated on a small number of compounds, can be 
readily extended to include a greater selection of other chemical classes, nitroaromatic or 
otherwise. In fact, due to the effects of reducing LmNTR copy number on L. major infectivity 
reported here, a new direction would be to begin screening potential inhibitors of LmNTR as 
possible therapeutic agents. Theoretically, by inhibiting this enzyme L. major would be no 
longer able to proliferate in the mammalian life cycle stage. The system reported here has 
been optimised for use in a 96-well plate but could be further refined to other multi-well plate 
formats. Additionally, the L. major reporter cell line in conjunction with appropriate imaging 
facilities could be applied to follow mouse infections, aimed at monitoring variables such as 
infection rates and tissue tropisms, and observing how nitroaromatic treatments in vivo may 
affect these. 
 
The nitroaromatic compounds that show promise in anti-parasitic screens can be further 
investigated for their mechanism of parasitic cell killing. It has been shown that nifurtimox 
and benznidazole, once reduced by TbNTR, produce cytotoxic metabolites (Hall, Bot et al. 
2011; Hall and Wilkinson 2012). It would be interesting to see if LmNTR-mediated 
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metabolism of these compounds (including other members of the same compound class) 
resulted in the same cytotoxic products. Equally, whatever metabolites are produced, the next 
step would be to discern their downstream targets within the cell, be it protein, lipid or 
nucleic acid. For example, the effect on DNA could be readily monitored using the bacterial 
Ames test, TUNEL assay or immunofluorescence labelling, for example using histone H2A 
antibodies. Such studies could incorporate the new leishmanicidal compounds identified here. 
 
To further investigate the function of LmNTR within the parasite itself, similar approaches to 
that reported by Wilkinson, Taylor et al. 2008) could be used to elucidate the localisation of 
LmNTR within the L. major cell. This would involve expression of recombinant proteins 
consisting of the putative LmNTR leader sequence fused to an appropriate epitope tag (e.g. a 
fluorescent protein) in the parasite. Additionally, LmNTR mutants could be produced (for 
example, in arginine 96 or one of the other catalytic residues conserved across kinetoplastids) 
and the activity in vitro and in vivo monitored. It would be interesting to see if, after the 
difficulty in transfecting ectopic copies of wild type LmNTR into L. major promastigotes, it 
would be possible to produce cell lines capable of expressing an inactive version of the 
enzyme. Equally, is it possible to reintroduce (through episomal or integrative vectors 
described in Section 5.4.1) an ectopic copy of wild type (or 9E10-epitope tagged) of the 
oxidoreductase into LmNTR
+/-
 heterozygote cell lines? If this is possible, does this reverse the 
resistance phenotype against nitroaromatic compounds shown in Figures 5.4.13, 6.1.3, 6.1.4 
and 6.3.3? The above analysis would help in establishing what the biological role of LmNTR 
actually is within the parasite itself. Additionally, the findings in regard to the LmNTR
+/-
 
heterozygote cell line could also take another direction – that of vaccine development. The 
mouse in Figure 5.4.16 that was challenged with LmNTR
+/-
 heterozygote parasites did not 
exhibit any external symptoms, however now has an immune system that has been exposed to 
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L. major. Consequently it could be possible that the mouse would now be resistant to 
subsequent L. major infection with wild type parasites. 
 
Finally, with further optimisation of the expression and purification process that produces 
high levels of pure recombinant LmNTR, it would hopefully be possible to produce suitable 
crystals to elucidate the structure of LmNTR through X-ray diffraction. This would allow for 
even greater insight into the biochemistry of nitroaromatic prodrug activation. Together with 
the structure-activity relationships already determined in this project, the LmNTR crystal 
structure could allow rational drug design methods to maximise the leishmanicidal properties 
of nitroaromatic compounds while maintaining selectivity against mammalian host cells, as 
well as providing a valuable resource in developing inhibitors to target this essential activity 
itself. 
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9. Thesis summary 
1. A novel luciferase-expression system, LmRIX-Luc, has been produced in L. major, 
which has no effect on the parasite’s ability to grow as either promastigotes or 
amastigotes; or to differentiate into infective metacyclic cells. 
2. Using the LmRIX-Luc cell line, a compound screening protocol has been developed 
and validated in the medically-relevant amastigote life cycle stage of L. major. 
3. LmNTR is a type I NTR that contains noncovalently-bound FMN as cofactor and uses 
NADH as a preferred electron donor to reduce a wide variety of nitroaromatic and 
quinone-based compounds via a ping-pong kinetic mechanism. 
4. It appears that introducing ectopic copies LmNTR into L. major promastigotes is 
deleterious, as is removing both LmNTR alleles. However, LmNTR
+/-
 heterozygote 
promastigote cells can be readily produced with no apparent effects on promastigote 
growth or metacyclogenesis. 
5.  LmNTR+/- heterozygote L. major are cross resistant to several nitroaromatics, though 
are not able to proliferate as amastigotes in vitro or in a mouse infection model. 
6. A series of nitroaromatics across 4 compound classes have been screened against 
recombinant ΔLmNTR protein, promastigote and amastigote L. major, as well as 
differentiated mammalian THP-1 macrohages. 
7. A number of nitroaromatic compounds, particularly those shown in Figure 6.3.5 show 
great potential as very effective antileishmanials with high selective toxicities. 
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10. Appendix A: Primers 
primer name primer sequence (5’ – 3’) 
LmrRNA-1 GAG GAGCTC CCTGCAGG TGATGAGGTGCCGCGTGTGTG 
LmrRNA-2 AAA GGATCC TCCGTCGTTGCCCAGACACTT 
LmrRNA-3 GGG GGTACC AAGGCAACAACGCAAGCGCAT 
LmrRNA-4 AAA GGTACC GGCGCGCC CCACGTGCGTCCTCTAAAAGG 
LmrRNA-5 CCC AGATCT TTTAATTATTTTTATCCCTTT 
LmrRNA-6 GGG GGATCC GACAAAGCTTTTCTTGTGTGT 
LmNTR-1 AAA GGATCC CTCGACGCCGTCGAGGCCGTCG 
LmNTR-2 GGG AAGCTT CTAGAACTTGTTCCACCGCAC 
LmNTR-4 AAA GGGTCC ATGCTTCGCCGCAGCCCCCG 
LmNTR-18 GGG GTCGAC CTAGAACTTGTTCCACCGCAC 
LmNTR-9 AAA GAGCTC CCGCGG CCGTCTCTGCCCTCTTTTCCT 
LmNTR-10 GGG TCTAGA TGTAGTTTCTCTTGCTGCTCT 
LmNTR-11 GGG GGGCCC TGTTGACTCAACACTAGAGAT 
LmNTR-13 GAA GGTACC AGGGAAGGCAAGCACCAGGTG 
 
Table 10.1: Oligonucleotides used in this study 
Restriction enzyme recognition sites included for cloning purposes are highlighted in bold 
italics. 
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11. Appendix B: Compound structures 
(A) 
 
(B) 
 
compound structure diastereomer 
 
compounds based on (A)   
LH3 X=O; Y=NH cis 
 
LH4 X=O; Y=NH trans 
 
LH5 X=NH; Y=O cis 
 
LH6 X=NH; Y=O trans 
 
LH12 X=NH; Y=NH cis 
 
LH13 X=NH;Y=NH trans 
compounds based on (B)   
LH8 X=O; Y=NH cis 
 
LH9 X=O; Y=NH trans 
 
Table 11.1: Structures of cyclic nitrobenzylphophoramide mustards 
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compound structure 
LH7 R3=NO2; X=P; Y=NH2; R1=R2=R4=R5=Z=H 
LH14 R3=NO2; X=P; Y=NH2; Z=CH3; R1=R2=R4=R5=H 
LH15 R5=NO2; X=P; Y=NH2; R1=R2=R3=R4=Z=H 
LH16 R4=NO2; X=P; Y=NH2; R1=R2=R3=R5=Z=H 
LH17 R3=NO2; R5=OCH3; X=P; Y=NH2; R1=R2=R4=Z=H 
LH18 R3=NO2; R4=OCH3; X=P; Y=NH2; R1=R2=R5=Z=H 
LH19 R3=NO2; R4=CH3; X=P; Y=NH2; R1=R2=R5=Z=H 
LH24 R3=NO2; X=P; Y=NH2; Z=CH3; R1=R2= R4=R5=H 
LH27 R3=NO2; X–Y=C; R1=R2= R4=R5=Z=H 
LH31 R2=F; R3=NO2; X=P; Y=NH2; R1=R4=R5=Z=H 
LH32 R1=F; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H 
LH33 R1=CF3; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H 
LH34 R1=Cl; R3=NO2; X=P; Y=NH2; R2= R4=R5=Z=H 
LH37 R1=R5=F; X=P;  R3=NO2; Y=NH2; R2= R4=Z=H 
 
Table 11.2: Structures of acyclic nitrobenzylphophoramide mustards 
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compound group structure 
CB1954 Ia R1=NO2; R2=CONH2; R3=H 
NH1 Ia R1=NO2; R2=CONH(CH2)2Nmorpholide; R3=H 
NH2 Ia R1=NO2; R2=CONH(CH2)2CO2Me; R3=H 
NH3 Ib R1=H; R2=CONH2; R3=H 
NH4 Ib R1= SO2Me; R2= CONH2; R3=H 
NH5 Ib R1=SO2Me; R2= NHCH2CH(OH)CH2OH; R3=H 
NH6 II R1= NO2; R2=H; R3=CONH2 
NH7 II R1= NO2; R2=H; R3=NHCH2CH(OH)CH2OH 
NH8 II R1= NO2; R2=H; R3=CONH(CH2)2Nmorpholide 
NH9 Ia R1= NO2; R2=oxazole; R3=H 
NH10 Ia R1=NO2; R2=CONHCH2CHCH2; R3=H 
NH11 Ia R1=NO2; R2=CON(CH3)CH3; R3=H 
NH12 Ia R1=NO2; R2=R3=H 
 
Table 11.3: Structures of aziridinyl nitrobenzamides 
 
 
 
 
 
 
 163 
 
 
 
 
compound structure 
IPK1 R1=NO2; R2= CH2(3-chloro)benzyl; n=0 
IPK2 R1=NH2 ; R2=CH2(3-chloro)benzyl; n=0 
IPK3 R1=NO2;  R2= CH2(2-fluoro)benzyl; n=0 
IPK4 R1=NO2; R2= (4-methoxy)benzyl; n=0 
IPK5 R1=NO2; R2= CH2 benzyl; n=0 
IPK6 R1=NO2; R2= (4-methoxy)benzyl; n=3 
IPK7 R1=NO2; R2=methylbenzoate; n=2 
IPK8 R1=NO2; R2= CH2(3-trifluoromethyl)benzyl; n=0 
IPK9 R1=NO; R2= (4-methoxy)benzyl; n=2 
 
Table 11.4: Structure of the non-azirinidyl nitrobenzamide compounds 
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compound structure 
AD1 R1=R2=H 
AD2 R1=H; R2=NO2 
AD3 R1=H; R2=OMe 
MNG5a R1=H; R2=CF3 
MNG7a R1=H; R2=F 
MNG10a R1=NO2; R2=H 
MNG11a R1=F; R2=H 
 
Table 11.5: Structure of the 5-nitrofuran compounds 
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